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ABSTRACT
SOLID-PHASE APPROACHES TO N-HETEROCYCLES USING A SULFUR LINKER 
CLEAVED BY SAMARIUM (II) IODIDE
Linker strategies lie at the heart of solid phase and combinatorial chemistry. HASC (a- 
Hetero-Atom Substituted Carbonyl) linkers have recently been developed and can be 
cleaved in a traceless manner using Sml2.
My project was concerned with assessing the compatibility of HASC linkers with 
palladium-catalysed transformations. More specifically, we wished to use the linker 
system in conjunction with palladium chemistry in the solid-phase synthesis of 
important heterocyclic systems.
We began by examining palladium-catalysed a-arylations as the basis of a possible 
solid-phase route to oxindoles and a-aryl carboxylic acids. The second part of my 
project involved the development of a solid-phase route to tetrahydroquinolones using 
a microwave-assisted Heck reaction and Michael cyclisation as the key steps. During 
this work, we also showed the feasibility of a cyclative-cleavage strategy using the 
HASC linker, where cleavage of the link with Sml2 is followed by cyclisation to give a 
heterocyclic product directly.
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CHAPTER 1 INTRODUCTION
1.0 INTRODUCTION TO LINKERS FOR SOLID-PHASE ORGANIC SYNTHESIS
The evolution of solid-phase organic synthesis (SPOS) can be traced back to the solid- 
phase peptide synthesis first described by Merrifield.1 His method was revolutionary 
and solid-phase peptide synthesis is now carried out in automated peptide synthesisers 
which make full use of the advantages of solid-phase techniques. The major benefits 
over standard solution-phase techniques include: the ease of product isolation via 
filtration; use of excess reagents to drive reactions to completion and ease of 
automation.2,3
Solid-phase synthesis remained a tool only for the peptide chemist until the early 
1990’s when Ellman and Bunin published a convenient and high-yielding solid-phase 
synthesis of 1,4-diazepines (scheme 1.1).4 This proved to be a key publication in the 
area and Ellman later went on to synthesise a library of 192 diazepine analogues using 
his solid-phase route.5
O^TX
HMPA polystyrene
X = OH, C 02H
X X . - N H F m o c
f
®  HMPA polystyrene
NHFmoc
(i) 20 % piperidine, DMF
NHFmoc
(i) 20 % piperidine, DMF 
(ii) 5 % AcOH, DMF
TFA : H2Q : Me2S
8 5 :5 :  10
HN
(i) base, THF, -78 °C
(ii) R4I, DMF
Scheme 1.1
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SPOS has now become a cornerstone in the combinatorial synthesis of “drug-like” 
small organic molecule libraries. In the last decade, a great many research groups in 
academia and industry have made efforts to transfer solution-phase reactions onto 
solid-phase. As a result SPOS and its application in a combinatorial sense has 
emerged as an indispensable tool to accelerate drug discovery.
1.1 TRACELESS LINKERS
New interest in using SPOS for the synthesis of libraries of drug-like molecules found 
limitations in the use of conventional linkers which were designed for the synthesis of 
peptides. Conventionally, the link to polymer was at the C-terminus of the peptide 
meaning traditional linkers such as Merrifield, Rink and Wang resins required 
carboxylic acid functionality in the substrate for loading onto resin.6,7 Fig. 1.1 shows 
some traditional resins originally used in peptide synthesis. They now form the basis of 
new SPOS resins.
q T °
OH
X OMe
q T ° OMe
chloromethylated polystyrene 
"Merrifield resin" Wang resin
Rink amide (X = NH2) 
Rink acid (X = OH)
C T
PEG
Tentagel, 
Argo-Gel 
X = Br, Cl, OH
C T °
OH 
OMe
Sassrin resin
HN
NH.
OMeMeO'
Knorr resin
Fig. 1.1
Following the synthesis, the carboxylic acid functionality is regenerated after 
conventional cleavage from the polymer support. In Ellman’s pioneering synthesis of 
1,4-benzodiazapines (scheme 1.1), the molecules are linked via a phenolic or 
carboxylic acid residue and after cleavage these functionalities were unmasked.
Functional groups have a dramatic outcome on the potential medicinal efficacy of the 
final products. The use of linkers that dictate the type of functionality present in a
12
substrate has limited the utility of SPOS for drug discovery. With this in mind, solid- 
phase chemists set about designing new linkers that were termed “traceless” linkers, 
where the point of attachment is not apparent in the final molecule.
Ellman was again a pioneer in this field and he developed the use of a silicon-based 
traceless linker for the synthesis of 1,4-benzodiazepine derivatives (scheme 1.2).8,9
The resin bound stannane 1 was coupled with acid chlorides using the Stille reaction 
and deprotection of the Bpoc group gave supported aniline 2. Following the procedure 
outlined in scheme 1.1, the functionalised, supported 1,4-benzodiazepines 3 were 
synthesised. Any protecting groups that remained in the side chains R1-R3 were 
removed with TFA and the molecules cleaved from the support using aqueous HF. No 
trace of the point of attachment to the support is found in the cleaved molecule and the 
functionality of the aryl ring could be adapted to access different target molecules. This 
was a significant step in SPOS however the linker 4, used in Ellman’s strategy (Fig.
1.2) was laborious to synthesise from aminomethylpolystyrene (5 steps).
NHBpoc
SnMe-
2
As scheme 1.1
(ii) aqueous HF
3
50-68 % yield
Scheme 1.2
o 4
Fig. 1.2
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Since this early work on traceless linkers there have been many contributions to the 
area with many heteroatom based linkers (Si, Ge, S, Se, N, P, B, O and Cr) used in 
SPOS.10 Protecting group- and auxiliary-based linkers have also been developed as 
well as target-specific traceless linkers. Such is the growth in the field, the meaning of 
the term traceless has become somewhat vague. Perhaps the best definition of a 
traceless linker is a linker that, when cleaved, leaves an aliphatic or aromatic hydrogen 
at what was the point of attachment to the support.11
1.2 INTRODUCTION TO SULFUR AND SELENIUM LINKERS.
1.2.1 Sulfur linkers
The first example of a sulfur-based linker was reported by Suto et al. in 1997 (scheme
1.3).12 Oxidative activation of a sulfide linker allowed nucleophilic displacement of the 
sulfone, introducing further diversity into the final compound.
|| TG Thiol resin,
N^ X O p E t  NEt3, DMF** C 02Et
R2
R l - N y N y C F j  R1R2NH
n' ^ co2e, CH’C'2
mCPBA,
CH2CI2
O O
S' N. .CF3N r N ' J
C 02Et
CF.CF- -CF-
NHBu
OPh
80% 50% Yields not reported
Scheme 1.3
The 2-chloropyrimidine 5 was loaded onto Tentagel thiol resin (a PEG based resin) and 
the resulting immobilised sulfide 6 oxidised to the sulfone 7 with mCPBA. Cleavage 
from the support using primary and secondary amines gave pyrimidines 8 in 50-93 % 
yield. The purity of the final compounds was excellent (> 90 %) and the ester group in 
intermediates such as 7 could also be manipulated to synthesise amides and ethers.
14
Janda and co-workers have reported the use of a “soluble” PEG based resin using a 
sulfur linker in the synthesis of a 3,5-pyrazolidinedione.13 Alkylation of the thiophenol 
resin 9 with a symmetrical dihalide gave the supported bromoalkane 10 (scheme 1.4). 
Alkylation with dimethyl malonate, followed by alkylation with a benzylic halide provided 
the cyclisation substrate 11. Treatment of 11 with base and methyl hydrazine resulted 
in cyclisation to give the supported 3,5-pyrazolidinedione 12. Chemoselective sulfide 
oxidation gave the sulfone 13 which was reductively cleaved with Na/Hg to release the 
free heterocycle 14. The polymer support is soluble in most organic solvents enabling 
the reactions to be carried out in a solution-like environment but can be conveniently 
precipitated with /-PrOH to facilitate isolation and washing.
SHo (ii) p-CI(C6H4)CH2CI, 
CS2C03
Br
CsCO-
9
OMe
OMe
NaOH,
MeNHNH2
0=5-HN-N
Scheme 1.4
1.2.2 Selenium linkers
Selenium has proved to be a useful element for traceless SPOS, attracting much 
recent interest. The first example of the use of a selenium-based traceless linker was 
in the solid-phase synthesis of a library of phenolic ethers described by Ruhland and 
co-workers (scheme 1.5).14
15
BuLi ^e’ ® ®
C j - B r   -------=— — ► C 3 —Li ---------------------► ( j - S e  -B(OEt)3Na
hexane:toluene (jj) h +, 0 2
15 1:1 (iii) NaBH4, EtOH 16
Br(CH2)6OH 17, 
EtOH
a Se
OH
PPh3l DIPAD, 
NMM
OMe
.OMe
57%
SnBu3H, AIBN, 
Toluene
90 °C
O — Se
OMe
18
Scheme 1.5
Commercial bromopolystyrene 15 was lithiated and treated with selenium powder. Air 
oxidation gave a diselenide resin, which was reduced using sodium borohydride to give 
the resin-bound sodium(triethyl)borate complex 16. Halo alcohols such as 17 were 
then immobilised and reacted with phenols under Mitsonobu conditions to give 
supported phenolic ethers such as 18. Cleavage via a radical reduction gave a library 
of phenolic ethers such as 19 in good yield (scheme 1.5).
At around the same time, Nicolaou carried out a more extensive study of the use of 
selenium linkers.15 A series of solid-phase resins were prepared from readily available 
starting materials. Polystyrene beads suspended in cyclohexane were treated with n- 
BuLi and TMEDA and the lithiated species quenched with dimethyldiselenide to give 
resin 20 (scheme 1.6). Exposure of 20 to bromine gave the polymer supported selenyl 
bromide resin 21. Selenium phthalimide reagent 22 was prepared from 21 by 
displacement with potassium phthalimide in the presence of 18-crown-6. The lithium 
selenide resin 23 was prepared by LiBH4 reduction of 21.
16
Q °
SeN,
6
■ o
(i) n-BuLi, 
TMEDA, 
cyclohexane
(ii) MeSeSeMe, 
THF, 0 °C
aSeMe
20
Br2, 
CHCI3, 0 
then 
( EtOH, 70
potassium phthalimide, 
18-C-6, benzene O l
’C
°c
LiBH4, THF
22
SeBr
21
aSeLi
23
Scheme 1.6
The use of resins 21-23 as polymer supports and as polymer supported reagents was 
then illustrated. Olefin 24 was immobilised using the selenium bromide resin 21 and 
subsequently released reductively upon treatment with Bu3SnH-AIBN. The starting 
olefin was recovered in 92 % yield. The polymer supported selenium bromide 21 was 
also found to be as effective as the corresponding solution-phase reagent, phenyl 
selenium bromide, for the transformation of PGF2a methyl ester 25 to the PGI2 
analogue 26 (scheme 1.7). In this case, immobilisation using 21 triggers cyclisation to 
form the tetrahydrofuran ring. Oxidation of the linking selenium atom to the selenoxide 
and elimination releases 26 from the support.
17
0 ^ S e B r  Q .
21 Se 0
'6 0E t c h 2ci2 Br^ ^ f T ^ O E t
24
]  Bu3SnH-AIBN
Tol, 110 °C, 92%
HO C 02Me
21, THF, -78 °C
S^e
HO
HO'
H20 2, 
-78 °C-RT
HO'
26
94%
2:1 ratio of C-6 epimers
Scheme 1.7
Phthalimide selenium resin 22 also proved to be a useful polymer bound reagent. 
Terminal olefin 24 was converted to the regioisomeric alcohols 27 and 28 in 82 % 
overall yield after reductive cleavage of the selenide linker (scheme 1.8).
(ii) Bu3SnH-AIBN, 
toluene, 110 °C
Scheme 1.8
The protected iodo alcohol 29 was loaded onto lithium selenide resin 23 to give 30. 
Oxidation followed by spontaneous cleavage released the terminal alkene 31.
18
Alternatively, radical cleavage of selenide 30 gave alkane 32. Moderate to good yields 
of product were reported (48-94 %) for a diverse range of substrates.
C X  23^^SeLi
H20 2, THF
'OTBDPS 'OTBDPS
29
THF
30 SnBu3H-AIBN,
toluene,
110°C
31
32
vOTBDPS
'OTBDPS
Scheme 1.9
1.3 PALLADIUM-CATALYSED TRANSFORMATIONS ON SUBSTRATES 
IMMOBILISED THROUGH SULFUR AND SELENIUM LINKERS.
Any new type of linker for use in solid-phase synthesis must be compatible with 
palladium mediated transformations such is the importance of this methodology in both 
academia and industry.16 The main advantage of solid-phase techniques is the 
avoidance of tedious work up procedures and this is particularly important for 
palladium-catalysed reactions as the soluble palladium catalyst can be easily removed 
by washing processes. In recent years, an increasing number of reports have 
appeared describing well-established palladium-mediated processes being performed 
on solid-phase substrates.16 In this short review I will concentrate on palladium- 
catalysed transformations carried out on supported substrates immobilised through a 
sulfur or selenium linker.
1.3.1 Sulfide linkers
Kunz et al. have illustrated the use of the palladium-catalysed removal of ally) 
protecting groups in the synthesis of a library of compounds from the orthogonally 
protected monosaccharide template 34 immobilised via a sulfur link to the support.17 
The template is synthesised in three steps from succinimide 33 (scheme 1.10).
OTBDPS
oac 0£>
33
Scheme 1.10
DTBDPS
OH H il
34
19
Derivatisation was first carried out at the 2-position followed by deprotection of the silyl 
ether and carbamoylation (scheme 1.11). Deprotection of the ethoxy ether group was 
followed by esterification or carbamoylation. Palladium-catalysed deprotection of the 
acid and base stable allyl ether group was then carried out using p-toluene-sulfinic acid 
as the proton source and allyl acceptor. The deprotected hydroxyl group at C-3 was 
carbamoylated, esterified or left underivatised to give the resin-bound glucoside 
intermediates 35 (scheme 1.11).
R6H N . ^ O  (j) KOt-Bu, DMF
o  R2'X ’ DMF OTBDPS
/  (iii) TBAF, THF /
(iv, R6-NCO, Ef S S H 2 ' iU ! ^ Q
OR2 cat. DMAP, dioxane OH
(v) PPTS, MeOH/dioxane ^
(i) esterification or carbomyiation at 4-position
(ii) p-TolS02H, cat. Pd(PPh3)4l DME
(iii) esterification or carbomyiation at 3-position 
or: no derivatisation at the 3-position.
R6HN^O
R4O^T~l?\ ‘
r3o -
OR2
35
r6HN^O
R40-T-i-0
R30 > -t^ O E t
OR2
36
(i) NBS, EtOH, DTBP, CH2CI2 
(ii) Et4NBr, cyclohexane, CH2CI2 
or
(i) Br2, DTBP, CH2CI2
(ii) EtjNBr, EtOH, cyclohexane, CH2CI2
Scheme 1.11
Cleavage from the solid-support was achieved by addition of bromine or NBS with a 
hindered base and led to the formation of reactive 1-bromo sugars which were 
converted into the corresponding 1-O-ethyl glycosides 36 by Lemieux activation with 
tetraethyl ammonium bromide and reaction with ethanol (scheme 1.11). A range of 
structurally diverse glucose derivatives was synthesised using this approach, some of 
which are shown in Fig. 1.3, in moderate to good yields and high purity illustrating the 
efficiency of each reaction on solid-phase.
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Fig. 1.3
The group of Sucholeiki at Eli Lilly described the use of a sulfur linker in a solid-phase 
synthesis of biaryls using the Stille reaction.18 The use of both a nitrogen and sulfur- 
based linker was investigated and their utilities compared.
Initial work concentrated on the immobilisation of the aryl stannane 37 using the Rink 
amide resin. Stille coupling was carried out with phenyl iodide to give biphenyl 38 after 
cleavage from the support (scheme 1.12). The intermediate resin-bound biaryl was 
characterised by gel-phase 13C NMR. Unfortunately, the maximum yield of 38 
achieved was only 15 %.
Rink amide resin
Scheme 1.12
The “sense” of the Stille reaction was then reversed. Immobilisation of iodo- 
substituted carboxylic acid 39 was achieved through a coupling onto the free amine of 
the linker to give the resin-bound aryl iodide 40 (scheme 1.13). Stille coupling with 
phenyltributyltin gave a 33 % yield of the desired biphenyl 38 after acid cleavage. The 
authors highlighted the possibility that the resin-bound tin species in scheme 1.12 was
21
changing the expansion-contraction properties of the cross-linked resin, restricting the 
access of the reagents to the interior of the support thus an improved yield was 
obtained when coupling a resin bound iodide with a solution-phase trialkylphenyltin.
(i) PhSnBu3, 
Pd2dba3, LiCI, TFP, 
NMP
Scheme 1.13
The use of a traceless sulfide linker was then investigated and 4-iodobenzylbromide 41 
was immobilised using thiol resin 42. NpSSMpact resin is a photoactive support 
developed by the group. Stille coupling and photolytic cleavage in deuterated 
acetonitrile resulted in a mixture of products (scheme 1.14) which was analysed by 1H 
NMR.
When the conditions optimised using the Rink amide resin were used in the Stille 
coupling with the sulfur linker system, only a very small amount of the corresponding 
biaryls 43 and 44 were isolated (table 1.1). In addition to the expected biaryls, 
unreacted aryl iodide 46 and trifurylphosphine sulfide 45 were produced (scheme 
1.14). The production of this sulfide by product was suppressed by reducing the 
number of equivalents of TFP used (table 1.1). It was found that much higher 
quantities of palladium catalyst and trialkylphenylstannane were needed with the sulfur 
linker system. It was proposed that this was due to chelation of the palladium catalyst 
to unreacted thiol on the resin.
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CM 
X
* 
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f T i
T
f T l
43 44
0.
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o
(i) PhSnMe3 or PhSnBu3 
Pd2dba3, LiCI, TFP, NMP
(ii) 350 nm light, MeCN-d3
45 46
Scheme 1.14
Adjusting the number of equivalents of each of the various reagents (entry 6, table 
1.1) gave a moderate yield of the desired product 43 (27 %).
Entry PhSnR3,
equiv
TFP,
equiv
Pd2dba3,
equiv
LiCI,
equiv
43 44
Equiv
45 46
% yield 
of 43
1 CH3, 1.5 0.21 0.11 1.4 1 0.25 1.67 0.29 3
2 CH3i 2.9 0.43 0.23 1.4 1 0.20 0.57 0 10
3 CH3, 2.9 0.12 0.21 1.4 1 0.7 0 0 4.5
4 CH3, 4.9 0.22 0.29 2.6 1 0.1 0.12 0 10
5 Butyl, 4.3 0.23 0.28 2.8 1 0.7 <0.05 0 3
6 CH3, 12 0.18 0.23 2.0 1 0.1 0 0 27
Table 1.1
The compatibility of a sulfur linker with Suzuki and Sonogashira cross coupling 
conditions has been reported by the group of Legraverand in a solid-phase synthesis of 
2,6,9-trisubstituted purines (scheme 1.15).19 The route was first validated in solution- 
phase studies employing benzyl thiol as a model for a Merrifield-derived thiol resin. 6- 
Chloro-2-iodo-9-/sopropylpurine 47 was stirred together with thiol resin 48 and 
potassium tert-butoxide to give the immobilised purine 49. Sonogashira coupling with a 
stoichiometric quantity of PdCI2(dppe) and Cul gave the 6-alkynyl derivative 50. 
Oxidative activation of the link with mCPBA followed by displacement with 4-methoxy 
benzylamine 51 gave the trisubstituted purine 52 in a 25 % yield after 4 steps. The 
conditions employed for the Sonogashira coupling on the solid-phase are different to 
those optimised in solution. The solution-phase route used (PPh3)2PdCI2 as the
stoichiometric catalyst and NEt3 as the base however when these conditions were 
transferred to solid-phase no reaction occurred. The use of a stoichiometric amount of 
palladium is an obvious disadvantage of this route. The need for a greater quantity of 
palladium may be due to chelation from remaining free thiol sites after immobilisation of 
47. This would not have caused any problems in the solution-phase optimisation of the 
route since purification would have been carried out following each reaction.
Q t  48
 ►
KOf-Bu, DMF 
80 °C
47
NH
MeO'
HO'
25 % (4 steps)
49
HO-^— = = — H
PdCI2(dppe) (1.1 eq.), 
Cul (2.2 eq.), DIEA, 
80 °C
HO'
OMe
Scheme 1.15
The Suzuki reaction of 49 was less successful. Treatment of the resin bound 2- 
iodopurine 49 with 4-methoxyphenyl boronic acid and 50 mol % of Pd(PPh3)4 followed 
by oxidation and displacement with 51 gave only 10 % of the cleaved product 53. The 
low yield was attributed to steric crowding and catalyst destruction through 
“irreversible” coordination of palladium to purine N-7 and the sulfur atom at position 6.
Pd(PPh3)4 (0.5 eq.) 
DIEA, DMF 
100 °C IMeO'
49
NH
MeO'
(ii) 51
MeO'
53
10 % (4 steps)
Scheme 1.16
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To confirm that steric crowding was contributing to the low yield, both the Suzuki and 
Sonogashira reactions were investigated using a resin bound purine 54 with a “spacer” 
between the sulfur atom linkage and the resin backbone (Fig. 1.4). The results 
showed an increased yield of the products 52 (64 % with the “spacer”, compared to 25 
% without) and 53 (35 % with the "spacer”, compared to 10 % without). This clearly 
suggests that steric crowding rather than “poisoning” of the palladium due to 
coordination to sulfur was the main problem.
54
Fig. 1.4
A Suzuki coupling-release strategy has been developed by Vanier et al. and used in a 
traceless, solid-phase synthesis of biarylmethanes (scheme 1.17).20 Solution-phase 
studies indicated that acyclic benzyl sulfonium salts should give the best yields of 
biarylmethane products in the Suzuki cross-coupling and attachment to resin was 
therefore carried out through a benzylic bond to an alkyl thiol resin.
X  ArB(OH)2
Scheme 1.17
Benzyl bromide derivative 55 was immobilised using a thiol resin and the sulfur atom 
linkage was activated by alkylation. A Suzuki coupling release was then carried out 
using optimised conditions involving Pd(dppf)2 and K2C 0 3 to give a range of 
biarylmethanes in good yields. Scheme 1.18 shows an illustrative sequence and a 
selection of biarylmethanes synthesised using the approach.
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DIPEA, DMF, 
70 °C
Pd(dppf)CI2,
PhB(OH)2,
k2c o 3,
THF, 60 °C
97%
OMe
OMe CN
42%63% 80%
OH
NO-
24%97%
Scheme 1.18
The versatility of the activation/cleavage sequence was illustrated by the synthesis of 
the biaryl cinnamate derivative 57 (scheme 1.19). Two successive palladium- 
catalysed reactions were carried out: Heck reaction to give the supported cinnamate 56 
followed by the Suzuki coupling-release to give 57 in 57 % yield.
a <^C02Et a
Br
Pd(OAc)2, PPh3, 
K2C 03, DMF 
70 °C
C 02Et
56
(i) Et3Q+BF4-
(ii) PhB(OH)2, 
Pd(dppf)2,
K2C 03, 
THF, 60 °C
'C 02Et
57 57 %
Scheme 1.19
1.3.2 Sulfone linkers
The chemistry of allylic sulfone derivatives has been used by Kurth et al. as the basis 
for a solid-phase synthesis of cyclobutylidenes (scheme 1.20).21
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The allyl sulfone resins 58 were synthesised in 2 steps from commercial polystyrene 
resin, the sulfone being linked directly to the aromatic backbone of the polymer. 
Reaction of the lithiated sulfone with epichlorohydrin gave the supported cyclobutanol 
59. When R1 = H, cleavage with /-PrMgBr gave the cyclobutylidene derivative 60 via 
allylic attack of the Grignard with displacement of the phenyl sulfinate resin. 
Alternatively, the alcohol was derivatised and cleaved using palladium-catalysed allylic 
alkylation with sodium carbanions to give cyclobutylidene derivatives 62. The copper- 
assisted Grignard displacements occurred in poor yield on the solid-phase while the 
palladium-catalysed allylic alkylations were found to be a more efficient method for the 
cleavage of products.
1.3.3 Sulfonamide linkers
An early paper by Ellmann and Backes describes the use of a sulfonamide “safety- 
catch” linker, which was originally developed by Kenner (Fig. 1.5) for peptide 
chemistry, in a synthesis of substituted aryl acetic acid derivatives.22 This report 
assesses the compatibility of the linker with carbon-carbon bond forming reactions 
including enolate alkylation and Suzuki coupling.
O x c.NH2
Fig. 1.5
C T N'
H " '■ _ .N H 2
o o
Kenner's acylsulfonamide linker 
63
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Pentafluorophenyl 4-bromophenyl acetate was immobilised using the sulfonamide resin 
63 to give a supported acyl sulfonamide 64. Alkylation could then be carried out using 
LDA and an alkyl halide (scheme 1.21). Suzuki coupling was then investigated with a 
range of electronically varied aryl boronic acids and alkyl boranes. Linker activation 
was then accomplished by first rinsing the acylsulfonamide 65 with TFA to ensure 
complete protonation, followed by treatment with CH2N2 to alkylate the sulfonamide 
nitrogen. The substituted acylacetic acid derivatives were then cleaved from the 
support by treatment with a nucleophilic amine or water.
c rf6r 5 63, a
Br 4-(DMAP)Pyridine
H
s 'N 
o/xo o
64
LDA, THF 
followed by
Br R1X
a Hs 'N 
6 'b  o
Br
66
(I) TFA 
(ii) CH2N2 
(iii) H20  or amine
alkyl-9-BBN 
or ArB(OH)2
a
0 * 0
Pd(PPh3)4, 
Na2C 0 3, 
THF, 
t  65 °C
R2
65
HO.
Ibuprofen 67
HO
96%
nx
Felbinac 6 8  
93% 91 %
BnHN
CF;
87%
BnHN
OMe
Scheme 1.21
As shown by the excellent yields, hydrolysis cleanly provided carboxylic acid 
derivatives such as ibuprofen 67 and feblinac 6 8 . Cleavage with nucleophilic amines 
such as benzylamine and pyrrolidine gave excellent yields of amides such as 69, 70 
and 71. The Suzuki coupling was very successful and no proto dehalogenation 
products were isolated.
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In another early report, the group of Spear reported the compatibility of a sulfonamide 
linker with Stille and Heck couplings.23 4-lodobenzene sulfonyl chloride 72 was 
immobilised using Rink amide resin (scheme 1.22). Treatment of the supported aryl 
iodide 73 with palladium (II) and methyl acrylate followed by cleavage with TFA gave 
74. A Stille coupling was achieved by treating 73 with 1-(ethoxyvinyl)tributyltin in the 
presence of palladium (0) and triphenylarsine and this gave the 4-acetyl sulfonamide 
75 after cleavage with TFA.
ci
0,0
72
Qt °"s"°
pyridine, N
CH2CI2 h
(i) Pd(OAc)2, NEt3, 
n-Bu4NCI, DMF
(ii) TFA, CH2CI2
x
Bu3S iV 'X >E t
(i) Pd2dba3, triphenylarsine, 
NMP
° wO
I
73
<^CO,Me
(ii) TFA, CH2CI2 H 2 N '  XXc
75 ■
Scheme 1.22
The solid-phase synthesis of indoles facilitated by an activating sulfonamide linker has 
been described by Zhang and co-workers.24 Immobilisation of 2-iodoaniline 76 onto a 
commercially available polystyrene sulfonyl chloride resin 77 gave supported aryl 
iodide 78 (scheme 1.23). Palladium-catalysed Sonogashira coupling under standard 
conditions with Pd(PPh3)2Cl2 and Cul gave an alkyne intermediate which underwent 
cyclisation to give the supported indole 79. The process was facilitated by the electron 
withdrawing nature of the linker which activates the amide nitrogen.
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o - O t - c 76
77
pyridine,
CH2CI2
0 >R - T B A F  
H THF
R-C=CH
78
Pd(PPh3)2CI2, 
Cul, NEt3l 
DMF, 70 °C
Scheme 1.23
The synthesis was also successful when a Merrifield based sulfonamide linker 80 was 
employed. The excellent yields obtained demonstrate that the palladium-mediated sp2- 
sp coupling of the aryl iodide derivatives of 80 with different acetylenes and the 
sulfonamide linker-activated indole cyclisation occur efficiently, in one pot, under 
relatively mild conditions (Fig. 1.6).
MeO.S-PhOH OMe
Bu
94%87%85%90%
Fig. 1.6
Further evidence of the compatibility of this linker system with palladium chemistry is 
shown in the further functionalisation of the supported indole 79 (R = 4-MeC6H4-) 
(scheme 1.24). Treatment of 79 with mercury(ll) acetate and a catalytic amount of 
HCI04 gave the resin bound organomercurial 81. This was coupled with methyl 
acrylate using Pd(OAc) 2 and the substituted indole 82 was isolated in 60 % yield after 
cleavage (scheme 1.24).
HgCI
HOAc, dioxane, NaCI
(i) H2C=CHC02Me, 
Pd(OAc)2
(ii) TBAF, THF
82
60%
Scheme 1.24
A sulfonyl hydrazide link 83 has been used by Porco et al. in a solid-phase “catch and 
release” synthesis of 1,2,3-thiadiazoles utilising a Stille coupling (scheme 1.25).25
V ' \y/ CH2R' (j) ArSnBu3, 
Pd(PPh3)2CI2, 
S— v DMF, 90 °C
NHNH- NHN:
p-Br-C6H4 CH2R'
10 % AcOH.THF, 
50 °C, 4 h
1^1/ oUL/12)
DCE, 60 °C, 5 h ArPS-Ts-NHNH-
87%71 % 93%
Scheme 1.25
Polymer-bound sulfonyl hydrazones 84 generated from ketones and sulfonylhydrazine 
resin 83 were reacted with aryl stannanes using Pd(PPh3)CI2 as a catalyst (10 mol %) 
in DMF. 1,2,3-Thiadiazoles 85 were then formed by treatment with thionyl chloride 
(scheme 1.25). Non-commercially available p-bromophenyl ketones were prepared by 
reacting /V-methoxy-A/-methyl-p-bromobenzamide 87 with Grignard reagents such as n- 
BuMgCI. The reaction mixture was quenched with a macroporous polystyrene-sulfonic 
acid resin (MP-TsOH) to decompose the tetrahedral intermediate. Acetic acid (10 % 
v/v) was added and the ketone solution 8 8  was then directly transferred by cannula into
31
a reaction vessel containing PS-Ts-NHNH2 83 (scheme 1.26). The synthesis is 
described by the authors as a hybrid solution/solid-phase sequence.
.OMe (0 n-BuMgCI 
THF, 0 °C, 3 h
(ii) MP-TsOH Br
PS-TsNHNH2 83, 
10 % AcOH, THF, 
50 °C, 4 h
Scheme 1.26
1.3.4 Sulfonate linkers
The use of an aryl sulfonate link in SPOS and the compatibility of the linker with a wide 
range of reaction conditions was investigated by Reitz and co-workers.26 Resins such 
as 90 were synthesised from the requisite 4-substituted phenethyl alcohols and a 
sulfonyl chloride resin. A number of reaction conditions were then investigated 
depending on the functional group on the aromatic ring (scheme 1.27).
90
! * 0
b
R = CHO - Grignard addition, Wittig, Reductive amination, NaBH4 reduction 
= Br - Suzuki coupling 
= NH2 - amide coupling
91
(i) 4-MePhB(OH)2, Pd(PPh3)4, 
aq. Na2C 0 3, toluene, EtOH,
Br _______ 90 °C, 20 h Et
(ii) Et2NH
Scheme 1.27
32
Good yields were obtained for most transformations with the exception of the Suzuki 
coupling on the aryl bromide substrate 91. Substrate 91 was reacted with 4- 
methylphenyl boronic acid and Pd(PPh3) 4 at 90 °C for 20 h but the product 92 was only 
isolated in 23 % yield after nucleophilic cleavage with diethylamine. The authors state 
that the reaction proceeded very cleanly and the product was isolated in excellent 
purity even though the overall yield was disappointing.
1.3.5 Perfluoroalkyl-sulfonate linkers
Holmes and co-workers have reported the preparation of a perfluoroalkyl-sulfonyl 
(PFS) fluoride resin and its application in the traceless synthesis of arenes using a 
palladium-mediated reductive deoxygenation (scheme 1.28).27
The application of this linker was also extended to a cross-coupling release strategy 
(scheme 1.29).28 Phenols were directly coupled to the electrophilic sulfonyl fluoride 
resin 93 using K2C 0 3 to create a perfluoroalkylsulfonate species 94. Treatment with a 
variety of arylboronic acids in the presence of PdCI2(dppf) and NEt3 in DMF at 80 °C for 
8  h gave the desired biaryl compounds 95 in good yield (scheme 1.29).
Pd(OAc)2, 
dppp, DMFArOH,
F F 
93
Scheme 1.28
R2C6 H4B(OH)2,
PdCI2(dppf), ( I ,
NEt3, DMF R2'
Scheme 1.29
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The generality of the traceless Suzuki cross-coupling release strategy was then 
explored in the synthesis of a small library of biarylamides 99 employing reductive 
amination and acylation steps in the sequence (scheme 1.30). 4-
Hydroxybenzaldehyde was tethered to the PFS support 93 to generate the resin bound 
aldehyde 96. Aldehyde 96 was split into 3 batches which were separately subjected to 
reductive amination with isobutylamine, furfurylamine, and isopropylamine in the 
presence of Na(CN)BH3 and acetic acid. The resulting benzylamines 97 were further 
split and treated with four acid chlorides (benzoyl chloride, p-toluoyl chloride, isobutyryl 
chloride, 2-furoyl chloride) to give the N-acylated products 98. Each product resin was 
then individually cleaved with an arylboronic acid to liberate the biarylamides 99, some 
of which are also shown in scheme 1.30.
F F  9 6  HOAC.THF FA F g 7
N ^ R 2 R3C6H4B(OH)2i
98
R2
77%65% 90%
Scheme 1.30
1.3.6 Selenide linkers
Nicolaou has made use of a palladium-catalysed deallylation strategy to cleave a 
selenium safety-catch linker under mild, specific conditions.29 This strategy has been 
illustrated in the solid-phase semisynthesis of Vancomycin.
The facile oxidation/elimination of the linking selenide group reveals an allylic 
functionality, thus serving as a pro-allyl safety catch linker. Thus compounds with 
acidic functionality 1 0 0  could be loaded onto a selenyl alkyl iodide resin 1 0 1  to give the 
pro-alloc derivative 102 (scheme 1.31). Oxidation with hydrogen peroxide promoted
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1,2-syn elimination to give the terminal alkene 103 and exposure to catalytic amounts 
of Pd(PPh3)4 and a tin hydride reagent returned the starting acid 100. Residual tin was 
detrimental to purification and biological assays so a polymer-bound tin hydride 104 
was used in the deprotection step.
o-Se' 101 0 ~Se
o
HoOo
102
Ox
HO R 
100
n-Buv n-Bu 
Q ^ / Sn H^ 104
Pd(PPh3)4 (cat.)
O s? 'q A °
©O  rl H
O
A ,
o
A *
103
[1 ,2 -syn elimination]
Scheme 1.31
Polymer bound chloroformate resin 105 was synthesised from a selenyl bromide resin 
and was used to immobilise alcohols and amines to give carbonates 106 and 
carbamates 107, respectively (scheme 1.32). Oxidation of the linking selenium atom 
and elimination, followed by palladium catalysed deprotection of the allyl group 
regenerated the alcohol or amine starting material.
o
JJ
O^CI o
(^ - S e ^ ^ ^ O ^ O ' R2R2-OH NEt3, DMAP 1 0 5
1.H 20 2 106
2.104, Pd(PPh3) 4 (cat.)
O
Q -S e ^ ^ ^ O ^ C I  
R3-NH2   NEt3,DMAP 105
*1. H20 2
2.104, Pd(PPh3)4 (cat.)
Scheme 1.32
In Nicolaou’s solid-phase semisynthesis of Vancomycin, the selenium linker strategy 
was used to demonstrate an efficient sequence of deglycosidation and reglycosidation 
reactions leading to Vancomycin (scheme 1.33). Protected Vancomycin derivative 108 
was loaded onto a selenyl resin 1 0 1  via the free carboxylic acid group in the presence
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of CsHC03. Cleavage of the polymer bound derivative 109 with hydrogen peroxide 
followed by tributyltin hydride and Pd(PPh3) 4 regenerated the carboxylic acid 
functionality to give 108.
OTBS .OTBSTBSO-
CbzHN
TBSO-
CbzHNTBSO OTBS ■OTBS
a) CsHC03TBSO,/( TBSO,,,
b) 1. H20 2 
2. Pd(PPh3)4 
n-Bu3SnH
-j-OTBS
OTBS
-7OTBS
OTBSTBSO' TBSO'
Scheme 1.33
Once Nicolaou had established an efficient loading and cleavage strategy, the selenide 
linker was used in a solid-phase semisynthesis of Vancomycin. As shown in scheme 
1.33, the vancomycin derivative 108 was loaded onto the resin 101 to give the 
supported derivative 109. This was then subjected to a number of transformations on 
the solid-support. The disaccharide moiety of 109 was removed under acidic 
conditions and then a glycosidation reaction was carried out to install an alloc protected 
sugar moiety, thus giving 110 (scheme 1.34). The compatibility of the link with 
palladium-catalysed transformations was then demonstrated by removal of the C-2 
alloc group of 110 using tributyltin hydride and catalytic Pd(PPh3)4. The free hydroxyl 
of 1 1 1  was then subjected to glycosidation, followed by cleavage from the support by 
oxidation of the selenide linkage with H20 2 and syn elimination. The solution-phase 
derivative was then transformed into Vancomycin in 3 steps.
36
Scheme 1.34
Nicolaou and co-workers have also illustrated the compatibility of their selenide linker 
with a number of palladium-mediated transformations in the solid-phase synthesis of a 
range of benzopyrans (scheme 1.35) . 30 o-Prenylated phenols 112 were immobilised 
through a cycloloading strategy employing the polystyrene-based selenyl bromide resin 
21 to give benzopyran scaffolds 113 which could be elaborated and subsequently 
cleaved via oxidation of the linking selenium atom and spontaneous syn-elimination.
a
21
SeBr
cycloloading
OH
Se
113
Elaboration
[syn-elimination]
R5 H H Cr
Oxidation
Scheme 1.35
Elaboration was carried out in a number of ways including palladium-catalysed Stille 
coupling of stannane 114 to give the aryl substituted benzopyrans 115 and 116 
(scheme 1.36). Construction of benzofuran 118 was acheived through a 
Sonogashira/Castro-stevens bis coupling strategy. Aryl iodide 117 was coupled with 
TMS-acetylene in the presence of PdCI2 at 50 °C. The resulting alkyne was then
deprotected with TBAF and subsequently coupled to 2-iodophenol using 
Pd(OAc)2(PPh3)2 catalysis.
Br
9
Se n-BuLi  ^
n-Bu3SnCI
Se
114
Pd2dba3,
P(2-furyl)3,
(5 mol %)^
4-RC6H4l
85%
Se H20 2 115
116
Se
117
TMS—C=CH
Tl_. _i R = TMS
t b a f | _ ^ r  = h
PdCI2,
Cul,
(50 mol %)
2-HOC6H4l,
Pd(OAc)2(PPh3)2
Cul,
(50 mol %) 
69%
2 2 118
(Overall yields not quoted)
Scheme 1.36
The Stille coupling of 114 was achieved with a low loading of palladium (0.05 
equivalent) and only 5 equivalents of the aryl iodide. The bis-Sonogashira coupling 
sequence was less efficient and required 0.5 equivalents of palladium and copper 
iodide.
Nicolaou et al. have also illustrated the compatibility of their selenide linker with 
palladium-catalysed Stille cross-coupling in a solid-phase synthesis of an 
unsymmetrical stilbene.31 The route uses the benzopyran scaffolds described in 
scheme 1.36 and uses the Takai iodo olefination of supported aldehyde 119 to install a 
vinyl iodide group. Subsequent Stille coupling with r?-Bu3SnPh and catalytic 
PdCI2(PPh3) 2 gave the resin bound stilbene 1 2 0  which was then cleaved from the resin 
by treatment with hydrogen peroxide to give a good overall yield of the unsymmetrical 
stilbene 121 (scheme 1.37).
38
9
°>eOHC CrCI2, CHI3, Se
THF:dioxane (10:1)
119
n-Bu3SnPh,
PdCl2(Ph3P)2
30 % H20 2, THF
120
41 % (3 steps based on 119)
Scheme 1.37
Horiwake and co workers have employed a selenide linker in the solid-phase synthesis 
of AM-toxin II using a palladium-catalysed deprotection strategy.32 AM-toxins are a 
group of dehydroamino acids (Fig. 1.7) and may show biological activity through a 
Michael acceptor pathway.
Allyl-protected carboxylic acid 123 was prepared in solution by reaction of a protected 
serine derivative 1 2 2  with o-nitro phenyl selenocyanate followed by reduction of the 
nitro group (scheme 1.38). Coupling with succinic anhydride gave the protected 
carboxylic acid 123 which was immobilised by coupling onto commercially available 
glycine-Wang resin with HATU and DIEA. Palladium-catalysed deprotection allowed 
access to the free acid 124 ready for coupling with another solution phase fragment, 
amine 125 (scheme 1.38).
I R = OMe
II R = H
III R = OH
AM-Toxins
Fig. 1.7
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Scheme 1.38
Amine 125 was prepared in solution from L-valine in a number of solution-phase steps 
and coupled with the supported acid 124 (scheme 1.39). Deprotection of the C- 
terminus acid with Pd(PPh3) 4 and dimedone was followed by removal of the Fmoc 
protecting group and cyclisation using pentafluorophenyl diphenylphosphinate (FDPP). 
This gave the supported AM-Toxin precursor 126. Cleavage of the selenide linker with 
concomitant double bond formation was achieved under mild oxidative conditions with 
fert-butylhydrogen peroxide.
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Scheme 1.39
This synthesis shows the compatibility of the selenide linker developed by the group of 
Nakamura with palladium-catalysed deprotection processes. However the efficiency of 
the solid-phase route cannot be assessed as no yield for the product was reported. In 
addition, apart from the key cyclisation step, many of the steps are carried out in 
solution with only a few relatively simple couplings and deprotections used on the 
support.
Further optimisation of the route to dihydropeptides using the selenide linker was 
discussed in a later report by Nakamura et al.33 In this report, some attempts were 
made to address the problems associated with the synthesis of AM-Toxin II.
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In this case the selenide linker was constructed from selenocyanate 127 (scheme 
1.40). The synthetic utility of the linker was demonstrated by the synthesis of a RGD- 
conjugated dehydropeptide 130. The RGD sequence is the common recognition motif 
for the integrin family of receptors, which are involved in cell-cell and cell-matrix 
adhesion. The C-terminal acid in 129 was deprotected by palladium-catalysed 
deallylation and subsequent peptide couplings and protections followed by oxidative 
cleavage gave the RGD-conjugated dehydropeptide 130 in a 77 % yield based on the 
loading of Fmoc protected resin 128.
Finally, Huang and co-workers have illustrated the compatibility of a selenide linker with 
palladium chemistry in the solid-phase synthesis of flavonoids.34 A series of 2- 
hydroxychalcones such as 131 were immobilised and cyclised using selenyl bromide 
resin 21 under Lewis acid conditions. Further derivatisation by palladium-catalysed 
Suzuki couplings with a range of aryl boronic acids was then carried out. Good overall 
yields of product were obtained for the three step sequence (scheme 1.41).
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1.3.7 SUMMARY
The reports in this review clearly illustrate the compatibility of sulfur and selenium 
linkers with palladium-mediated transformations. A number of reactions are commonly 
used on solid-phase including a range of cross-coupling reactions such as Stille, 
Suzuki and Sonogashira reactions. Palladium-catalysed deprotection of acids and 
alcohols has been shown to be an efficient reaction on solid-phase and has been used 
in the solid-phase synthesis of natural products. Some problems with catalyst loading 
and turnover have been highlighted in these reports and this mainly applies to sulfur 
linkers. More equivalents of palladium were required in some cross-couplings and in 
some cases, stoichiometric quantities were used. The presence of free thiol sites on 
the polymer support is though to lead to “poisoning” of palladium catalysts. In addition 
in some cases, it has been suggested that the sulfide or selenide linkages coordinate 
to palladium thus impeding turnover of the catalysts.
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CHAPTER 2: PALLADIUM CATALYSED a-ARYLATIONS OF ESTERS AND AMIDES 
ON SOLID-PHASE
2.1 INTRODUCTION
Solid-phase synthesis remains an important tool for the synthesis of collections of 
small organic molecules.35 ,36 The development of versatile linker designs is important 
for continued advancements in the area. Previous work in our group led to the 
development of a new traceless linker strategy for solid-phase organic synthesis where 
the link to resin is cleaved using samarium(ll) iodide (Sm^ ) . 37-46 We refer to this family 
of linkers as HASC (a-Hetero-Atom-Substituted Carbonyl) linkers. The group originally 
focused on an oxygen-based HASC linker 4 7 ,48 which was used in the synthesis of a 
library of carbonyl compounds (scheme 2.1). A diverse range of amides and ketones 
was synthesised in moderate yields after 4 or 6  steps. y-Butyrolactone 132 was 
immobilised through an oxygen HASC linkage to a polystyrene support. Lewis acid 
catalysed ring-opening of 133 with a variety of secondary amines, followed by 
acetylation or silylation of the resultant alcohols gave protected alcohols 134. Tert- 
butyldiphenylsilyl protected morpholine amides were converted to ketones 135 by 
reaction with Grignard reagents. Cleavage of protected amides 134 and ketones 135 
with Sml2 gave the expected amides 136 and ketones 137 in moderate yields.
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The group have recently begun to explore the considerable potential of sulfur-based 
HASC linkers.49 For example, a-sulfanyl N-aryl acetamides such as 138, attached to 
resin via a sulfur atom, undergo efficient Pummerer cyclisation upon activation of the 
sulfur link by oxidation to the sulfoxide and treatment with TFAA to give supported 
oxindoles 139 (scheme 2.2). The group has shown that neutral, electron-rich and 
electron deficient aromatic systems can be cyclised in this way. The addition of 
BF3 Et20  is necessary for the cyclisation of neutral and electron deficient systems 
(scheme 2 .2 ).
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Scheme 2.2
Modification of the immobilised heterocycles can be carried out and the oxindole 
products can then be tracelessly cleaved from the polymer support using Sml2 and 
DMPU .49 This provides an efficient solid-phase route to libraries of oxindoles. In this 
approach, the linking sulfur atom operates in a multifunctional sense; mediating C-C 
bond formation, in addition to its fundamental role as a link to the support.49
The aim of my project was to further explore the potential of the HASC linker approach 
by assessing the compatibility of the system with common reagent systems and in 
particular palladium catalysis. We were also interested in illustrating the ability of the 
system to access other important heterocyclic systems.
In recent years, the palladium-catalysed a-arylation of a wide range of carbonyl 
compounds has been reported.50-60 The solution-phase methodology has only recently 
reached its full potential with a greater understanding of the full scope, ligand 
requirements and mechanism of the process. One of the aims of the project was to 
adapt palladium-catalysed a-arylation methodology to solid phase synthesis using our 
linker technology.
2.1.1 The intermolecular a-arylation of esters
Hartwig has recently shown that esters and protected amino acids can be effectively a- 
arylated using palladium catalysis.56 The a-arylation of amino acid derivatives 
specifically shows that substrates bearing a-heteroatom substituents are well tolerated.
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Scheme 2.3 shows the a-arylation of N,N-dimethylglycine ethyl ester 140 with A-tert- 
butylbromobenzene using the bulky trialkyl phosphine P(f-Bu)3.
Pd(dba)2 (2  mol%),
I O P(f-Bu) 3 (2 mol %),
m U K3PO4 , toluene, 100° C,
 ►
140
84%
Scheme 2.3
Our proposed solid-phase route to a-aryl esters is outlined in scheme 2.4. A wide 
range of a-haloesters are commercially available and these would be immobilised 
using our standard conditions. The option of alkylation at the point of attachment will 
allow further diversity to be introduced if desired. Subsequent palladium-catalysed a- 
arylation would then allow a wide range of a-aryl carboxylic acid derivatives to be 
prepared
a o ArBr. r \  o Sml2, o
M Pd(dba)2, P(f-Bu)3, V - X  II DMPU, THF Ar X
x - A o r ------------------------------   x v A o r ---Y— "100° C ]Ar cx
Scheme 2.4
a-Aryl carboxylic acids are important structural motifs in several important 
pharmaceuticals (e.g. members of the profen group, ibuprofen, naproxen, fig 2.1). We 
expected that our solid phase approach would allow convenient access to libraries of 
these compounds.
(
Me Me Me
iPT W yoh i fV v *
M e O ^ ^ 0 Ph XJ 0
naproxen flurbiprofen ibuprofen
Fig. 2.1
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2.1.2 The intramolecular a-arylation of amides
Hartwig has recently described the palladium-catalysed synthesis of oxindoles by 
intramolecular amide a-arylation.57 In these studies it has again been shown that the 
reaction conditions are tolerant of a-alkoxy substituents. For example, 
tetrahydrofuranyl amide 142 underwent cyclisation to give spirocyclic oxindole 143 
using Pd(OAc) 2 and PCy3 in an excellent yield (scheme 2.5).
Interestingly, Hartwig found that a a-phenoxy substrate 144 failed to undergo 
cyclisation under similar conditions. We envisaged that adaptation of Hartwig’s 
intramolecular palladium-catalysed amide a-arylation to solid phase using our linker 
technology would allow oxindole libraries to be prepared conveniently. Scheme 2.6 
shows our proposed solid-phase route to oxindoles using the palladium-catalysed a- 
arylation process.
142
Pd(OAc)2 (5 mol %), 
PCy3 (5 mol %),
NaOf-Bu,
1,4-dioxane, 
100°C, 98 %
Scheme 2.5
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ligand, 
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Scheme 2.6
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2.2 PALLADIUM-CATALYSED a-ARYLATION OF AMIDES ON SOLID-PHASE
Initial experimental work concentrated on the solution phase synthesis of model 
substrates for intramolecular palladium-catalysed a-arylations. Two possible solid 
phase hydroxy resin systems were identified (scheme 2.7). Phenol resin 148 has an 
oxygen based phenol linker which was designed within the group and previously used 
in a solid-phase synthesis of ketones and amides.47 A suitable solution-phase model 
for this resin is benzyloxyphenol while benzyl alcohol is a solution-phase model for 
commercially available hydroxymethyl polystyrene resin 145. Preparation of solid- 
supported amides such as 146 and 149 followed by palladium-catalysed a-arylation 
should give access to solid-supported oxindoles 147 and 150 and in principal the 
technology could be used to synthesise a library of such compounds.
Q f^ O H
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145
o r ° ^ A N'R
Pd-catalysed 
a -arylation
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X -r  i
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v KV
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148
O ' " " 0
°jv
Pd-catalysed 
a -arylation
Br
X -f  i
149 150
Scheme 2.7
2.2.1 Solution phase studies using benzyloxyphenol and benzyl alcohol model 
systems
Using benzyloxyphenol as a model for phenol resin 148, reactions were carried out in 
solution to assess the viability of our solid-phase route to oxindoles (scheme 2.8). Two 
routes were investigated. The first involved coupling of benzyloxyphenol with 
ethylbromoacetate to give ester 152 which was then hydrolysed with LiOH in DMF:H20  
to give acid 153 before coupling with 2-bromoaniline to give amide 154. All steps 
occurred in moderate yield. The second route relied on the efficient acylation of 2- 
bromo aniline with bromoacetyl bromide and coupling of the resultant a-bromo amide 
151 with benzyloxyphenol to give the common intermediate amide 154. N-methylation
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of amide 154 was then attempted, but proved difficult. The use of 1.1 equivalents of 
NaH resulted in no N-methylation whilst using 3 equivalents of NaH and 5 equivalents 
of Mel saw methylation a- to the amide carbonyl in addition to the desired alkylation on 
nitrogen.
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We also began to look at the synthesis of a solution phase model for a substrate linked 
through an aliphatic oxygen linker. Reaction of benzyl alcohol with bromoacetic acid 
proceeded in good yield to give acid 155 which was subjected to an EDCI mediated 
amide coupling with 2-bromo aniline (scheme 2.9). Unfortunately this reaction 
returned only starting material.
OH
O -Br
OH
NaH (2.5 eq.), EDCI (1.5 eq.),
THF 155 DMAP (0.1 eq.),
73 % CH2CI2
Scheme 2.9
The problems described above regarding selective N-methylation in the synthesis of 
the solution-phase substrates led us to look at the use of 2-bromo-N-methyl aniline 156 
in the coupling reactions. N-Methylation of 2-bromoaniline was carried out as 
described by Barluenga et al 61 (scheme 2.10). This resulted in 50% yield of N-
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methylated product 156 and 40% recovery of starting material. Modification of 
Barluengas’ procedure by addition of a second 0.5 equivalent portion of n-BuLi/Mel 
after the initial overnight reaction resulted in a yield of 76 % with 10 % recovery of 
starting material.
n-BuLi (0.5 eq.) -40 °C, 
Mel (0.5 eq.) - 60 °C
THF
156
1 addition = 50 %
2 additions = 76 %
Scheme 2.10
Attempts were then made to couple acid 155 directly with 2-bromo-N-methylaniline 156 
(scheme 2.11). This reaction proved to be difficult and a range of conditions were tried 
including various coupling reagents (Fig 2.2) .62,63
EDCI (1.5 eq.), 
DMAP (0.1 eq.),
155 NH
156
157
c r ° r
158
Scheme 2.11
Our attempts to prepare amide 158 are summarised in table 2.1. The most effective 
coupling reagent was found to be BOP-CI (Fig. 2.2) which is known to be useful in 
coupling sterically hindered amino acids, which are difficult or unreactive with 
carbodiimide-based systems.64 These conditions gave amide 158 in a yield of 72 % 
after 4 days (table 2.1). Conversion to the acid chloride 157 was also investigated 
however coupling with the secondary amine again gave disappointing results (scheme 
2.11). Amide 158 showed AB quartets in the 1H NMR spectrum. The source of 
additional chirality from which these signals arise is discussed in section 3.2.4.
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Acid Amine Coupling reagent Base/Additive Time Yield (%)
eq. eq. (eq) (eq.) (h)
1 1.5 EDCI (1.5) DMAP (0.1) 
HOBt (cat.)
72 0
1 1.5 EDCI (1.5) DMAP (0.1) 36 27
1 1.5 EDCI (1.5) - 24 25
1 2.4 BOP-CI 64 (2) NEt3 (6) 96 72
1 1 BOP-CI (1) DIEA (2) 48 12
1 1 BOP-CI (1) NEt3 (2) 48 38
1.2 1 BOP-CI (1.2) DIEA (2) 40 32
1 1.3 PyBOP bb (2) NEt3 (1.5) 24 7
1 1.1 HATU bb(1) NMM (2.2) 24 0
1 1 HATU (1) DIEA (3) 48 18
Table 2.1
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Fig. 2.2
With a relatively effective route to solution-phase model substrate 158 now established 
we moved on to examine the cyclisation reaction.
2.2.3 Preliminary attempts at palladium-catalysed intramolecular a-arylation
My initial work focused on the reproduction of results reported by Hartwig to gain 
experience carrying out palladium-catalysed a-arylations.54 Coupling of 
cyclohexylcarbonyl chloride with 2-bromo-N-methyl aniline 156 gave test amide 159 in 
good yield (scheme 2 .1 2 ).
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Scheme 2.12
Preliminary attempts at cyclising substrate 159 by palladium-catalysed a-arylation 
using Pd(OAc) 2 and PCy3 as described by Hartwig 54 were unsuccessful (scheme
2.13).
Hartwig found PCy3 to be the most general ligand for the cyclisations to give oxindoles. 
In particular, he reported that the cyclisation of bromoanilide 159 under these 
conditions gave a 93 % yield of oxindole 160 after 3 h at 50 °C. PCy3 was obtained 
from Aldrich and made up into a standard solution in fresh, degassed 1,4-dioxane 
under an inert atmosphere. After two unsuccessful cyclisation attempts the ligand 
solution was subjected to 31P NMR analysis which showed a significant amount of 
tricyclohexylphosphine oxide was present. Assuming the preparation of the solution 
allowed no air into the vessel it was concluded that the commercial PCy3 obtained was 
impure. Procedures to reduce the oxide back to the required phosphine generally use 
harsh conditions, and it was felt that tricyclohexylphosphine may not be stable enough 
to allow us the flexibility to optimise reaction conditions when transferring to solid 
phase.
Imidazolinium salts SIPr-C1161 and SIPr-BF4 162 (Fig. 2.3) are precursors of carbene 
ligands and have been identified by Hartwig as excellent ligands for the synthesis of 
oxindoles using the palladium-catalysed intramolecular a-arylation process. Reaction 
times using these ligands are comparable to those using PCy3 as a ligand and 
reactions can be carried out at 50 °C .54
Pd(OAc)2 (5 mol %), 
PCy3 (5 mol %),
NaOf-Bu (1.5 eq.), 
1,4-dioxane
O
159 160
Scheme 2.13
SIPr-CI
161
SIPr-BF4
162
Fig. 2.3
Carbene ligands derived from the imidazolinium salts 161 and 162 have significant 
advantages over PCy3. They are stable to air and therefore can be made in bulk and 
stored for later use, allowing convenient use in library synthesis. They also have 
improved thermal stability allowing elevated temperatures to be used if required.67 
Nucleophilic carbene ligands derived from the salts SIPr-C1161 and SIPr-BF4 162 (Fig. 
2.3) have also been shown to have a stabilising effect resulting in the metal complex 
having increased resistance to ligand dissociation. We believed these advantages 
would allow us greater flexibility when optimising reaction conditions to run on solid 
phase.
2.2.4 Synthesis of carbene ligand precursors SIPr-BF4 and SIPr-CI
The carbene precursors SIPr-CI 161 and SIPr-BF4 162 were prepared from 2,6- 
diisopropyl aniline using the procedure described by Arduengo.68 2,6-Diisopropyl 
aniline 163 was reacted with glyoxal to form the bis imine 164 in good yield (scheme
2.14). This was followed by reduction to the diamine 165 and reaction with 
triethylorthoformate using the appropriate ammonium salt to form the imidazolinium 
salts SIPr-BF4162 and SIPr-C1161. SIPr-C1161 was synthesised in 42 % overall yield 
and SIPr-BF4 162 in 14 % overall yield. The disappointing yield obtained for SIPr-BF4 
is probably due to the quality of the NH4BF4 used in the salt forming step. Since the 
formation of chloride salt was more efficient a counter ion exchange experiment was 
carried out using AgBF4 and this proceeded to give SIPr-BF4 162 in moderate yield. 
The SIPr-BF4 salt was recrystallised and a crystal structure obtained to unambiguously 
confirm the structure (Fig. 2.4).
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Fig. 2.4 : X-ray structure of 162
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2.2.5 Palladium-catalysed a- arylation of test substrate using carbene ligands
Immediately after preparation of the carbene precursors SIPr-C1161 and SIPr-BF4 162 
the palladium-catalysed a-arylation of the test substrate 159 was carried out (scheme
2.15). This gave the expected product 160 in 58 % yield with some recovery of starting 
material.
Subsequent attempts to replicate this result using the same conditions were however 
unsuccessful, giving only quantitative recovery of starting material. The reaction 
conditions were screened in order to discover the reason behind this frustrating 
observation. Several different batches of NaOf-Bu and Pd(OAc)2 were used in the 
reaction. Fresh NaOf-Bu was prepared from sodium and f-BuOH and dried prior to 
each use. The dioxane still was refreshed and Pd(dba)2 was tried as an alternative 
palladium source. Surprisingly, none of these changes led to successful a-arylation to 
give 160.
Quantitative recovery of starting material with absolutely no product formation 
suggested that the ligand and Pd(OAc)2 were not combining to form the active 
complex. It was decided to attempt to isolate the active carbene species prior to 
reaction instead of in situ formation with NaOf-Bu. This would eliminate one possible 
reason for the failure of the reaction. Following a documented procedure68 the SIPr-CI 
salt 161 was treated with KH in THF in order to generate the active carbene species 
(scheme 2.16).
Pd(OAc)2 (5 mol %), 
SIPr-BF4 162 (5 mol %j,
NaOf-Bu (1.5 eq.),
1,4-dioxane 
58%
Scheme 2.15
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This gave an unexpected result. The product obtained was formamide 166, 
presumably resulting from hydrolysis of the salt. The identity of 166 was confirmed by 
X-ray crystallographic analysis (Fig. 2.5). The procedure was repeated with the SlPr- 
BF4 salt and the same product was obtained.
O
Fig. 2.5 : X-ray structure of 166.
It was therefore concluded that both imidazolinium salts SIPr-CI 161 and SIPr-BF4 162 
are hygroscopic. Water present in the salt appeared to be causing hydrolysis to the 
formamide 166 upon treatment with NaOf-Bu, preventing formation of the active 
complex. Various strategies for drying the salt were attempted. The carbene precursor
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SIPr-BF4 was initially dried under high vacuum at 100 °C for 24 h and stored over silica 
gel in a dessicator and the reaction repeated. Product was obtained in 10 % yield 
together with starting material. The salt was then dissolved in dioxane prior to reaction 
and stirred with powdered molecular sieves but salt “dried” in this way resulted in no 
product formation in the reaction and quantitative recovery of starting material.
Another test substrate 167 was prepared and this substrate was subjected to the a- 
arylation conditions. Hartwig obtained 92 % yield of 168 after 3 h using 5 mol % 
Pd(OAc)2 and PCy3 (scheme 2.17).
or*Brn  Pd(OAc)2 (15 mol %),SIPr-BF4 162 (15 mol %),
NaOf-Bu (1.5 eq.),
1,4-dioxane \
10-30 %
167 168
Scheme 2.17
A suspension of NaOf-Bu was prepared by the reaction of Na and f-BuOH in dioxane. 
Initial attempts using SIPr-BF4 salt 162 dried under high vacuum at 100°C for 2 h and 
NaOf-Bu suspension gave 10 % yield of the oxindole 168 together with starting 
material. Different methods for drying the SiPr-BF4 salt were screened in combination 
with the other parameters of the reaction. Drying of the desired quantity of ligand in a 
Kugelrohr oven at 150°C and 0.01-0.5 mmHg overnight prior to the reaction proved to 
be the most effective method and this, combined with the use of freshly prepared 
NaOf-Bu resulted in 30 % conversion to oxindole 168 by 1H NMR. The combination of 
dry ligand and commercial NaOf-Bu resulted in no reaction indicating that the purity of 
the base is also important.
In light of our difficulties cyclising model substrates from Hartwig’s studies we were not 
surprised to find that attempts to cyclise solution-phase model substrate 158, required 
for our solid-phase approach, were unsuccessful (scheme 2.18).
Pd(OAc)2 (5 mol %), 
SIPr-BF4 (5 mol %),
NaOf-Bu,
1,4-dioxane 
50°C, 0 %
158
Scheme 2.18
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2.3 PALLADIUM CATALYSED a-ARYLATION OF ESTERS
Concerned at our inability to reproduce Hartwig’s results, we chose next to investigate 
the palladium-catalysed intermolecular a-arylation of esters. Initial work concentrated 
on the reproduction of the results reported by Hartwig to demonstrate that the catalytic 
process would work in our hands. Hartwig reported the a-arylation of N,N- 
dimethylglycine ethyl ester using Pd(dba)2 and P(f-Bu)3 in 84 % yield (see scheme
2.3). Our initial attempt gave a promising result, and we obtained 141 in 40 % isolated 
yield (scheme 2.19).
- N ^ X OEt
140
Pd(dba)2 ( 1 0  mol %) 
P(f-Bu)3 (10 % soln in hexane) 
K3P04i toluene, 100°C
40%
Scheme 2.19
With some confidence in the catalyst system, O-linked model substrate ester 169 was 
prepared by acid catalysed esterification of the corresponding acid 155 (Scheme 2.20).
9 3%v/v H2S04i
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toluene, reflux 
91 %
Pd(dba)2 ,P(f-Bu)3, 
KHMDS, toluene, 
100°C _°^ ^ O E t
169
OEt
Scheme 2.20
Unfortunately, all attempts to carry out the intermolecular a-arylation of 169 were 
unsuccessful. K 3 P O 4  and KHMDS were tried as bases and the amount of palladium 
was increased to 20 mol %. However, in all cases no conversion to the desired 
product was observed.
Whilst we were working on the project Hartwig described the a-arylation of TMS ketene 
acetals 170 as a milder method for accessing a-aryl esters 171 ,69 Excellent yields
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were reported on a variety of substrates including substrates bearing a-heteroatom 
substituents (scheme 2.21).
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Scheme 2.21
TMS ketene acetals 170 were treated with an aryl bromide, catalytic Pd(dba)2 and P(t- 
Bu)3 together with ZnF2 in DMF. Good yields of products were obtained and the 
reaction tolerates a wide range of esters (t-Bu 172, Et 173, Me 174) as well as electron 
rich and electron deficient aryl bromides. The reaction also tolerates the presence of 
the benzyloxy group in the a-position which could provide a useful link in a solid-phase 
route. Unfortunately, we had insufficient time to study this approach in detail. In 
principle however, the a-arylation of TMS ketene acetals should be compatible with our 
linker system and thus provide a solid-phase route to a-aryl esters.
2.4 SUMMARY
We have prepared amide 158 as a model for cyclisation substrates immobilised using a 
hydroxyl methyl polystyrene support. Unfortunately attempts to cyclise these 
compounds using conditions described by Hartwig were unsuccessful. Our attempts to 
reproduce the intramolecular palladium-catalysed a-arylation from Hartwig’s publication 
have met with limited success, using both phosphine and N-heterocyclic carbene 
ligand systems. The analogous intermolecular processes were also investigated using 
model substrate 169 but again no coupling was observed. This has led us to conclude 
that the palladium-catalysed a-arylation of supported enolates is unlikely to be a viable 
process on solid-phase using our linker system. The use of immobilised TMS ketene 
acetals69 may provide a solution to this problem.
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CHAPTER 3: DEVELOPMENT OF A SOLID-PHASE ROUTE TO 
TETRAHYDROQUINOLONES
3.1 INTRODUCTION
We recognised that systems such as 176 that had proved ineffective in our 
intramolecular palladium-catalysed a-arylation studies might allow access to other 
heterocycle frameworks (Fig. 3.1). We also remained interested in assessing the 
compatibility of HASC linkers with palladium catalysis.
c rxA
X = 0 , 158 
X = S, 175
176
Fig. 3.1
We chose to develop an approach to tetrahydroquinolones using a sulfur HASC linker, 
and a palladium-catalysed Heck reaction of the aryl bromide group in 176.
The tetrahydroquinolone framework 177 can be found in a number of natural and non­
natural biologically active compounds and is therefore an attractive scaffold for 
synthesis (Fig. 3.2). The group of compounds with the general structure 178 have 
been investigated as they are known to be antagonists of the 5-HT3 receptor. 
Evidence has been presented for the therapeutic roles of 5-HT3 antagonists in 
migraine, schizophrenia, anxiety and chemotherapy-induced emesis.70 Pinolinone 179 
is a natural product isolated from the shrub Boronia p/nnafa.71 Compound 180 has 
been evaluated as a HIV-1 reverse transcriptase inhibitor.72 N-Methyl-D-aspartate 
(NMDA) receptor antagonists such as 181 may have potential as treatments for stroke, 
epilepsy and Alzheimers disease.73 A number of related compounds were synthesised 
by a group at Merck in a small solution-phase library synthesis. The approach was 
however not combinatorial and each derivative required different conditions for 
synthesis. To the best of our knowledge there are no reports in the literature of a solid- 
phase approach to the tetrahydroquinolone structural motif.
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Our proposed, solid-phase approach to tetrahydroquinolones 182 is outlined in 
scheme 3.1. Heck reactions of immobilised aryl halides 185 should allow access to 
alkene intermediates 184. Base-induced Michael cyclisation should then furnish the 
tetrahydroquinolone core 183 which can be modified on the solid-support and then 
cleaved to give a library of heterocycles with the general structure 182. The nature of 
the linker will allow the cyclisation to be carried out using a variety of conditions 
according to the oxidation state of sulfur. This should give us greater flexibility when 
searching for reaction conditions compatible with the functionality present in the 
substrates.
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Scheme 3.1
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3.2 SO LUTIO N-PHASE STUDIES
Solution-phase studies were carried out to evaluate the reactions in the planned route. 
Benzyl alcohol and benzyl thiol were used as suitable models for the resin. As 
illustrated in chapter 2, we initially concentrated on ether HASC linkages and then 
switched to more versatile sulfur linkages which allowed us to tune the reactivity by 
adjusting the oxidation state of the sulfur atom.
3.2.1 Preparation of solution-phase model substrates
Our route to tetrahydroquinolones began from bromoaryl acetamide substrates 158 
and 175. The palladium-catalysed Heck reactions of a range of S and O-linked model 
substrates with methyl and tert-butyl acrylate was investigated74 and the reaction 
conditions were optimised (Table 3.1).
An increase in conversion and yield was obtained by carrying out the reactions in a 
one-piece condensor flask to minimise loss of methyl acrylate. Using a greater excess 
of methyl acrylate also increased the conversion. The use of microwave heating was 
also investigated (entry 6, Table 3.1). Using conventional heating S-substrates were 
less efficient than the O-analogues, reaction times were doubled to 48 h. Microwave 
heating allowed the reaction time to be reduced from 48 h to 7 h and increased the 
conversion. Microwave heating has recently received a great deal of attention75'79, 
particularly with reference to organo-palladium reactions. Although there is some 
disagreement over the reason for the greatly reduced heating times and increased 
catalyst turnover experienced with microwave heating76, 77, there is a great deal of 
evidence showing that it is a useful process for improving sluggish palladium-catalysed 
cross couplings.
o o
BnX^AN.R' ^ C 0 2R BnX^X^R'
30 mol % Pd(OAc)2, P(o-tol)3, 
NEt3, o-xylene,100 °C
X = O, R' = Me 158 
X = S, R' = Me 175
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Entry Product X R R’ Rxn time Acrylate Conv. Yield.
h Eq. % %
1 186 O Me Me 24 1.1 64 83
2 187 O Me H 24 1.1 55 82
3 188 S Me Me 48 1.1 46 34
4 188 Sa Me Me 48 2 56 86
5 188 Sa Me Me 48 5 80 96
6 189 Sb f-Bu Me 7 6 88 100
Yields based upon conversion, a thermal heating with a fitted condenser flask, b microwave heating in 
sealed vial.
Table 3.1
Few examples of the Heck reactions of N-2-halophenylamides and carbamates have 
been reported. Our conditions were adapted from those reported by de Mayo.74 He 
treated bromoanilide 190 with acrylonitrile using Pd(OAc)2 and P(o-tol)3 and isolated 
the product 191 in a moderate yield (scheme 3.2). De Mayo’s work clearly illustrates 
the sluggish nature of Heck reactions on these substrates using conventional heating.
o
Pd(OAc)z (5 mol %),
^ CN pJ°±°»±e ™L%±  T  .  ,
(1 eq.) NEt3’ xylene,
v M ; 100 °C, 4 h L  J
30 %
CN
190 191
Scheme 3.2
3.2.2 A solution-phase route to tetrahydroquinolones with cyclisation at the sulfide 
oxidation state
Continuing our proposed route, treatment of sulfide 188 with NaH gave the desired 
tetrahydroquinolone product 192 in moderate yield (scheme 3.3). However, acid 193 
was also isolated as a major-product in 67 % yield after acidification and extraction of 
the aqueous phase.
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LiOH, DMF:H20  (4:1)
quant.
.SBn+
193
NaH, THF SBn
192188
33 % 67 %
Scheme 3.3
This suggests almost 100 % conversion to the tetrahydroquinolone ester 192 but 
highlights problems with the stability of the methyl ester. Several strategies to minimise 
the hydrolysis of ester 192 were explored. Quenching with anhydrous methanol 
decreased the amount of acid but did not suppress hydrolysis completely and 
conversely quenching with water did not lead to complete hydrolysis. Hydrolysis of 
ester 192 to acid 193 could be achieved quantitatively by treatment with LiOH (scheme
3.3).
The prevention of hydrolysis by the use of a hindered ester was explored using the tert- 
butyl ester 189. Cyclisation was attempted using NaH and this gave cyclised ester 194 
(69 %) and acid 193 (16 %). Again quenching with f-BuOH or with water did not lead to 
complete formation of either the ester 194 or acid 193. Hydrolysis of the ester was 
possible by treatment of 194 with a 1:1 (v/v) mixture of TFA and CH2CI2 and this 
proceeded in moderate yield (scheme 3.4).
TFA:CH2CI2 (1:1)
54%
SBnNaH (3 eq.), THF
69%
SBn
+
16%
189
Scheme 3.4
To investigate the synthetic utility of acid 193 as a means of introducing diversity, we 
investigated the coupling of acid 193 with amines such as morpholine. EDCI/HOBt
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coupling gave the expected morpholine amide 195 in moderate, unoptimised yield 
(scheme 3.5). Direct access to amide 195 from ester 194 by reaction with MesAI and 
morpholine was investigated however this reaction was unsuccessful. The preparation 
of amide 195 illustrates the possibility of the introduction of a further point of diversity 
on the heterocyclic framework.
It was hoped that the use of a bulkier base such as LDA in the cyclisation might limit 
the amount of hydrolysis but similar results were obtained even when the reaction was 
cooled. Cyclisation of 189 with LDA gave yields of ester 194 ranging from 60 % (0 °C) 
to 69 % (-20 °C).
The model cleavage of the sulfide linkage of the tetrahydroquinolone was then 
attempted for the first time. We were pleased to find that treatment of 194 with an 
excess of Sml2 and an additive LiCI, gave tetrahydroquinolone 196 in a moderate, 
unoptimised yield (scheme 3.6).
The effect of LiCI on the reactivity of Sml2 in THF has been investigated by Flowers 
and co-workers.80 The oxidation potential of Sml2 is -1.33 V whereas the oxidation 
potential of Sml2 containing 12 or more equivalents of LiCI is -2.11 V. Thus, the 
Sml2/LiCI reagent system is a more powerful reducing agent.
■o
(i) Me3AI, 
SBn toluene
f-pnn„r.
■o
SBn
51 %
193 195 194
Scheme 3.5
52%
Unoptimised
194 196
Scheme 3.6
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3.2.3 A solution-phase route to tetrahydroquinolones with cyclisation at the sulfone 
oxidation state
Cyclisation of sulfone substrates was expected to proceed under milder conditions and 
we felt this might limit hydrolysis of the ester group.
o
BnS^X
188 R = Me
189 R= t-Bu
C 02R
a mCPBA, 
(K2C 03), 
c h 2ci2^
b oxone 
DMF:H20  
(4:1)
Bn
c o 2r
k2c o 3,
DMF
197 R = Me (a 54 %, b 55 %)
198 R= f-Bu (a 71 %, b 90 %)
199 R = Me (46 %)
200 R= f-Bu (99 %)
Scheme 3.7
Oxidation of conjugated esters 188 and 189 proceeded smoothly with both mCPBA 
and Oxone (scheme 3.7). Yields were higher for the tert-butyl ester but longer reaction 
times and the use of more equivalents of mCPBA led to some epoxidation of the 
electron deficient alkene. This was minimised by using only 2 equivalents of mCPBA 
together with K2C 0 3 and a reaction time of only 30 min.
Base induced cyclisation to give the dihydroquinolones 199 and 200 proceeded 
smoothly and again better yields were obtained in the terf-butyl series. Acidification of 
the aqueous phases showed no acid present which supported our view that the milder 
conditions would suppress the hydrolysis. X-ray analysis of the ferf-butyl 
dihydroquinolone 200 allowed the anti-relative stereochemistry around the ring to be 
confirmed (Fig. 3.3).
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GFigure 3.3: X-ray structure of 200.
The conditions previously described for the model cleavage of the corresponding 
sulfide compound 194 were also found to successfully cleave the sulfone 200 to give 
196 in moderate yield (scheme 3.8).
Sml2  (3 eq ), 
LiCI (9 eq.), 
THF
57 % 
Unoptimised
FBu0 2C
Scheme 3.8
We next examined the alkylation with allyl bromide as another possible method for the 
introduction of diversity to the heterocyclic framework (scheme 3.9). The alkylation of 
200 proceeded in high yield under mild conditions to give 201 as a single diastereomer.
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.Br
K2 C 0 3, DMF, 60 °C
76 %
Scheme 3.9
X-ray analysis showed that the alkylation of the enolate had occurred from the opposite 
face to the tert-butyl ester “sidechain” (Fig. 3.4).
Fig. 3.4 : X-ray structure of 201.
As the basic conditions for the alkylation were the same as those used in the previous 
cyclisation step, we attempted a one-pot cyclisation, alkylation sequence. a,p- 
Unsaturated ester 198 was treated with excess K2C 0 3 in DMF for 2 h before addition of 
allyl bromide. Unfortunately, only unalkylated heterocycle 200 was obtained. No 
further attempts to carry out such a sequence were made.
Sml2 cleavage of the alkylated heterocycle 201 was attempted using f-BuOH as a bulky 
proton source. It was hoped that the bulky proton source would give rise to some 
selectivity in the delivery of the proton to the intermediate samarium (III) enolate.
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Pleasingly, cleavage proceeded in good yield and a 5:1 ratio of syn.anti products was 
obtained (scheme 3.10)
Sml2, LiCI,
f-BuOH, THF 
79 %
5:1syn.anti
Scheme 3.10
The major diastereomer 202 could be separated from the mixture and analysis by X- 
ray crystallography showed this to be the expected syn diastereomer resulting from 
protonation of the intermediate Sm(lll) enolate from the opposite face to the bulky ester 
substituent (Fig. 3.5). Cleavage in the presence of MeOH gave a 1:1 mixture of 
diastereomers supporting our hypothesis that the bulk of the proton source influences 
the diastereoselectivity of the cleavage step.
KJ
\J
o
Fig. 3.5 : X-ray structure of 202.
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The introduction of diversity via the parent aniline was next investigated. A number of 
substituted anilines are commercially available and the route was investigated using 
4,6-difluoro aniline. Yields were consistent with those in the unsubstituted series, 
clearly indicating that the route tolerates functionality on the aromatic ring. 
Interestingly, the Heck reaction of 203 proceeded in a better yield than in the 
unsubstituted series, assisted by the electron withdrawing nature of the substituents 
(scheme 3.11).
^^C02f-Bu
Pd(OAc)2 (5 mol %), 
P(o-tol)3 (5 mol %^ , 
NEt3, o-xylene,
100 °C, mw, 7 h 
99%
C 0 2f-Bu
(i) Oxone, 
DMF: H20  (4:1) 
95 % %
(ii) K2C 0 3 DMF 
92%
f-Bu02C
205
Scheme 3.11
Oxidation and cyclisation proceeded with similar yields to those obtained in the 
unsubstituted series and the anti-tetrahydroquinolone 205 was again isolated and the 
relative stereochemistry of the product confirmed by X-ray crystallography (Fig. 3.6).
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Fig. 3.6 : X-ray structure of 205.
Cleavage of the benzyl sulfonyl group using Sml2/LiCI gave the expected product 206 
although the yield of this model reaction was not optimised (scheme 3.12).
Sml2  (3 eq ), 
LiCI (9 eq.), 
THF
45%
Scheme 3.12
3.2.4 Axial chirality in substituted anilides
The 1H NMR spectrum of 158 showed interesting characteristics (fig. 3.7). On face- 
value the spectrum should be simple since each methylene is isolated and the 
methylene protons are enantiotopic.
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J = 11.8 
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Fig. 3.7
However, the spectrum of 158 showed characteristic AB system quartets integrating to 
two protons for both the benzylic CH2 and the CH2 a  to the carbonyl. This indicates 
that there must be another source of chirality in the molecule which is responsible for 
the complexity of the methylene signals. A search of the literature reveals that 
substituted anilides are known to exhibit slow rotation leading to the the existence of 
atropisomers. In 1969 Siddall and Stewart calculated barrier heights for rotation
around the nitrogen-benzene bond for a number of substituted anilides of the type 207.
81
The barrier heights for rotation were calculated by matching the experimental AB 
patterns with calculated patterns; the experimental patterns arose from the non­
equivalent methylene protons of the benzyl group. The calculations show that o-halo 
substituted anilides show barriers to rotation around the C-N bond in the order of 20 
kcal.mol'1.
In a later paper by Simpkins the utility of atropisomeric amides 208 for stereoselective 
synthesis was explored.82 The chiral C-N axis was exploited as a stereocontrolling 
element in enolate alkylations.
o o  o
r 1A n ,CH2Ph I A N- CH2Ph
21.4 kcal.mol' 1 19.8 kcal.mol' 1
Fig. 3.8
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Returning to the compounds synthesised in this thesis, C-N axial chirality is found in a 
number of closely related compounds. It is present in all the N-Me substituted a-bromo 
amides and is greatest when there are two ortho substituents as shown in 212 (fig. 
3.9). a-Bromo amide 210 is also closely related to the substrates analysed by Siddall 
and Stewart. No rotational barrier is observed in the secondary anilide 151.
o o
‘’V ' N H  “ V ' N
s ( I )  j =  1 1 3  
151 209
Br
J =  14.4
O H H 
JV 
N Ph
J=11 .3  ^ J l  
210
J =  15.0
J = 9.2
Fig. 3.9
When Br is substituted by BnS or BnO the chiral C-N axis also affects the benzylic 
methylene signals.
Ph
J =  11.8 
H H
A
158
V y
J = 14.9 L ] l
Br
Ph
J =  13.3 
H H
X
175
vy
J =  13.2
Br
Ph-
203
J =  14.7
Fig. 3.10
A similar effect is seen in the 1H NMR of a, (3-unsaturated esters 186 and 188 but not 
in NH compound 187 (fig. 3.11).
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3.3 SOLID-PHASE SYNTHESIS
Satisfied that the solid-phase approach to tetrahydroquinolones using our sulfur linker 
was feasible, we moved from solution-phase model studies to work on polymer 
support.
3.3.1 Developing a solid-phase synthesis of tetrahydroquinolones
Thiol resin 48 was prepared from commercially available Merrifield resin by first 
preparing the thioacetate and then reducing with LiBH4.39
In order to determine accurate yields of products cleaved from the solid support the 
loading of free SH sites on the resin was first determined. A simple a-bromo amide 
213 was immobilised using the thiol resin 48 and then cleaved using Sml2 (scheme 
3.14). The mass of acetamide 215 obtained allowed the loading to be determined as 
0.54 mmol/g (an average across 3 runs).
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(i) KSCOCH3 
DMF Theoretical 
SH loading 
1.19 mmol/g(ii) UBH4, THF
Merrifield Resin 
L = 1.20 mmol/g
48
O
NEt3l DMF
213
O
Loading of free SH sites 
0.54 mmol/g
Sml2, LiCI, THF
Scheme 3.14
This is comparable to loadings determined previously in the group where the loading of 
free SH sites was determined to be 0.55 mmol/g compared to a theoretical loading of 
1.10 mmol/g.49 The discrepancy between the free SH sites and the theoretical loading 
is probably due to sulfur cross-linking reducing the number of sites available for 
immobilisation of substrates (Fig. 3.12).
Successful immobilisation of a-bromoamide 209 (scheme 3.15) was indicated by the 
presence of a strong amide carbonyl stretch in the IR spectrum at 1660 cm'1 and also 
by diagnostic signals in the Magic Angle Spinning NMR spectrum (Fig. 3.13). MAS 
NMR is a solid-phase NMR technique which can be used to analyse molecules 
immobilised on solid-phase resins. Spinning the swollen sample at the “magic angle” 
minimises the response from nuclei on the resin backbone allowing a clean spectrum 
of the immobilised molecule to be obtained.
Fig. 3.12
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Scheme 3.15
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Fig. 3.13: APT spectrum of 216. Plotted with CH/CH2 positive and qC/CH3 negative
The Heck reaction of 216 with tert-butyl acrylate was carried out using the conditions 
optimised in solution. The reaction time was gradually increased to maximise the 
intensity of the ester stretch observed in the IR spectrum of the product resin 217 
(scheme 3.16).
a
216
^ ^ C 0 2f-Bu
Pd(OAc)2 (10 mol %), 
P(o-tol)3 (10 mol %),
NEt3, o-xylene, 
100 °C, 20 hx2,  
microwave
f-Bu02C
(i) Oxone, 
DMF:H20  (4:1)
(ii) K2C 03, DMF
t- BuO
v =  1660, 1718 cm□ [ v= 1660,1724 cm' 1 |
Scheme 3.16
IR analysis of the product resin 217 after 10 h looked promising with the absorption at 
1718 cm'1 indicating the presence of an a,(3-unsaturated ester group. The ester stretch 
was only slightly less intense than the amide stretch. Unfortunately, after completion of 
the reaction sequence (oxidation/cyclisation), cleavage of this batch of resin using 
Sml2-LiCI, gave only 15 % of product 196 (5 steps from 48) (scheme 3.17).
Scheme 3.17
The isolation of amide byproducts 215 and 219 indicated that the Heck reaction was 
not proceeding to completion on solid-phase. Acetamide 215 most probably arises 
from the reduction of the C-Br bond from either 216 during the palladium-catalysed 
coupling or of 219 with Sml2 after cleavage from the resin. It was clear that we had to 
improve the efficiency of the Heck reaction.
We first turned our attention to the solvent used in the reaction. The swelling volume of 
the resin is an important factor in the efficiency of reactions on solid-phase. Whilst o- 
xylene is the traditional solvent of choice 83-86 for the Heck reaction it produces only 
minimal swelling of Merrifield resin. oXylene is also inefficient as a solvent in 
microwave reactions since it is non-polar and virtually “transparent” to microwaves.79 
Our attention therefore turned to maximising the resin swelling and perhaps maximising 
the microwave activity of our system. A survey of the literature showed that non-polar 
solvents such as toluene and benzene were commonly used in the Heck reaction and
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indeed in many palladium catalysed cross couplings. These solvents also tend to have 
minimal resin swelling volumes so may be incompatible with solid-phase synthesis. 
Some examples of Heck reactions utilising DMF as a solvent have been reported.87 
DMF has excellent resin swelling properties and is also a good solvent for microwave 
reactions. Initially DMF gave poor results and we concentrated on ‘doping’ o-xylene 
with DMF (table 3.2).
0
b"s^ A nX
^Br
O
Pd(OAc) 2 (5 mol %) B S II 
P(o-tol) 3  (5 mol %)
NEt3, 100 °C 1
u
175
solvent, mw
^ x  K s
Entry Product Acrylate Conditions Time (h) isolated yield
1 190 0 o-xylene, thermal 48 39%
2 190 O
^ ^ ^ O f - B u
o-xylene, microwave 7 88%
3 190 O
^ ^ " O f - B u
DMF-o-xylene (3:7) 
microwave
10x2 75%
4 190 O
" ^ ^ O f - B u
DMF, microwave 10x2 90%
5 220 O DMF, microwave 10x2 76 %
Table 3.2
Table 3.2 shows the results obtained from screening a number of solvents and reaction 
conditions. Our studies showed that the use of microwave heating significantly 
reduces the reaction time and increases conversion although reaction times are still 
quite long. A 3:7 mixture of DMF and o-xylene (entry 3) gave good results however 
much longer reaction times were required as well as a retreatment after the first 10 h of 
the reaction. The reaction was repeated with a fresh batch of anhydrous DMF (entry 4) 
and an excellent conversion was obtained. The conditions were applied to the Heck 
reaction of substrate 175 with acryloyl morpholine (entry 5) and this also gave good 
results. Heck reactions with other alkene partners allow another point of diversity to be 
introduced to the heterocyclic framework.
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P(o-tol) 3  (10 mol %),
100 °C, DMF, mw^ . ^ ^ ^ C 0 2f-BiJ
2 x 20 h 217 (f J
v = 1660 cm v= 1660, 1718 cm'1)
Scheme 3.18
The optimised conditions were then transferred onto solid-phase (scheme 3.18) and 
the formation of solid-supported ester 217 was indicated by the presence of an IR 
stretch at 1718 cm'1 and by characteristic signals in the MAS NMR (Fig. 3.14). 
Although this was less helpful than in the case of acetamide 216 it clearly showed the 
presence of the tert-butyl group and two carbonyl groups.
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Fig. 3.14: APT spectrum of 217. Plotted with CH/CH3 positive and qC/CH2 negative.
The use of a different polymer support was also investigated as a way of increasing the 
efficiency of the Heck reaction. JandaJels are insoluble supports that contain a flexible 
THF derived cross linker (Fig. 3.15).88
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Fig. 3.15
JandaJels have been utilised in the synthesis of a number of combinatorial chemistry 
libraries 89-91 and their properties have been extensively studied. A recent study 
showed that diffusion values for solvents and small molecules are 20-30% higher in 
JandaJel compared to Merrifield resin. The results showed that the microenvironments 
of JandaJels are more solution-like than that of Merrifield resins.92 The swelling 
volume of the support is also increased due to the flexibility of the cross-links. It was 
hoped that this would enable a more efficient Heck reaction and increase the 
accessibility of the reacting sites. Our synthetic sequence to tetrahydroquinolones was 
carried out using JandaJel-CI resin and looked to be proceeding smoothly by IR 
spectroscopy. Upon cleavage however, only a low yield of product 196 was obtained. 
Throughout the sequence the resin proved difficult to dry which may also have 
adversely affected the efficiency of the Heck reaction.
Finally, the Heck reaction of sulfone 221 was also investigated (scheme 3.19). It was 
hoped that switching the order of the Heck reaction and oxidation might give rise to a 
more efficient Heck reaction and therefore greater yields for the overall sequence. 
Disappointingly, Heck reaction of 221 gave 198 in a low yield, possibly due to chelation 
of the palladium by the sulfone oxygens hindering catalyst turnover.
Bn'
mCPBAfc
CH2CI2
93%
175
<*xP 0
Bn'
221
^ C 0 2f-Bu 
Pd(OAc)2, P(o-tol)3,
NEt3, DMF,
100 °C, mw,
2  x 1 0  h 
26%
O O O\\r
Bn'
198
C 0 2f-Bu
Scheme 3.19
Having arrived at reasonable conditions for the Heck reaction, we turned our attention 
to the oxidation step. The oxidation of sulfide 217 with oxone also proved to be a 
problem on solid-phase. The inorganic nature of the reagent together with the 
requirement for a water co-solvent appeared to reduce the efficiency of the reaction
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when transferred to solid-phase. Water is required to dissolve the oxone and a 4:1 
mixture of DMF-water is commonly employed. As is typical in many solid-phase 
reactions, excess reagent is used to drive the reaction to completion. We believe that 
insufficient oxone was soluble in the solvent mixture to afford reaction. Addition of 
more water would increase the amount of oxone in solution however it would also 
cause the resin to contract. mCPBA proved to be a suitable alternative however, as 
previously described, the reaction had to be carefully controlled to avoid epoxidation of 
the double bond (scheme 3.20).
(i) mCPBA (2 eq.), 
CH2CI2, 30 mina s^ x
(.buo2c ^ I  <">k2c o 3,d m f
f-Bu02C
217 218
Sml2 (4.5 eq.), 
LiCI (13.5 eq.),
THF
196
27%  
over 5 steps
Scheme 3.20
When these improved conditions were applied in our sequence, an improved yield of 
27 % (5 steps) of product 196 was obtained. Our attention now turned to the solid- 
phase synthesis of a library of tetrahydroquinolones using our sulfur linker system.
3.3.2 A solid-phase synthesis of a library of tetrahydroquinolones
We have utilised the optimised approach described above to synthesise a collection of 
tetrahydroquinolones using a-bromo amide starting materials 151, 209-212 and 222 
(Fig. 3.16).
151 222 X = I 
209 X = Br
210
Fig. 3.16
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The synthesis of these a-bromo amides utilised a range of substituted anilines. The 
secondary anilines 156 and 223-225 were prepared by direct N-alkylation (scheme
3.21).
Compound X R1 R2 Yield%
156 Br H H 76
223 Br F F 79
224 Br H >Pr 6 6
225 I H H 58
Scheme 3.21
The N-benzyl substituted aniline 227 was prepared by reaction of 2-bromoaniline with 
benzoyl chloride to give the amide 226 followed by reduction with LiAIH4 (scheme
3.22).
PhCOCI,
CH2CI2
Br LiAIH4, 94 % over 
2  steps
226 227
Scheme 3.22
The secondary anilines were then reacted with bromoacetyl bromide to give the 
corresponding a-bromoamides 151, 210 and 217-220 (scheme 3.23).
'NH
NEt3, CH2CI2
R2
O
R3-NA ^ Br
Compound X R1 R2 R3 Yield%
151 Br H H H 81
209 Br H H Me 79
2 1 0 Br H H Bn 70
2 1 1 Br 'Pr H Me 75
2 1 2 Br F F Me 90
2 2 2 I H H Me 76
Scheme 3.23
Additional diversity was introduced by Heck reaction with a different olefin and by 
alkylation of an intermediate sulfone prior to cleavage.
f-BuO
Of-Bu
27 % from aryl bromide 209 
35 % from aryl iodide 222a 
196
Of-Bu
31 %' 
230
18%
231
f-BuO’
27%
f-BuO
f-BuO
Of-Bu
12 % b 
233
5 steps, 6 steps.
Fig. 3.16: Library of tetrahydroquinolones.
The expected products were mostly obtained in acceptable yields for 5 and 6 steps on 
solid-phase (Fig. 3.16). The use of an aryl iodide gave improved yields of 196 due to 
more efficient Heck reactions. The nature of the substituent on the nitrogen had little 
effect on the yield of the product obtained and similar yields of product were obtained 
for N-methyl and N-benzyl substituted compounds 196 and 232. Alkylations of 
intermediate sulfones proved to be more difficult than solution models had predicted 
and more forcing conditions were required (scheme 3.24). Alkylation with allyl bromide 
to produce product 228 required the use of Kl and heat (60 °C). Alkylation with prenyl 
bromide was carried out with DBU as an additive.93 Products 228 and 233 were 
obtained with little diastereoselectivity possibly due to residual moisture present in the 
resin acting as an alternative proton source to the added f-BuOH.
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Of-Bu Of-Bu
K2C 03, Kl, 
DMF 
60 °COf-Bu
235
M'O
Of-Bu
Br
234
"'OK2C 0 3 , 
DBU, Kl, 
DMF, 
60 °C
Sml2 (4.5 eq.), 
LiCI (13.5 eq.),
f-BuOH (50 eq.) 
THF
16%  
(6  steps)
Sml2 (4.5 eq.), 
LiCI (13.5 eq.),
f-BuOH (50 eq.) 
THF
Of-Bu
236
12% 
(6  steps)
Scheme 3.24
Access to free NH compounds was possible using the route however the yield was 
poor at approximately 5 % for 5 steps. It may be possible to synthesise NH 
compounds from a-bromo amides bearing a protecting group on nitrogen however we 
had insufficient time to examine this.
Finally, we have also investigated the feasibility of a cyclative cleavage strategy using 
the HASC linker. Treatment of sulfone 237 with Sml2 resulted in cleavage of the sulfur 
linkage and cyclisation to give 230 in a moderate overall yield. This could occur by 
either an anionic or radical mechanism (scheme 3.25).
OSm'
237
230
25%  
(4 steps)
Scheme 3.25
This cyclative-cleavage approach could have exciting possibilities for the construction 
of polycyclic systems on solid-phase.
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3.4 SUMMARY
We have developed an efficient solid-phase synthesis of tetrahydroquinolones. The 
sequence involves a microwave assisted palladium-catalysed Heck reaction which 
allows access to a.B-unsaturated ester intermediates. The oxidation state of the sulfur 
linkage is manipulated to facilitate the Michael cyclisation of a,R-unsaturated ester and 
amide intermediates under mild, basic conditions. Diversity is introduced into the 
library by enolate alkylations, Heck reaction with different acrylates and acrylamides, 
and from the choice of substitution on the starting aniline. Using our approach, we 
have prepared 8 tetrahydroquinolones in acceptable yield and purity, in addition, we 
have illustrated the feasibility of a cyclative-cleavage strategy using Sml2, where 
cleavage of the link is followed by cyclisation to give the heterocyclic product directly. 
Our studies have illustrated the compatibility of sulfur HASC linkers with palladium- 
catalysed transformations and also provided a further illustration of the multi-functional 
roles possible with sulfur linkers.
3.5 FUTURE WORK
The cyclative-cleavage approach discovered in the course of this project could provide 
exciting possibilities for future work. We have shown that samarium enolates or 
radicals can be captured by electron deficient alkenes in an intramolecular fashion 
(scheme 3.25). It may also be possible to extend this chemistry towards an 
intermolecular cleavage-trapping strategy. A general outline is shown in scheme 3.26. 
Treatment of intermediate 238 with Sml2 in the presence of an external electrophile 
should allow the installation of groups a-to the carbonyl.
x
x x
X) S m ,2
N OSm111 
R1 E
X ■o
R1
238
E R1
239
'O
Scheme 3.26
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Scheme 3.27 shows some of the possible substituents that could be installed if 
intermediate 234 was cleaved by Sml2 in the presence of ketone and aldehyde 
electrophiles and illustrates the considerable diversity that could be provided by this 
method.
Of-Bu
1 . split
2 . Sml2
Of-Bu
Of-Bu
1 . split
2 . Sml2
Of-Bu
Of-Bu
1 . split
2. Sml:
Of-Bu
OH
Or
Of-Bu
Scheme 3.27
During the solution-phase studies we were able to achieve some selectivity in the 
cleavage of the alkylated intermediate 201. The use of f-BuOH as a bulky proton 
source gave moderate selectivity for the syn diastereomer of 202. This however did 
not transfer well onto solid-phase. The possibility of accessing single diastereomers 
would greatly increase the potential use of this route in discovery chemistry. Other 
proton sources such as bulkier alcohols or organice acids could be investigated in this 
reaction however the issue of drying the resin must also be overcome (scheme 3.28). 
The lack of selectivity in the solid-phase cleavage of 201 was attributed to water in the 
resin providing an alternative proton source. The drying of the resin could perhaps be 
carried out by placing the resin in a drying chamber under vacuum for an extended 
period of time, prior to the cleavage reaction with Sml2.
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Proton source 
THF
Scheme 3.28
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CHAPTER 4: EXPERIMENTAL SECTION
4.1 GENERAL METHODS.
All experiments were carried out under an atmosphere of nitrogen or argon using 
anhydrous solvents unless otherwise stated. Reactions were carried out using oven- 
dried glassware. THF was distilled from sodium and benzophenone. CH2CI2 was 
distilled from CaH2. NEt3 was distilled from CaH2 and stored over KOH and under 
Ar/N2. Anhydrous o-xylene and DMF was purchased and stored under Ar/N2. 
Reagents were purchased and used without purification unless stated.
Samarium (II) iodide was prepared by the method of Imamoto 94 with the modification 
that the samarium-iodine solution was heated at 60 °C rather than at reflux. Anhydrous 
LiCI was obtained in ampules and stored under nitrogen. LiCI was dried under vacuum 
prior to use.
Column chromatography was carried out using Fischer Matrix silica gel 60. Aluminium 
backed plates, precoated with silica gel 60 (UV254) were used for thin layer 
chromatography and were visualized by UV or staining with alkali KMn04.
1H and 13C NMR spectra were recorded on a Fourier transform spectrometer with 
chemical shift values being reported in ppm relative to residual chloroform (6H. = 7.27 
or 6C = 77.2) as an internal standard unless otherwise stated. NMR signals were 
assigned using DEPT 45, 90 and 135, HMQC and COSY spectra. All coupling 
constants are reported in Hertz (Hz). Mass Spectra were recorded at the University of 
Glasgow and the University of Manchester. ATR IR spectra were recorded on a Bio- 
Rad Merlin Excaliber spectrometer.
Microwave reactions were carried out in a Biotage Initiator, in microwave reactor vials 
sealed with a crimp cap. Variable power was used to ensure the temperature remained 
constant. Vials were equipped with stirrer bars and reactions were stirred throughout 
the heating.
4.1.1 General methods for solid phase reactions
Solid phase reactions were carried out in round bottom flasks and were performed with 
gentle stirring. In some cases reactions were performed in polypropylene bond elute 
cartridges which were placed in a carousel and rotated, such reactions are indicated
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within the experimental. Commercially available Merrifiled resin with a loading of 1.1 
mmol/g [copoly(styrene-1 % DVB), 200-400 mesh] was used. Solvents and soluble 
reagents were removed by high pressure water suction after transferral of the reaction 
suspension into polypropylene bond elute cartridges (25 ml or 50 ml fitted with a 
polyethylene porous disc), using 50 ml solvent/g resin for each wash.
THF used for washing resin was distilled prior to use.
Calculation of the theoretical loading of resins was carried out according to the 
equation:
f-----------------------------------\
S(„O ____  (£)__
(th) ~ S xWt ^ I °(.y)A r r  l (ad d ri)
1000
S(th) -Theoretical substitution 
S(S) - Starting substitution mmol/g 
Wt(add) - g/mol added to resin
Magic Angle Spinning NMR spectra were recorded by the EPSRC solid-state NMR 
facility at the University of Durham.
General washing and drying procedure
The resin was washed with THF (30 ml), THF:H20  (3:1) (3 x 30 ml), THF:H20  (1:1) (3 x 
30 ml), THF:H20  (1:3) (3 x 30 ml), THF (2 x 30 ml), then alternate washings with 
CH2CI2 (3 x 30 ml) and MeOH (3 x 30 ml), finishing with THF ( 2 x 30 ml). The resin 
was then left to dry for 10 min under water pump pressure before being dried for at 
least 6 h under high vacuum.
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2-(4-ferf-Butylphenyl)-2-dimethylamino acetic acid ethyl ester 14156
To a round bottomed flask containing N,N-dimethylglycine ethyl ester (0.16 ml, 1.10 
mmol), and 1-bromo-4-ferf-butylbenzene (0.17 ml, 1.00 mmol) was added P(f-Bu)3 
(0.08 ml, 10 % solution in hexanes, 0.04 mmol), Pd(dba)2 (11.5 mg, 0.02 mmol) and 
K 3 P O 4  (637 mg, 3.00 mmol) followed by toluene (3 ml). The flask was placed in an oil 
bath and stirred at 100 °C overnight. The reaction mixture was filtered through a plug 
of celite and concentrated in vacuo to give the crude product. Purification by flash 
chromatography on silica gel eluting with 1 % NEt^pet ether gave 141 as a yellow oil 
(105 mg, 0.40 mmol, 40 %).
6h (400 MHz, C D C I 3 ) 1.14 (3H, t, J 7.1, OCH2CH3), 1.23 (9H, s, C(CH3)3), 2.28 (6H, s, 
N(CH3)2), 3.76 (1H, s, CH), 4.03-4.17 (2H, m, OChbCHa), 7.28 (4H, s, ArH).
6 c (100 MHz, C D C I 3 )  14.5 (CH3), 31.7 (C(CH3)3), 34.9 (C(CH3)3), 43.9 (N(CH3)2), 61.2 
(CH2), 75.5 (CH), 125.8 (2 x ArCH), 128.7 (2 x ArCH), 133.8 (ArC), 151.6 (ArC), 172.3 
(C=0).
MS (Cl mode) 264.3 (M+ + H, 99 %), 221.3 (6), 190.2 (14), 97.2 (12), 71.1 (22). HRMS 
C i6H26N 02 requires 264.1964 found 264.1965.
2-Bromo-N-(2-bromophenyl)acetamide 151
o
Br
C8H7Br2NO 
Mol Wt: 292.96
To a mixture of 2-bromoaniline (1.00 ml, 9.2 mmol) in CH2CI2 (30 ml) was added NEt3 
(1.55 ml, 11.0 mmol). The mixture was cooled to 0 °C and bromoacetyl bromide (0.96 
ml, 11.0 mmol) was added dropwise with continuous stirring. The mixture was allowed 
to warm to room temperature and stirred for 1 week. The reaction mixture was diluted 
with Et20  (25 ml) and quenched with saturated aqueous NH4CI (10 ml). The organic 
phase was washed with brine, dried (MgS04), filtered and concentrated in vacuo to
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give 2-bromo-N-(2-bromophenyl)acetamide 151 as a dark brown solid (2.16 g, 7.42 
mmol, 81% yield).
6 h (400 MHz, CDCI3) 4.01 (2H, s, Chh), 6.94 (1H, apparent t, J 8.2, ArH), 7.19 (1H, 
apparent t, J 8 .2 , ArH), 7.42 (1H, d, J 8 .2 , ArH), 8.25 (1H, d, J 8 .2 , ArH), 8.73 (1 H, bs, 
NH).
6 c (100 MHz, C D C I 3 ), 30.3 (CH2),114.3 (ArC), 121.9 (ArCH), 126.4 (ArCH), 128.8 
(ArCH), 132.8 (ArCH), 135.4 (ArC-Br), 163.9 (C=0).
MS (El mode) 295 (M *, 81Br x 2, 4 %), 293 (M \ s1Br, 79Br, 6  %), 291 (M*. 79Br x 2, 4%), 
214 (81Br, 24,), 212 (79Br, 24), 173 (81Br, 19), 171 (79Br, 20), 85 (81Br, 64), 83 (79Br, 98) 
HRMS C6H8N 0 79Br2 requires 291.8967 found 291.8973.
o max (ATR, cm'1) 3225, 3030, 1654 (C=0), 1512, 1420, 1285, 1157, 748,653, 531.
4-Benzyloxyphenoxyethylacetate 152 95
C17H180 4 
U  n  M n i  \ a h - o n e
°17n 18v-'4
5 T  Mol. Wt: 286.32 
O
To a solution of 4-benzyloxyphenol (2.00 g, 10.0 mmol), in DMF (50 ml) was added 18- 
crown- 6  (260 mg, 1.00 mmol), ethylbromoacetate (4.43 ml, 40.0 mmol), and K2C 0 3 
(6.91 g, 50 mmol) and the mixture stirred at room temperature for 3 h. The reaction 
was quenched with saturated aqueous NH4CI ( 6  ml), washed with water (15 ml) and 
extracted with 20 % EtOAcPet ether ( 2 x 1 5  ml). The combined organic extracts were 
dried (MgS04), filtered and concentrated in vacuo to give a chalky white solid. The 
crude product was purified by column chromatography on silica gel using 2 0  % ethyl 
acetate: pet ether as eluent to give (4-benzyloxyphenoxy)ethylacetate 152 as a white 
solid (1.42 g, 4.97 mmol, 43%).
6 h (400 MHz, C D C I 3 ), 1.20 (3H, t, J 7.1, CH3), 4.14 (2H, q, J7.1, CFhCHa), 4.60 (2H, s, 
OCH2C=0 ), 4.94 (2H, s, PhCFhO), 6.77-6.85 (4H, m, ArH), 7.23-7.36 (5H, m, ArH).
5c (100 MHz, C D C I 3 )  14.6 (CH3), 61.7 (OCH2CH3), 66.7 (PhCH20), 71.0 (0CH 2C=0),
116.2 (4 x ArCH), 116.3 (ArCH), 127.9 (2 x ArCH), 128.3 (ArCH), 128.9 (ArCH), 137.5 
(ArC), 152.6 (ArC), 154.1 (ArC), 169.6 (C=0).
MS (El mode) 286.2 (M+,25 %), 213.1 (4), 189.1 (10), 91.1 (98), 83.0 (37), 69.1 (7),
47.0 (6 ). HRMS C17Hi80 4 requires 286.1205 found 286.1203.
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(4-Benzyloxyphenoxy)acetic acid 153 95
BnO
Mol. Wt: 258.27
O
LiOH (0.94 g, 22.4 mmol) was added to a solution of (4-benzyloxyphenoxy)ethyl 
acetate 152 (0.80 g, 2.79 mmol) in THF: H20  (20 ml: 5 ml) and heated at 40 °C until 
TLC showed complete hydrolysis. Water (15 mi) was added and the reaction mixture 
extracted with ethyl acetate (2 x 15 ml). The aqueous layer was separated and 
acidified with 2M HCI and extracted with ethyl acetate ( 3 x 1 5  ml). The organic extracts 
were combined, washed, dried (MgS04), filtered and evaporated to give (4- 
benzyloxyphenoxy)acetic acid 153 as a white solid (0.40 g, 1.55 mmol, 56 %) which 
was used without further purification.
5h (400 MHz, C D C I 3 ) 4.55 (2H, s, 0 0 ^ 0 =0 ), 4.95 (2H, s, PhCHP), 6.79-6.86 (4H, m, 
ArH), 7.19-7.35 (5H, m, ArH).
5C (100 MHz, CDCI3) 66.2 (PhCH20), 71.0 (OCH2C=0), 116.3 (ArCH), 116.4 (2 x 
ArCH), 127.8 (2 x ArCH), 128.4 (2 x ArCH), 129.9 (2 x ArCH), 137.4 (ArC), 152.9 
(ArC), 154.0 (ArC), 169.7 (C=0).
MS (El mode) 258.2 (M+, 26 %), 91.1 (98), 83.0 (13). HRMS C15H140 4 requires 
258.0892 found 258.0893.
2-(4-Benzyloxyphenoxy)-N-(2-bromophenyl)acetamide 154
From 4-benzyloxyphenoxyacetic acid 153 and 2-bromoaniline:-
To a solution of (4-benzyloxy)phenoxyacetic acid 153 (200 mg, 0.76 mmol), 2- 
bromoaniline (200 mg, 1.14 mmol) and DMAP (10 mg, 0.08 mmol) in CH2CI2 (2 ml) at 0 
°C was added EDCI (219 mg, 1.14 mmol) in CH2CI2 (4 ml). The reaction was stirred at 
0 °C for 15 min then stirred at room temperature for 48 h. The reaction mixture was 
then washed with 1M HCI (2 x 20 ml), brine (2 x 20 ml) and saturated aqueous 
NaHCQ3 (2 x 20 ml). The organic phase was dried (MgSQ4), filtered and concentrated
C 2iH igBrN 0 3  
Mol. Wt: 412.28
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in vacuo to give the crude product which was recrystallised from pet ether and CH2CI2 
to give 2-(4-benzyloxyphenoxy)-N-(2-bromophenyl)acetamide 154 as gold coloured 
crystals (138 mg, 0.34 mmol, 43 %).
From of 4-benzyloxyphenol and 2-bromo-N-(2-bromophenyl)acetamide 151:-
To a solution of 4-benzyloxyphenol (172 mg, 0.86 mmol) in DMF (30 ml) was added 
18-crown-6 (228 mg, 0.09 mmol), 2-bromo-N-(2-bromophenyl)acetamide 151 (1.00 g, 
3.44 mmol) and K2C 0 3 (594 mg, 4.3 mmol). The reaction mixture was stirred for 24 h 
and quenched with saturated aqueous NH4CI (5 ml) and washed with water (15 ml). 
The aqueous mixture was extracted with 20 % EtOAc/pet ether (2 x 30 ml) and the 
organic phase was dried (MgS04), filtered and concentrated in vacuo to give the crude 
product. The crude solid was recrystallised from pet ether and CH2CI2 to give 2-(4- 
benzyloxyphenoxy)-N-(2-bromophenyl)acetamide 154 as gold coloured crystals (49 
mg, 0.12 mmol, 14 %).
M.p. 138.5-139.5 °C
6h (400 MHz, CDCI3) 4.52 (2H, s, OCFbCO), 4.96 (2H, s, PhCFhO), 6.92-6.95 (4H, m, 
ArH), 7.18 (5H, m, ArH), 7.46-7.49 (2H, m, ArH), 8.36-8.38 (2H, m, ArH), 8.98 (1H, bs, 
NH).
6C (100 MHz, CDCI3) 68.8 (OCH2CO), 71.0 (PhCH20), 114.0 (ArC), 116.3 (2 x ArCH),
116.5 (2 x ArCH), 121.9 (ArCH), 125.9 (ArCH), 127.9 (ArCH), 128.4 (2 x ArCH), 128.8 
(ArCH), 129.0 (2 x ArCH), 132.8 (ArCH), 135.4 (ArC), 137.4 (ArC), 151.7 (ArC), 154.5 
(ArC), 167.0 (C=0).
MS (El mode) 413.2 (M+ , 81Br, 25 %), 411.2 (M+ , 79Br, 24 %), 322.1 (81Br, 3), 320.1 
(79Br, 3), 214.0 (81Br, 4), 212.0 (79Br, 4), 186.0 (81Br, 6), 184.0 (79Br, 5), 91.1 (99). 
HRMS C21H18N 0 379Br requires 411.0470 found 411.0470.
Benzyloxy acetic acid 15596
P h ^ O - V OH C9H10°3
^  Mol. Wt: 166.17
Benzyl alcohol (2.90 ml, 27.7 mmol) was added to a stirred suspension of NaH (1.68 g,
69.4 mmol) in THF at 0 °C (100 ml). After stirring at 0 °C for 30 min, bromoacetic acid 
(3.85 g, 27.7 mmol) was added and the mixture stirred at 0 °C for a further 15 min, 
refluxed for 6 h, and stirred overnight with no further heating. The reaction mixture was 
quenched with methanol (20 ml), concentrated in vacuo and partitioned between Et2Q
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(50 ml) and water (50 ml). The ether layer was washed with water (2 x 50 ml) and the 
combined aqueous extracts acidified to pH 4 with 2M HCI. The acidified aqueous 
extracts were extracted with CH2CI2, dried (MgS04), filtered and concentrated in vacuo 
to give the product benzyloxy acetic acid 155 as an orange oil (3.35 g, 20.2 mmol, 73 
%) which was used without further purification.
6 h (400 MHz, CDCI3) 4.08 (2H, s, O C H ^ O ),  4.62 (2H, s, PhCHy, 7.23-7.32 (5H, m, 
ArH), 10.59 (1H, bs, OH).
6 C (100 MHz, C D C I 3 ) 67.0 (PhCH2), 73.9 (0 ^ 0 = 0 ) ,  128.5 (2 x ArCH), 128.7 (ArCH).
129.0 (2 x ArCH), 136.9 (ArC), 175.1 (C=0).
MS (El mode) 166.1 (M+>31 %), 107.1 (97), 91.1 (100), 79.1 (53), 65.1 (36), 60.1 (29), 
51.0(14).
2-Bromo-N-methyl aniline 156 see general procedure B 61 
2-Benzyloxy-N-(2-bromophenyl)-N-methylacetamide 158
From reaction of benzyloxyacetic acid 155 and 2-bromo-N-methylaniline 156 via the 
acid chloride 157.
Oxalyl chloride (0.32 ml, 3.60 mmol) was added to a solution of benzyloxyacetic acid 
155 (230 mg, 1.20 mmol) in CH2CI2 (5 ml). The reaction mixture was stirred at room 
temperature for 3 h. Concentration of the reaction mixture in vacuo gave 
benzyloxyethanoylchloride 157 as a brown oil (246 mg, 1.33 mmol, 96 %).
6 h (400 MHz, C D C I 3 )  4.40 (2H, s, PhCH2), 4.60 (2H, s, ChhC=0), 7.24-7.33 (5H, m, 
ArH).
6 c (100 MHz, C D C I 3 )  74.0 (PhCH2) 75.2 (CH2C=0), 128.5 (2 x ArCH). 128.8 (ArCH),
129.1 (2 x ArCH), 136.4 (ArC), 172.3 (C=0).
To a solution of 2-bromo-N-methyl aniline 156 (195 mg, 1.05 mmol) and NEt3 (0.22 ml,
1.57 mmol) in CH2CI2 (3 ml) at 0 °C was added benzyloxyethanoyl chloride 157 (232 
mg, 1.26 mmol) in CH2Ci2 (3 ml). The reaction was allowed to warm to room
o
^16^16^^02  
Mol. Wt: 334.21
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temperature and stirred overnight. The reaction mixture was diluted with Et20  (15 ml) 
and quenched by addition of saturated aqueous NH4CI (7 ml). The organic phase was 
washed with brine, dried (MgS04), filtered and concentrated in vacuo to give the crude 
product. Purification by flash chromatography on silica gel eluting with 75 % CH2CI2: 
pet ether gave 2-benzyloxy-N-(2-bromophenyl)-N-methylacetamide 158 as a yellow oil 
(116 mg, 0.35 mmol, 33 %).
From benzyloxyacetic acid 155 and 2-bromo-N-methyl aniline 156 with EDCI
To a solution of benzyloxyacetic acid 155 (100 mg, 0.60 mmol), 2-bromo-N- 
methylaniline 156 (112 mg, 0.60 mmol) and DMAP (7.4 mg, 0.06 mmol) in CH2CI2 (2 
ml) at 0 °C was added EDCI (173 mg, 0.90 mmol) in CH2CI2 (4.5 ml). The reaction was 
stirred at 0 °C for 15 min then stirred at room temperature for 48 h. TLC after this time 
indicated very little reaction and a further portion of 2-bromo-N-methyl aniline 156 (66.0 
mg, 0.30 mmol) was added. TLC after 60 h showed little product formation and a 
further portion of EDCI (173 mg, 0.90 mmol) was added. The reaction was stirred for 2 
weeks. The reaction mixture was washed with 1M HCI ( 3 x 1 0  ml), brine (20 ml) and 
saturated aqueous NaHC03 (3 x 10 ml). The organic phase was dried (MgS04), 
filtered and concentrated in vacuo to give 2-benzyloxy-N-(2-bromophenyl)-N- 
methylacetamide 158 as a yellow oil (67 mg, 0.20 mmol, 27 %) which was used without 
further purification.
From benzyloxyacetic acid 155 and 2-bromo-N-methyl aniline 156 with BOP-CI
BOP-CI (140 mg, 0.55 mmol) was added to a stirred solution of benzyloxyacetic acid 
155 (45.6 mg, 0.27 mmol), 2-bromo-N-methyl aniline 156 (168 mg, 0.90 mmol) and 
NEt3 (0.23 ml, 1.65 mmol) in CH2CI2 (5 ml) at 0 °C. The reaction mixture was stirred at 
0 °C for 0.5 h and then at room temperature for 4 days. The reaction mixture was 
washed with saturated aqueous NaHC03 ( 2 x 5  ml), dried (MgS04), filtered and 
concentrated in vacuo to give the crude product. Flash chromatography on silica gel 
eluting with 5 % EtOAc/ pet ether gave 2-Benzyloxy-N-(2-bromophenyl)-N- 
methylacetamide 158 (67 mg, 0.20 mmol, 72 %) as a pale yellow oil.
5h (400 MHz, CDCI3) 3.16 (3H, s, NCH3), 3.69 (1H, d, AB system, J 14.9, 1H of 
OCHsCO), 3.77 (1H, d, AB system, J 14.9, 1H of OCFkCO), 4 . 4 4  (1H, d, AB system, J
11.8, 1H of PhCFbO), 4.52 (1H, d, AB system, J 11.8, 1H of PhCFhO), 7.15-7.30 (8 H, 
m, ArH), 7.59-8.00 (1H, m, ArH).
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6c (100 MHz, CDCb) 36.3 (NCH3), 68.5 (OCH2CO), 73.6 (PhCH20), 123.6 (ArC), 128.1 
(ArCH), 128.4 (2 x ArCH), 128.7 (ArCH), 129.5 (ArCH), 130.2 (ArCH), 130.5 (ArCH),
134.1 (ArCH), 134.4 (ArCH), 137.9 (ArC), 141.5 (ArC), 169.5 (C=0).
MS (Cl mode) 336.2 (M+ + H, 81Br, 100 %), 334.2 (M+ + H, 79Br, 99 %), 292.1 (81Br, 4),
290.1 (79Br, 4), 148.1 (7), 911 (8 ), 57.1 (99). HRMS C16H17N 0279Br requires 334.0443 
found 334.0438.
o max (ATR, cm'1) 2873, 1676 (C=0), 1583, 1475, 1390, 1331, 1292, 1113, 1053, 1026, 
949, 766.
Cyclohexanecarboxylic acid (2-bromophenyl)methylamide 1 5957
Cyclohexane carbonyl chloride (0.70 ml, 5.20 mmol) was added dropwise to a stirred 
solution of 2-bromo-N-methylaniline 156 (0.803 g, 4.30 mmol) and NEt3 (0.91 ml, 6.40 
mmol) in CH2CI2 (25 ml) and stirred overnight at room temperature. The reaction 
mixture was diluted with Et20  and quenched with saturated aqueous NH4CI (20 ml). 
The organic layer was washed with brine (20 ml), dried (MgS04), filtered and 
concentrated in vacuo to give the crude product. The crude solid was recrystallised 
from pet ether: CH2CI2 to give cyclohexanecarboxylic acid (2-
bromophenyl)methylamide 159 as white crystals (0.871 g, 2.94 mmol, 6 8  %).
M.p. 96-98 °C.
5h (400 MHz, C D C I 3 )  0.85-0.98 (2H, m, CH2), 1.06-1.15 (2H, m, Chk), 1.36-1.71 (6 H, 
m, 3 x Chh), 1.82-1.88 (1H, m, CHC=0), 3.10 (3H, s, CH3), 7.15-7.20 (2H, m, ArH), 
7.31 (1H, m, ArH), 7.62 (1H, d, J 8.4, ArH).
6 c (100 MHz, CDCb) 25.8 (CH2), 25.9 (CH2), 26.0 (CH2), 29.4 (CH2), 30.2 (CH2), 36.2 
(CH3), 42.4 (CHC=0), 124.0 (ArC-N), 129.2 (ArCH), 129.9 (ArCH), 130.9 (ArCH), 134.3 
(ArCH), 143.4 (ArC-Br), 176.7 (C=0).
MS (Cl mode) 298.2 (M* + H, 81Br, 28 %), 296.2 (M*+ H, 78Br, 30 %), 216.2 (11), 57.1 
(99). HRMS C14H19N 0 79Br requires 296.0650 found 296.0648.
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1-Methyl-3-spirocyclohexyloxindole 160 57
Pd(OAc) 2 (1.9 mg, 0.01 mmol), SIPr-BF4 162 (4.1 mg, 0.01 mmol) and NaOf-Bu (24.9 
mg, 0.26 mmol) were combined together in a round-bottomed flask. 1,4-Dioxane (3.1 
ml) was added and the resulting mixture allowed to stir for 1 min before addition of 
cyclohexanecarboxylic acid (2-bromophenyl)methylamide 159 (50.3 mg, 0.17 mmol). 
The flask was heated in an oil bath at 50 °C and stirred for 3.5 h. The reaction mixture 
was poured into saturated aqueous NH4CI (10 ml) and extracted in turn with Et20  (3 x 
10 ml), CH2CI2 (15 ml) and EtOAc (10 ml). The organic extracts were dried, filtered 
and concentrated in vacuo to give the crude product. Purification by flash 
chromatography on silica gel eluting with 15 % EtOAc: pet ether, gave 1-methyl-3- 
spirocyclohexyloxindole 160 as a pale yellow oil (21 mg, 0.10 mmol, 58 %) and 
recovered starting material 159 (18 mg, 0.06 mmol).
6 h (400 MHz, CDCI3) 1.46 (10H, m, 5 x CHs), 3.13 (3H, s, NCH3), 6.77 (1H, d, J 7.7, 
ArH), 6.98 (1H, app t, J 7.7, ArH), 7.21 (1H, app t, J 7.7, ArH), 7.38 (1H, d, J 7.7, ArH). 
5C (100 MHz, CDCI3) 21.6 (2 x CH2), 25.6 (CH2), 26.5 (NCH3), 33.4 (2 x CH2), 47.9 (C),
108.2 (ArCH), 122.3 (ArCH), 124.2 (ArCH), 127.8 (ArCH), 135.8 (ArC), 143.2 (ArC),
181.1 (C=0).
MS (El mode) 215.3 (M+, 55 %), 160.2 (99), 159.2 (19), 147.2 (14), 85.0 (52), 
83.0(87), 47.0 (16). HRMS C14H17NO requires 215.1310 found 215.1311.
Glyoxal-bis-{2,6-diisopropylphenyl)imine 164 68
{. \  C26H36N2
\N / /  Mol. Wt: 376.58
To a solution of 2,6-di/sopropylaniline 163 (15.8 ml, 84 mmol) in n-propanol (60 ml) 
were added glyoxal (4.80 ml of a 40 % w/w aqueous solution, 42 mmol), n-propanol ( 6  
ml) and distilled water (15 ml) and the reaction mixture stirred at 70 °C for 2 h. The 
reaction mixture was cooled to room temperature and the resulting solid filtered and
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washed with a small amount of methanol to give glyoxal-bis-(2 ,6 - 
di/sopropylphenyl)imine 164 as bright yellow needles ( 1 1 . 0  g, 29.2 mmol, 7 0  % ) .
M.p. 92.5 - 94.5.°C
6 h (400 MHz, CDCI3) 1.12 (24H, d, J6.9, 8  x CH3), 2.87 (4H, sept, J 6.9, 4 x CH), 7.09 
(6 H, m, 6  x ArH), 8.03 (2H, s, 2 x N=CH).
6 c (100 MHz, CDCI3) 23.8 ( 8  x CH3), 28.4 (2 x CH), 123.6 (2 x ArCH), 125.5 (4 x 
ArCH), 137.1 (2 x ArC), 138.5 (2 x ArC), 148.4 (2 x ArC), 163.5 (2 x N=CH).
MS (FAB mode) 377.3 (M+ + H, 35 %), 333.2 (98), 188.1 (26), 146.0 (24), 73.7 (28). 
HRMS C26H37N2 requires 377.2957 found 377.2953.
u  max (ATR, cm'1) 3 0 6 2 ,  2 9 6 0 ,  2 8 6 4 ,  2 3 5 9 ,  1 6 2 3  ( C = N ) ,  1 5 8 9 ,  1 4 6 4 ,  1 4 3 5 ,  1 3 8 3 ,  1 3 6 2 ,  
1 3 2 9 ,  1 2 9 0 ,  1 2 5 4 ,  1 1 7 5 .
Anal, calculated C26H36N2: C 82.93; H, 9.64; N, 7.44 %. Found: C, 82.93; H, 9.68; N, 
7.41 %.
N,N-Bis (2,6-di/sopropyl-phenyl)-ethane-1,2-diamine 165 68
NH HN—(\ /> v-'26n40l’2
1 >  Mol. Wt: 380.61
Glyoxal-bis-(2,6-di/sopropylphenyl)imine 164 (11.0 g, 29.2 mmol) was added to a 
stirred suspension of NaBH4 (10.9 g, 29.2 mmol) in MeOH:THF (72 ml: 108 ml) at 0 °C 
and the reaction mixture stirred at room temperature until the suspension turned white, 
indicating complete reduction. The reaction was quenched with saturated aqueous 
NH4CI (90 ml) and extracted with ether (3 x 100 ml). The combined organic extracts 
were washed with water (100 ml), dried (MgS04), filtered and concentrated in vacuo to 
give N.N-bis (2,6-di/sopropyl-phenyl)-ethane-1,2-diamine 165 as a white, crystalline 
solid (10.8 g, 28.5 mmol, 97 % yield).
M.p 94-96 °C.
6 h (400 MHz, CDCI3) 1.18 (24H, d, J 6.9, 8  x CH3), 3.09 (4H, s, 2 x ChhN), 3.28 (4H, 
sept, J 6.9, 4 x CFO, 7.02 (6 H, m, 6  x ArCH).
5c (100 MHz, C D C I 3 )  24.6 (4 x CH3), 28.1 (4 x CH3), 52.7 (2 x CH2N), 124.0 (4 x ArCH),
124.2 (2 x ArCH), 142.9 (2 x ArC), 143.7 (4 x ArC).
MS (El mode) 380.4 (M+, 15 %), 190.2 (97), 160.2 (23). HRMS C26H40N2 requires 
380.3191 found 380.3191.
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Anal, calculated C26H40N2: C 82.05; H, 10.59; N, 7.36 %. Found: C, 81.87; H, 10.70; 
N, 7.47 %.
1,3-Bis(2,6-di/sopropylphenyl)imidazolinium chloride (SIPr-CI) 161 68
D c 27h 39cin2Mol. Wt: 427.06
A mixture of N,N-bis (2,6-di/sopropyl-phenyl)-ethane-1,2-diamine 165 (1.50 g, 5.07 
mmol), N H 4 C I  (0.30 g, 5.59 mmol) and triethylorthoformate (210 ml, 12.7 mmol) were 
stirred together at 110 °C until the reaction mixture solidified. The reaction mixture was 
then cooled to room temperature before isolation of the crude product by filtration. The 
solid was dissolved in a minimum amount of C H 2 C I 2  and re-precipitated with Et20  to 
give 1,3-bis(2,6-di/sopropylphenyl)imidazolinium chloride 161 as a white, crystalline 
solid (1.06 g, 2.48 mmol, 62 %).
M.p. 214-215 °C
6 h (400 MHz, C D C I 3 ) 1.19 (12H, d, J 6 .8 , 4 x CH3), 1.33 (12H, d, J 6 .8 , 4 x CH3), 2.96 
(4H, sept, J 6 .8 , 4 x CH), 4.82 (4H, s, 2 x Chh), 7.21 (4H, d, J 7.8, 4 x ArH), 7.41 (2H, t, 
J 7.8, 2 x ArH), 8.28 (1H, s, NCH).
6 c (100 MHz, CDCI3) 24.1 (4 x CH3), 25.8 (4 x CH3), 29.6 (CH), 55.9 (2 x CH2), 125.4 
(2 x ArCH), 129.6 (2 x ArC), 132.0 (2 x ArCH), 146.5 ( 6  x ArC), 158.4 (NCH).
MS (FAB mode) 391.3 (M+-CI, 100 %). HRMS C27H39N2 requires 391.3113 found
391.3108.
1,3-Bis(2,6-di/sopropylphenyl)imidazolinium tetrafluoroborate (SIPr-BF4) 162 68
A mixture of diamine 165 (0.15 g, 0.39 mmol), NH4BF4 (0.05 g, 0.43 mmol) and 
triethylorthoformate (0.32 ml, 1.97 mmol) were stirred together at 110 °C until the 
reaction mixture solidified. The mixture was then cooled to room temperature before 
isolation of the crude product by filtration. The solid was dissolved in a minimum
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amount of CH2CI2 and re-precipitated with Et20  to give the product 1,3-bis(2,6- 
di/sopropylphenyl)imidazolinium tetrafluoroborate 162 as a white, crystalline solid 
(0.039 g, 0.01 mmol, 21 % yield).
The structure was confrimed by X-ray crystallography (see appendix I).
M.p. >285 °C
5h (400 MHz, DMSO) 1.19 (12H, d, J 6.8, 4 x CH3), 1.35 (12H, d, J 6 .8 , 4 x CH3), 3.09 
(4H, sept, J 6 .8 , 4 x CH), 4.53 (4H, s, Ch^), 7.42 (4H, d, J 7.8, 4 x ArCH), 7.54 (2H, app 
t, J 7.8, 2 x ArCH), 9.53 (1H, s, NCH).
6 c (100 MHz) 23.7 (4 x CH3), 25.3 (4 x CH3), 28.6 (2 x CH), 54.0 (2 x CH2), 125.2 (3 x 
ArCH), 130.2 (3xArC), 131.4 (3xArCH), 146.5 (3xArC), 161.1 (NCH).
MS (FAB mode) 391.3 (M+-BF4, 100 %). HRMS C27H39N2 requires 391.3113 found
391.3108.
N-(2,6-Diisopropylphenyl)-N-[2-(2,6-di/sopropylphenylamino)-ethyl]formamide
164
To a suspension of potassium hydride (0.29 g, 7.23 mmol) in THF (10 ml) at room 
temperature were added a suspension of 1,4-bis(2,6-di/sopropylphenyl)imidazolinium 
chloride 161 (782 mg, 1.77 mmol) and a single crystal of 18-crown-6 in THF (21 ml) 
and the reaction stirred at room temperature for 5 h. The inorganic salts were filtered 
from the mixture and the filtrate evaporated to give the crude product, which was 
recrystallised from THF: hexane (1:1) to give N-(2,6-di/sopropylphenyl)-N-[2-(2,6- 
di/sopropylphenylamino)-ethyl]formamide 164 as a white, crystalline solid (197 mg, 
0.48 mmol, 27 %).
The structure was confirmed by X-ray crystallography (see appendix I).
6 h (400 MHz, benzene-c/6) 0.94 (6 H, d, J 6.9, 2 x CH3), 1.08 (6 H, d, J 6.9, 2 x CH3),
1.22 (12H, d, J 6.9, 4 x CH3), 3.05 (2H, sept, J 6.9, 2 x CH), 3.17 (2H, t, J 6.9, CFh), 
3.37 (2H, sept, J 6.9, 2 x CH), 3.85 (2H, t, J 6.9, CHs), 6.94 (2H, d, J 7.7, 2 x ArCH),
7.04-7.11 (4H, m, 4 x ArCH), 8.23 (1 H, s, HC=Q).
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6 c (100 MHz, benzene-d6) 23.9 (CH3), 24.6 (2 x CH), 25.8 (CH3), 28.1 (CH3), 28.7 
(CH3), 49.1 (CH2), 49.2 (CH2), 123.9 ( 2  x ArCH), 124.0 (ArCH), 124.1 (2 x ArCH), 124.9 
(ArCH), 142.6 (2 x ArC), 142.9 (2 x ArC), 148.0 (2 x ArC), 164.3 (C=0).
MS (El mode) 408.6 (M+, 25 %), 190.3 (98), 188.3 (34), 160.2 (25), 132.2 (14). HRMS 
C27H40NO2 requires 408.3141 found 408.3141.
Isobutylcarboxylic acid (2-bromophenyl)methylamide 1 6 5 57
2-Bromo-N-methyl aniline 156 (2.73 g, 14.7 mmol) in CH2CI2 (20 ml) was added 
dropwise to a solution of isobutyryl chloride (1.85 ml, 17.6 mmol) and NEt3 (3.1 ml, 22.0 
mmol) in CH2CI2 (25 ml) at 0 °C and the reaction mixture was allowed to warm to room 
temperature and stirred overnight. The reaction mixture was diluted with Et20  (50 ml) 
and the reaction quenched by addition of saturated aqueous NH4CI. The organic 
phase was dried (MgS04), filtered and concentrated to give the crude product. 
Recrystallisation from hot pet ether gave isobutylcarboxylic acid (2- 
bromophenyl)methylamide 165 as colourless needles (2.94 g, 11.5 mmol, 78 %).
M.p. 79.5-80.5 °C
6 h (400 MHz, CDCI3) 0.84 (3H, d, J 6.9, CH3), 0.91 (3H, d, J 6.9, CH3), 2.19 (1H, sept, 
J 6.9, CH), 3.12 (3H, s, NCH3), 7.15-7.22 (2H, m, ArH), 7.32 (1H, app t, J 7.6, ArH), 
7.62 (1H, d, JQ.0, ArH).
6 C (100 MHz, C D C I 3 )  19.8 (CH3), 20.3 (CH3), 32.0 (CH), 36.3 (NCH3), 124.0 (ArC),
129.3 (ArCH), 130.0 (ArCH), 130.1 (ArCH), 134.3 (ArCH), 143.0 (ArC), 178.2 (C=0).
MS (Cl mode) 258.07 (M* + H , 81 Br, 97 %), 256.07 (M* + H, 79Br, 99 %), 176.14 (41). 
HRMS C „H 15N 079Br requires 256.0337 found 256.0331.
Anal, calculated C ,,H i4NOBr: C 51.59; H, 5.47, N, 5.47, Br 32.65 %. Found; C, 51.33; 
H, 5.42; N, 5.41, Br 32.52 %.
Benzyloxyethyl acetate 168
o
CnHuBrNO 
Br Mol. Wt: 256.14
O
102
Using a Dean-Stark apparatus, benzyloxy acetic acid 155 (4.75 g, 38.6 mmol) was 
dissolved in toluene (45 ml) and EtOH (20 ml) and concentrated aqueous H2S 0 4 (0.15 
g, 3 % w/w) added. The reaction mixture was heated under reflux for 48 h and then 
washed with H20  (2 x 50 ml). Et20  was added and the organic phase separated, dried 
(MgS04), filtered and concentrated in vacuo to give benzyloxyethyl acetate 168 as a 
pale yellow liquid (5.06 g, 26.1 mmol, 91 % yield) which was used without further 
purification.
6 h (400 MHz, CDCh) 1.31 (3H, t, J 7.2, OCH2CH3), 4.11 (2H, s, CH2), 4.26 (2H, q, J 
7.2, OChbCHs), 4.66 (2H, s, PhC ji), 7.28-7.41 (5H, m, ArH).
6 c (100 MHz, C D C I 3 ) 14.6 (CH3), 61.3 (OCH2Me), 67.6 (CH2), 73.7 (PhCH2), 128.4 
(ArCH), 128.5 (2 x ArCH), 128.9 (2 x ArCH), 137.5 (ArC), 170.8 (C=0).
O max (ATR, c m 1) 2073, 2031, 1959, 1751 (C=0), 1201, 1130.
2-(Benzylsulfanyl)-N-(2-bromophenyl)-N-methylacetamide 175
Benzyl thiol (0.24 ml, 2.02 mmol) was added to a solution of 2-bromo-N-(2- 
bromophenyl)-N-methylacetamide 210 (620 mg, 2.02 mmol) and NEt3 (0.71 ml, 5.05 
mmol) in DMF (20 ml) and the reaction stirred at room temperature overnight. The 
reaction mixture was diluted with 40 % EtOAc/ pet ether (20 ml) and washed with H20  
(3 x 50 ml). The organic phase was dried (MgS04), filtered and concentrated in vacuo 
to give the crude product 2-(benzylsulfanyl)-N-(2-bromophenyl)-N-methylacetamide 
175 as a pale yellow oil which solidified on standing (571 mg, 1.63 mmol, 81 %) and 
was used without further purification. A portion of the solid was recrystallised from 
CH2CI2/Pet ether to give pale yellow crystals.
M.p. 42-43.5 °C
5h (400 MHz, CDCI3) 2.70 (1H, d, AB system, J 14.6, 1H of SCH2CO), 2.82 (1H, d, AB 
system, J 14.6, 1H of SCH2CO), 3.15 (3H, s, NCH3), 3.77 (1H, d, AB system, J 13.3, 
1H of PhChbS), 3.81 (1H, d, AB system, J 13.3, 1H of PhCFkS), 7.12-7.30 (8H, m, 
ArH), 7.56 (1H, d, J9.3, ArH)-
o
C16H16BrNOS 
Mol. Wt: 350.27
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6c (100 MHz, CDCb) 32.3 (PhCH2S), 36.6 (SCH2CO) 36.7 (NCH3), 123.7 (ArC), 127.4 
(ArCH), 128.8 (ArCH), 129.1 (2 x ArCH), 129.6 (2 x ArCH), 130.3 (ArCH), 130.6 
(ArCH), 134.2 (ArCH), 138.0 (ArC), 142.5 (ArC), 169.8 (C=0).
MS (El mode) 351.1 (M+, 3 %), 270.2 (15), 227.0 (18), 148.1 (73), 83.0 (99), HRMS 
BrC16H16NOS requires 351.0116 found 351.0117.
O max (ATR, cm'1) 2 3 6 0 ,  1 6 6 0  ( 0 = 0 ) ,  1 5 8 3 ,  1 5 2 7 ,  1 4 7 7 ,  1 3 6 9 ,  1 3 0 7 ,  1 2 6 4 .
Anal, calculated 79BrC16H16NOS: C 54.86; H, 4.60; Br, 22.81; N, 4.00; S, 9.15%. 
Found: C, 55.05; H, 4.56; Br, 22.67; N, 4.05; S, 9.37.
f£J-Methyl-3-(2-(2-benzyloxy)-N-methylacetamido)phenyl acrylate 186
o
<5N5^ ,C02Me
2-Benzyloxy-N-(2-bromophenyl)-N-methylacetamide 157 (86.5 mg, 0.259 mmol) was 
weighed into a round-bottomed flask and dried under high vacuum. The flask was then 
flushed with argon and P(o-tol)3 (24 mg, 0.08 mmol), Pd(OAc) 2 (18 mg, 0.08 mmol), 
NEt3 (40 pi, 0.285 mmol), methyl acrylate (26 pi, 0.285 mmol) and anhydrous o-xylene 
(1 ml) were added and the flask sealed with a rubber septum. The flask was placed in 
an oil bath at 100 °C and stirred overnight. A further portion of Pd(OAc) 2 (18 mg, 0.08 
mmol) and P(o-tol) 3 (24 mg, 0.08 mmol) was added and the reaction stirred at 100 °C 
for a further 2 hours. The reaction mixture was then cooled and quenched by dropwise 
addition of H20 . The mixture was extracted with Et20  (3 x 15 ml), dried (MgS04), 
filtered and concentrated in vacuo to give the crude product. Purification by flash 
chromatography on silica gel gave recovered starting material 157 (31.4 mg, 0.09 
mmol, 36 % recovery) and (EJ-methyl-3-(2-(2-benzyloxy)-N-methylacetamido)phenyl 
acrylate 186 as an orange oil (46.5 mg, 0.14 mmol, 83 % based upon 64 % 
conversion).
5h (400 MHz, CDCI3) 3.18 (3H, s, NCH3), 3.60 (1H, d, J 14.7, 1H of OCtfeCO), 3.73 
(1H, d, J 14.7, 1H of OCHzCO), 3.74 (3H, s, CH3), 4.42 - 4.47 (2H, m, PhChbO), 6.34 
(1 H, d J 16.0, =CH), 7.01-7.36 (9H, m, ArH), 7.55 (1 H, d, J 16.0, =CH).
5c (100 MHz, CDCI3) 37.6 (NCH3), 52.3 (CH3), 68.5 (PhCH2S), 73.6 (OCH2CO), 121.7 
(=CH), 128.1 (ArCH), 128.7 (ArC), 129.1 (ArCH), 129.5 (ArCH), 129.6 (ArCH), 130.2 
(ArCH), 130.5 (ArCH), 132.0 (ArCH), 132.4 (ArCH), 133.3 (ArCH), 137.7 (ArC), 138.7 
(=CH), 141.8 (ArC), 166.9 (C=Q), 169.7 (C=Q).
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MS (Cl mode) 340.2 (M+ +H, 99 %), 107.1 (72), 85.1 (22), 71.1 (32). HRMS 
C20H22NO4 requires 340.1549 found 340.1550.
u max (ATR, cm'1) 2947, 1714 (C=0, ester), 1672 (C=0, amide), 1597, 1487, 1433, 
1390, 1319, 1272, 1196, 1173, 1117, 1088, 1028, 982, 862.
(rEi)-Methyl-3-(2-(2-benzyloxy)acetamido)phenyl acrylate 187
o
Ci9H19N04 
C 0 2Me Mol. Wt: 325.36
2-Benzyloxy-N-(2-bromophenyl)-N-acetamide (85.1 mg, 0.266 mmol) was weighed into 
a round-bottomed flask and dried under high vacuum. The flask was then flushed with 
argon and P(o-tol) 3 (24.3 mg, 0.08 mmol), Pd(OAc) 2 (17.9 mg, 0.08 mmol), NEt3 (0.04 
ml, 0.292 mmol), methyl acrylate (0.03 ml, 0.292 mmol) and anhydrous o-xylene (1.5 
ml) were added and the flask sealed with a rubber septum. The reaction was heated in 
an oil bath at 100 °C and stirred overnight. The reaction mixture was then cooled and 
quenched by dropwise addition of H20 . The mixture was extracted with Et20  ( 3 x 1 0  
ml), dried (MgS04), filtered and concentrated in vacuo to give the crude product. 
Purification by flash chromatography on silica gel gave recovered starting material 
(38.0 mg, 0.12 mmol, 45 % recovery) and pure product (rE)-methyl-3-(2-(2- 
benzyloxy)acetamido)phenyl acrylate 187 (38.8 mg, 0.12 mmol, 82 % based upon 55 
% conversion).
5h (400 MHz, CDCI3) 3.72 (3H, s, COzCHa), 4.08 (2H, s, OCH2CO), 4.56 (2H, s, 
PhCH20), 5.99 (1H, d J 15.9, =CHC02Me), 7.07-7.15 (1H, m, ArH), 7.25-7.34 (6 H, m, 
ArH), 7.47 (1H, app d, J 7.8, ArH), 7.75 (1H, d, J 15.9, PhCH=), 7.83 (1H, app d, J8.2, 
ArhD, 8.42 (1H, bs, NH).
6 c  (100 MHz, C D C I 3 )  52.2 (CH3), 70.0 (OCH2CO), 74.1 (PhCH20 ), 121.2 (=CHC02Me),
124.4 (ArCH), 126.1 (ArCH), 126.1 (ArCH), 127.4 (ArC), 128.0 (ArCH), 128.1 (ArCH),
128.4 (ArCH), 128.8 (ArCH), 129.2 (ArCH), 131.3 (ArCH), 135.5 (ArC), 136.9 (ArC),
139.7 (PhCH=), 167.2 (C=0), 168.3 (C=0).
MS (El mode) 325.2 (M+ , 6  %), 219.1 (13), 160.1 (27), 91.1 (64), 85.0 (65), 83.0 (99),
63.0 (14), 47.0 (20). HRMS C19H19N 0 4 requires 325.1314 found 325.1313.
NH
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(£j-Methyl-3-(2-(2-benzylsulfanyl)-N-methylacetamido)phenyl acrylate 188
o
BnS^X
CO2M6 C 2 0 H 2 1 N O 3 S  Mol. Wt.: 355.45
2-(Benzylsulfanyl)-N-(2-bromophenyl)-N-methylacetamide 175 (460 mg, 1.31 mmol) 
was weighed into a one-piece condenser flask and the flask flushed with argon. 
Pd(OAc)2 (89 mg, 0.39 mmol), P(o-tol)3 (120 mg, 0.394 mmol), NEt3 (0.20 ml, 1.45 
mmol) and methyl acrylate (0.60 ml, 6.57 mmol) were added to the flask followed by 
degassed o-xylene (5 ml) and the flask placed in an oil bath at 100 °C and stirred for 45 
h. The reaction was quenched by addition of water (5 ml) and extracted with Et20  (3 x 
10 ml). The combined ethereal extracts were dried (MgS04), filtered and concentrated 
in vacuo to give the crude product as an orange oil. Purification by flash 
chromatography on silica gel eluting with 30 % ethyl acetate/ petroleum ether gave 
starting material 175 (92 mg, 0.26 mmol, 20 %) and (rEJ-Methyl-3-(2-(2-benzylsulfanyl)- 
N-methylacetamido)phenyl acrylate 188 (356 mg, 1.00 mmol, 96 % based on 80 % 
conversion).
6h (400 MHz, C D C I 3 )  2.70 (1H, d, J 14.4, 1H of CHh), 2.75 (1H, d, J 14.4, 1H of CHz),
3.22 (3H, s, NCH3), 3.75 (3H, s, CH3), 3.70-3.82 (2H, m, PhCJi), 6.35 (1H, d, J 16.0, 
=CHCO), 7.09-7.23 (5H, m, ArH), 7.25-7.37 (4H, m, ArH), 7.68 (1H, d, J 16.0, PhCH=). 
5C (100 MHz, C D C I 3 )  32.3 (CH2), 36.7 (PhCH2), 37.8 (NCH3), 52.3 (CH3), 121.6 
(=CHCO), 127.4 (ArCH), 127.7 (ArCH), 128.2 (ArCH), 128.8 (2 x ArCH), 129.4 (ArCH),
129.5 (ArCH), 129.6 (ArCH), 129.9 (ArCH), 131.9 (ArCH), 132.7 (ArC), 139.1 (CH=),
142.8 (ArC), 167.0 (C=0), 170.0 (C=0).
MS (El mode) 355.1 (M+, 10 %), 233.1 (97), 201.1 (26), 174.1 (82), 147.1 (73), 91.1 
(99), 82.9 (57), 44.0 (94). HRMS C20H21NO3S requires 355.1242 found 355.1246. 
u m„  (ATR, cm’1) 1714 (C=0, ester), 1653 (C=0, amide), 1486, 1452, 1171.
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(E)-tert-Butyl 3-(2-(2-(benzylsulfanyl)-N-methylacetamido)phenyl)acrylate 189
o
o
C 2 3 H 2 7 N 0 3 S  
Of-Bu Mol. Wt.: 397.53
2-(Benzylsulfanyl)-A/-(2-bromophenyl)-/V-methylacetamide 175 (1.05 g, 3.00 mmol) was 
weighed into a microwave reactor vial. Pd(OAc) 2 (34 mg, 0.15 mmol), P(o-tol) 3 (46 mg, 
0.15 mmol) and distilled tert-butyl acrylate (2.63 ml, 18.0 mmol) were added to the 
vessel and it was sealed with a crimp cap septum. The vessel was flushed with argon 
and dry o-xylene (1.5 ml) and NEt3 (0.85 ml, 6.00 mmol) were added. The vessel was 
placed in the microwave cavity and heated to 100 °C for 7 h. The reaction mixture was 
diluted with Et20  (20 ml) and quenched with H20  (5 ml). The organic phase was dried 
(MgS04), filtered and concentrated in vacuo to give the crude product as an orange oil. 
Purification by flash chromatography on silica gel eluting with 3 % EtOAc/Pet Ether 
gave recovered 175 (142 mg, 0.40 mmol, 13 %) and (E)-tert-butyl 3-(2-(2- 
benzylsulfanyl-N-methylacetamido)phenyl)acrylate 189 as an orange oil (1.07 g, 2.69 
mmol, 87 %).
6 h (400 MHz, C D C I 3 )  1.45 (9H, s, C(CH3)3), 2.70 (1 H, d, AB system, J 14.4, 1H of 
SCHzCO), 2.75 (1H, d, AB system, J 14.4, 1H of SCH2CO) 3 . 1 6  (3H, s, NCH3), 3.72 
(1H, d, AB system, J 13.2, 1H of PhCHzS), 3.76 (1H, d, AB system, J 13.2, 1H of 
PhChbS), 6.28 (1H, d, J 16.0, O H C O ), 7.10-7.33 (8 H, m, ArH), 7.50 (1H, d, J 16.0, 
CH=), 7.56 (1H, d, J 7.3, ArH).
6 c (100 MHz, CDCI3) 27.1 (C(CH3)3), 31.0 (SCH2CO), 35.2 (PhCH2S), 36.4 (NCH3), 
79.9 (C(CH3)3), 122.4 (ArCH), 126.0 (ArCH), 126.7 (ArCH), 127.4 (ArCH), 127.9 
(ArCH), 128.1 (ArCH), 128.2 (ArCH), 128.5 (ArCH), 128.8 (ArCH), 130.0 (O H C O ),
131.5 (2 x ArC), 136.5 (CH=), 141.3 (ArC), 164.54 (C O ), 168.5 (C O ).
MS (El mode) 397.2 (5 %, M+), 341.2 (13), 275.2 (9), 219.1 (99), 201.1 (12), 174.1 
(41), 160.1 (61), 147.1 (62), 91.1 (67), 57.1 (27) HRMS C23H27N 0 3S requires 397.1712 
found 397.1713.
o max (ATR, cm'1) 2977, 1707 (C O , conjugated ester), 1656 (C O , amide), 1598, 
1487, 1454, 1421, 1367, 1321, 1203, 1149, 1089.
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3-(Benzylsulfanyl)-1-methyl-2-oxo-1,2,3,4-tetrahydroquinolin-4-yl) acetate 192 and
3-(benzylsulfanyl)-1-methyl-2-oxo-1,2,3,4-tetrahydroquinolin-4-yl) acetic acid 193
by cyclisation of sulfide 190 with NaH.
BnSBnS
C20H21NO3S C-jgHigNOgS
Mol. Wt.: 355.45 Mol. Wt.: 341.42
NaH (3.0 mg, 0.122 mmol) was added to a solution of (E)-tert-butyl 3-(2-(2- 
(benzylsulfanyl)-A/-methylacetamido)phenyl)acrylate 189 (28.8 mg, 0.081 mmol) in THF 
(3 ml) and the reaction stirred at room temperature for 1 h. The reaction was quenched 
by dropwise addition of MeOH (until effervescence ceased) and concentrated in vacuo. 
The reaction mixture was then partitioned between Et20  (5 ml) and H20  (5 ml). The 
organic phase was dried (MgS04), filtered and concentrated in vacuo to give the crude 
product. This was purified by flash chromatography on silica gel using 40 % ethyl 
acetate: petroleum ether as eluent to give 3-(benzylsulfanyl)-1-methyl-2-oxo-1,2,3,4- 
tetrahydroquinolin-4-yl) acetate 193 (10.7 mg, 0.030 mmol, 36 %).
6 h (400 MHz, CDCI3) 2.32-2.48 (2H, m, CHzCO), 3.03-3.34 (4H, m, NCH3 + CH), 3.42 
(1H, s, CH), 3.50 (3H, s, C 0 2CH3), 3.77 (1H, d, AB system, J 13.4, 1H of PhCHz), 3.86 
(1H, d, AB system, J 13.4, 1H of PhCHz), 6.93-7.04 (2H, m, ArH), 7.09 (1H, d, J 7.4, 
ArH), 7.14-7.37 (6 H, m, ArH).
6 c (100 MHz, CDCI3) 30.0 (NCH3), 36.1 (PhCH2), 39.3 (CH), 39.4 (CH2CO), 47.8 (CH),
52.3 (COzCHa), 115.2 (2 x ArCH), 123.8 (ArCH), 125.5 (ArC), 127.6 (ArCH), 128.9 (2 x 
ArCH), 129.2 (ArCH), 129.7 (2 x ArCH), 137.8 (ArC), 138.9 (ArC), 167.7 (C=0), 171.3 
(C=0).
The hydrolysis product 193 was obtained by acidification of the aqueous extract with 5 
M HCI and extraction with EtOAc ( 2 x 1 0  ml). The organic extract was dried (MgS04), 
filtered and concentrated in vacuo to give 3-(benzylsulfanyl)-1-methyl-2-oxo-1,2,3,4- 
tetrahydroquinolin-4-yl) acetic acid 193 (17.8 mg, 0.052 mmol, 64 %).
6 h (400 MHz, CDCI3) 2.41-2.53 (2H, m, CHzCO), 3.02-3032 (4H, s, NCH3 + CH), 3.55 
(1H, s, CH), 3.77 (1H, d, AB system, J 13.4, 1H of PhChb), 3.89 (1H, d, AB system, J
13.4, 1 H of PhChb), 6.96-7.37 (9H, m, ArH).
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2-(3-{Benzylsulfanyl)-1 -methyl-2-oxo-1,2,3,4-tetrahydroquinolin-4-yl)acetic acid
193 by hydrolysis of methyl ester 192 with LiOH.
o
h o 2c
Bn!
C 1 9 H - 1 9 N O 3 S  
Mol. Wt.: 341.42
LiOH (21 mg, 0.494 mmol) was added to a solution of 3-(benzylsulfanyl)-1-methyl-2- 
oxo-1,2,3,4-tetrahydroquinolin-4-yl) acetate 192 (21 mg, 0.062 mmol) in THF (2 ml) and 
H20  (0.5 ml) and the flask placed in an oil bath and stirred at 40 °C for 24 h. The 
reaction was quenched by addition of H20  (10 ml) and extracted with EtOAc (2 x 15 
ml). The aqueous phase was acidified with aqueous 1M HCI and re-extracted with 
EtOAc ( 2 x 1 5  ml). The organic extracts were combined, dried (MgS04), filtered and 
concentrated in vacuo to give 2-(3-(benzylsulfanyl)-1-methyl-2-oxo-1,2,3,4- 
tetrahydroquinolin-4-yl)acetic acid 193 as a yellow oil (21.1 mg, 0.62 mmol, 100 %) 
which was used without further purification.
tert- Butyl 2-(3-(benzylsulfanyl)-1 -methyl-2-oxo-1,2,3,4-tetrahydroquinolin-4-
yi)acetate 194
LDA (0.17 ml of a 2.0 M solution in THF, 0.334 mmol) was added dropwise to a 
solution of (E)-tert-butyl 3-(2-(2-(benzylsulfanyl)-A/-methylacetamido)phenyl)acrylate 
189 (111 mg, 0.29 mmol) in THF (2.5 ml) at -10°C. The reaction was quenched, when 
TLC showed no starting material remained (approx 15 min) by addition of saturated 
aqueous NH4CI (2 ml) and extracted with EtOAc ( 2 x 1 5  ml). The organic phase was 
dried (MgS04), filtered and concentrated in vacuo to give the crude product. 
Purification by flash chromatography on silica gel eluting with 30 % EtOAc/Pet ether 
gave terf-butyl 2-(3-(benzylsulfanyl)-1-methyl-2-oxo-1,2,3,4-tetrahydroquinolin-4- 
yl)acetate 194 (74.9 mg, 0.188 mmol, 69 %) and 2-(3-(benzylsulfanyl)-1-methyl-2-oxo-
1,2,3,4-tetrahydroquinolin-4-yl)acetic acid 193 (15.0 mg, 0.04 mmol, 16 %).
6h (400 MHz, C D C I 3 )  1.26 (9H, s, C(CH3)3), 2.26 (1H, dd, AB system, J 15.5, 7.8, 1H of 
CFbCOzf-Bu), 2.34 (1H, dd, AB system, J 15.5, 7.8, 1H of CHzCOzf-Bu), 3.28 (1H, dt, J
0
C23H27NO3S 
Mol. Wt.: 397.53
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2.0, 7.8, CH(CH2C 0 2f-Bu), 3.36 (3H, s, NCH3), 3.40 (1H, d, J 2.0, SCHCO), 3.66 (1H, 
d, AB system, J 13.5, 1H of PhChhS), 3.85 (1H, d, AB system, J 13.5, 1H of PhC iiS ), 
6.94 (1H, t, J 7.4, ArH), 7.08-7.32 (8H, m, ArH).
5c (100 MHz, CDCI3) 28.4 (C(CH3)3), 30.0 (NCH3), 35.6 (ChhC02f-Bu), 39.5 
(CH(CH2C 0 2f-Bu)), 40.71 (PhCH2S) 46.7 (SCH(CO)), 81.6 (C(CH3)3), 115.1 (ArCH),
123.6 (ArCH), 126.0 (ArC), 127.5 (ArC), 127.5 (ArCH), 128.6 (ArCH), 128.9 (ArCH),
129.3 (ArCH), 129.6 (ArCH), 129.7 (ArCH), 138.9 (ArC), 138.0 (ArC), 167.7 (C=0),
170.1 (C=0).
MS (El mode) 397.2 (2 %, M+ ), 282.1 (11), 250.1 (9), 218.1 (18), 160.1 (99), 91.1 (28) 
HRMS C23H270 3NS requires 397.1712 found 397.1711.
u max (ATR, cm'1) 2983, 2359, 1726 (C=0, ester), 1666 (C O , amide), 1603, 1473, 
1367, 1254, 115.
3-(Benzylsulfanyl)-1-methyl-4-(2-morpholino-2-oxoethyl)-3,4-dihydroquinolin- 
2(1H)-one 195
o
EDCI (15.8 mg, 0.08 mmol) was added to a solution of acid 193 (18.7 mg, 0.05 mmol), 
morpholine (7.2 pi, 0.0824 mmol) and HOBt (1.5 mg, 0.011 mmol) in CH2CI2 (2 ml). 
The reaction was stirred at room temperature for 60 h. The reaction mixtured was 
diluted with CH2CI2 (8 ml) and washed with aqueous 1 M HCI (10 ml), NaHC03 (10 ml) 
and brine (10 ml). The organic phase was dried (MgS04), filtered and concentrated in 
vacuo. The crude product was purified by flash chromatography on silica gel eluting 
with 50 % EtOAc/Pet ether to give 3-(benzylsulfanyl)-1-methyl-4-(2-morpholino-2- 
oxoethyl)-3,4-dihydroquinolin-2(1H)-one 195 as a yellow oil (11.4 mg, 0.03 mmol, 51 
%).
5 h (400 MHz, C D C I 3 )  2.34-2.46 (2H, m, ChhCO), 2.92-2.98 (1H, m, 1H of Chh), 3.11- 
3.20 (1H, m, 1H of Chh), 3.34 (3H, s, NCH3), 3.37-3.88 (8H, m, 3 x Chh. CHCO + 
CHCH2CO), 3.81 (1h, d, J 13.3, 1H of PhChhS), 3.86 (1H, d, J 13.3, 1H of PhChhS), 
6.93-7.03 (2H, m, 2 x ArH), 7.14-7.30 (7H, m, 7 x ArH).
5c (100 MHz, C D C I 3 )  30.0 (NCH3), 36.2 (PhCH2S), 37.1 (CH2CO), 39.6 (CHCH2CO),
42.4 (CH2N), 46.3 (CH2N), 47.3 (SCHCO), 66.6 (CH20), 67.0 (CH20 ), 115.0 (ArCH),
110
123.8 (ArCH), 126.0 (ArC), 127.5 (2 x ArCH), 128.8 (ArCH), 129.6 (2 x ArCH), 129.7 (2 
x ArCH), 137.7 (ArC), 139.0 (ArC), 168.1 (C=0), 168.7 (C=0)
MS (Cl mode) 411.2 (M++H, 100 %), 289.2 (48), 287.2 (46), 160.0 (23) HRMS 
C23H27O3N2S requires 411.1742 found 411.1743.
Cleavage from solution-phase model, tert-butyl 2-(3-(benzylsulfanyl)-1-methyl-2-oxo-
1.2.3.4-tetrahydroquinolin-4-yl)acetate 194
LiCI (20.7 mg, 0.489 mmol) was placed in a dry 25 ml round-bottomed flask and dried 
under vacuum for 5 min, the flask was then flushed with nitrogen. THF (1 ml) was 
added followed by a solution of tert-butyl 2-(3-(benzylsulfanyl)-1-methyl-2-oxo-1,2,3,4,- 
tetrahydroquinolin-4-yl)acetate 194 (32.4 mg, 0.082 mmol) in THF (1.5 ml). Sml2 (2.46 
ml of a 0.1 M solution in THF, 0.45 mmol) was added and the reaction stirred for 18 h. 
The reaction mixture was diluted with CH2CI2 ( 1 0  ml) and quenched with saturated 
aqueous NaHC03 ( 8  ml). The organic phase was dried (MgS04), filtered and 
concentrated in vacuo to give the crude product. Purification by flash chromatography 
on silica gel using 30 % EtOAc/Pet ether as eluent gave terf-butyl 2-(1-methyl-2-oxo-
1.2.3.4-tetrahydroquinolin-4-yl)acetate 196 (11.3 mg, 0.0418 mmol, 52 %, unoptimised) 
as a pale yellow oil.
Cleavage from solution phase model, terf-butyl 2-(3-benzylsulfonyl-1-methyl-2-oxo-
1,2,3,4,-tetrahydroquinolin-4-yl)acetate 200
LiCI (205 mg, 4.82 mmol) was placed in a dry 25 ml round-bottomed flask and dried 
under vacuum for 5 min, the flask was then flushed with nitrogen. THF (5 ml) was 
added followed by a solution of terf-butyl 2-(3-(benzylsulfonyl)-1-methyl-2-oxo-1,2,3,4,- 
tetrahydroquinolin-4-yl)acetate 200 (230 mg, 0.54 mmol) in THF (5 ml). Sml2 (21.4 ml, 
of a 0.1 M solution in THF, 2.14 mmol) was added and the reaction stirred for 18 h.
u max (ATR, cm'1) 2856, 2357, 1653 (C=0, amide), 1600, 1496, 1459, 1368, 1271 
1241, 1114, 1070, 1030.
tert-Butyl 2-(1 -methyl-2-oxo-1,2,3,4-tetrahydroquinolin-4-yl)acetate 196
o
t - E
111
The reaction mixture was diluted with CH2CI2 (15 ml) and quenched with saturated 
aqueous NaHC03 (15 ml). The organic phase was dried (MgS04), filtered and 
concentrated in vacuo to give the crude product. Purification by flash chromatography 
on silica gel using 30 % EtOAc/Pet ether as eluent gave ferf-butyl 2-(1-methyl-2-oxo-
1,2,3,4-tetrahydroquinolin-4-yl)acetate 196 (84.8 mg, 0.34 mmol, 57 %, unoptimised) 
as a pale yellow oil.
6 h (400 MHz, CDCI3) 1.36 (9H, s, C(CH3)3), 2.34-2.45 (2H, m, CHzCOzf-Bu), 2.55 (1H, 
dd, J 16.1, 5.4, 1H of CH2CON), 2.70 (1H, dd, J 16.1, 5.4, 1H of CH2CON), 3.30 (3H, s, 
NCH3), 3.37 (1H, app quintet, J 5.4, CH), 6.96-6.98 (2H, m, 2 x ArH), 7.14 (1H, d, J7.5, 
ArH), 7.18-7.22 (1H, m, ArH).
6c (100 MHz, C D C I 3 )  28.1 (C(CH3)3), 29.4 (NCH3), 32.7 (CH), 36.9 (CH2CON), 39.6 
(CH2C 0 2f-Bu), 81.1 (C(CH3)3), 115.0 (ArCH), 123.0 (ArCH), 127.4 (ArCH), 128.0 
(ArCH), 128.3 (ArC), 139.8 (ArC), 169.1 (C=0), 170.7 (C=0).
MS (El mode) 275.2 (4 % M+ ), 219.1 (9), 218.1(8), 160.1 (26), 85.0 (65), 83.0 (100),
47.0 (17) HRMS Ci6H21N 0 3 requires 275.1521 found 275.1518. 
u m„  (ATR, cm'1) 2979, 2359, 2010, 1726 (C=0, ester), 1681 (C=0, amide), 1603, 
1474, 1367, 1269, 1140, 784.
Preparation of f£J-Methyl-3-(2-(2-benzylsulfonyl-N-methylacetamido)phenyi) 
acrylate 197
n  n  O
C20H21NO5S 
C 02Me Mol. Wt: 387.45
Oxidation with Oxone.
Oxone (2.62 g, 4.26 mmol) was added to a solution of (EJ-methyl 3-(2-(2- 
benzylsulfanyl-N-methylacetamido)phenyl)acrylate 188 (252 mg, 0.71 mmol) in DMF 
(20 ml) and H20  (5 ml) and the reaction stirred overnight. The reaction was quenched 
by addition of H20  (20 ml) and the mixture extracted with CH2CI2 (2 x 30 ml). The 
organic phase was dried (MgS04), filtered and concentrated in vacuo to give (E)- 
methyl-3-(2-(2-benzylsulfonyl-N-methylacetamido)phenyl)acrylate 197 as a pale yellow 
oil which solidified on standing (151 mg, 0.46 mmol, 55 %).
Oxidation with mCPBA.
112
mCPBA (163 mg, max 72 % mCPBA, 0.68 mmol) was added to a solution of (E)- 
methyl-3-(2-(2-benzylsulfanyl-N-methylacetamido)phenyl)acrylate 188 (30.0 mg, 0.08 
mmol) in CH2CI2 (5 ml) at 0 °C. The reaction was stirred at 0 °C for 10 min and warmed 
to room temperature and stirred for 6 h. The reaction was quenched by addition of H20  
(10 ml) and then diluted with CH2CI2 (15 ml) before washing with saturated aqueous 
NaHC03 (10 ml). The organic phase was dried (Na2S 0 4), filtered and concentrated in 
vacuo to give the crude product as a yellow oil. Purification by flash chromatography 
on silica gel eluting with 30 % EtOAc/Pet ether gave fEj-methyl-3-(2-(2-benzylsulfonyl- 
N-methylacetamido)phenyl)acrylate 197 as a pale yellow oil (17.6 mg, 0.05 mmol, 54
7.01-7.54 (10 H, m, 9 x ArH + CH=).
5C (100 MHz, CDCI3) 38.0 (CH3), 52.4 (SO^H^CO), 53.1 (NCH3), 59.8 (PhCH2S 0 2),
122.3 (=CHCO), 128.4 (ArCH). 128.6 (ArC), 129.4 (2 x ArCH), 129.9 (2 x ArCH), 130.1 
(ArCH), 131.6 (ArCH), 132.5 (ArCH), 132.6 (ArCH), 138.3 (CH=), 138.5 (ArC), 141.6 
(ArC), 163.1 (C=0), 166.9 (C=0).
MS (El mode) 387.2 (M+ , 29 %), 231.1 (58), 200.1 (5), 160.1 (12), 144.1 (23), 130.1 
(9), 91.1 (99), 83.0 (13). HRMS C20H21NO5S requires 387.1140 found 387.1139.
(E)-tert-Butyl 3-(2-(2-benzylsulfonyl-N-methylacetamido)phenyl) acrylate 198
Oxidation with Oxone.
Oxone (914 mg, 1.49 mmol) was added to a solution of (E)-tert-butyl 3-(2-(2- 
benzylsulfanyl-N-methylacetamido)phenyl)acrylate 189 (148 mg, 0.37 mmol) in DMF (8 
ml) and H20  (2 ml) and the reaction stirred overnight. The reaction was quenched by 
addition of H20  (10 ml) and the mixture extracted with CH2CI2 ( 2 x 1 5  ml). The organic 
phase was dried (MgS04), filtered and concentrated in vacuo to give (E)-tert-butyl 3-(2- 
(2-benzylsulfonyl-N-methylacetamido)phenyl)acrylate 198 as a pale yellow oil which 
solidified on standing (147 mg, 0.37 mmol, 100 %).
%).
6h (300 MHz, C D C I 3 )  3.15 (3H, s, CH3), 3.33 (1H, d, J 13.6, 1H of SOzChbCO), 3.37 
(1H, d, J 13.6, 1H of SOzChbCO), 3.75 (3H, m, NCH3), 4.43 (1H, d, J 13.5, 1H of 
PhCHzSOz), 4.72 (1H, d, J 13.5, 1H of PhChbSOz), 6.36 (1H, d, J 16.0, CH=CHCO),
0 0  9
C23H27NO5S 
^ ^ C 0 2f-Bu Mol. Wt: 429.53
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Oxidation with mCPBA.
mCPBA (266 mg, max 77 % mCPBA, 1.19 mmol) was added to a solution of (E)-tert- 
butyl 3-(2-(2-benzylsulfanyl-N-methylacetamido)phenyl)acrylate 189 (236 mg, 0.59 
mmol) and K2C 0 3 (164 mg, 1.19 mmol) in CH2CI2 (5 ml) at 0 °C. The reaction was 
stirred at 0 °C for 10 min and warmed to room temperature and stirred for 20 min. The 
reaction was quenched by addition of H20  (10 ml) and then diluted with CH2CI2 (15 ml) 
before washing with saturated aqueous NaHC03 (10 ml). The organic phase was dried 
(Na2S 0 4), filtered and concentrated in vacuo to give the crude product as a yellow oil. 
Purification by flash chromatography on silica gel eluting with 30 % EtOAc/Pet ether 
gave (E)-tert-butyl 3-(2-(2-benzylsulfonyl-N-methylacetamido)phenyl)acrylate 198 as a 
yellow oil (179 mg, 4.17 mmol, 71 %).
5h (300 MHz, CDCI3) 1.57 (9H, s, C(CH3)3), 3.36 (3H, s, NCH3), 3.51 (1H, d, AB 
system, J 15.0, 1H of SOzChhCO), 3.54 (1H, d, AB system, J 15.0, 1H of SOzCHzCO), 
4.52 (1H, d, AB system, J 15.0, 1H of PhCHkSOz), 4 . 8 6  (1H, d, AB system, J 15.0, 1H 
of PhChbSOz), 6.41 (1H, d, J 18.0, CH=CHCO), 7.35-7.71 (10H, m, 9 x ArH + CH=).
6c (100 MHz, C D C I 3 ) 28.4 (3 x C(CH3)3), 37.9 (NCH3), 52.9 (SOzCH2CO), 59.7 
(PhCH2S 0 2), 81.4 (C(CH3)3), 124.4 (ArC), 128.1 (ArCH), 128.5 (=CHCO), 129.2 (ArCH 
x 2), 129.8 (ArCH), 129.9 (ArCH), 131.4 (ArCH), 132.1 (ArCH), 132.7 (ArCH x 2), 136.9 
(ArC x 2), 141.4 (CH=), 162.9 (C=0), 165.6 (C=0).
MS (El mode) 447 (M+ + NH4, 36 %), 391(98), 237 (43), 188 (40), 174 (51), 160 (100), 
108 (49). HRMS C23H3i NOsS requires 447.1948, found 447.1949.
U max (ATR, c m 1) 3036, 2975, 1706 (C=0, ester), 1657 (C=0, amide), 1601, 1485, 
1450, 1367, 1313, 1257, 1146, 1122.
rac-Methyl 2-(3S,4/?-3-benzylsulfonyl-1 -methyl-2 -oxo-1 ,2,3,4,-tetrahydroquinolin-
4-yl)acetate 199
K2C 0 3 (39.2 mg, 0.28 mmol) was added to a solution of (EJ-methyl 3-(2-(2- 
benzylsulfonyl-N-methylacetamido)phenyl)acrylate 197 (22.0 mg, 0.06 mmol) in DMF 
(5 ml) at room temperature. The reaction was stirred overnight. The reaction was
o
C 2 0 H 2 1 N O 5 S  
Mol. Wt: 387.45
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quenched by addition of H20  ( 1 0  ml) and the mixture extracted into CH2CI2 ( 2 x 1 0  ml). 
The organic phase was dried (MgS04), filtered and concentrated in vacuo to give the 
crude product. Purification by flash chromatography on silica gel eluting with 50 % 
EtOAc/Pet ether gave rac-methyl 2-(3-benzylsulfonyl-1-methyl-2-oxo-1,2,3,4,- 
tetrahydroquinolin-4-yl)acetate 199 (10.2 mg, 0.03 mmol, 46 %).
6 h (300 MHz, CDCI3) 2.36-2.50 (2 H, m, CHzCOzMe), 3.43 (CH3), 3.44 (NCH3), 3.97 
(1 H, apparent t, J 7.6, CHCH2C 0 2Me), 4.10 (1H, s, CH). 4.21 (1H, d, J 14.0, 1H of 
PhCHzSOz), 4.58 (1H, d, J 14.0, PhCHkSOz), 6.99-7.05 (2H, m, 2 x ArH), 7.08-7.33 
(5H, m, 5 x ArH), 7.49-7.51 (2H, m, 2 x ArH).
6 C (100 MHz, CDCI3) 30.0 (CH3), 32.3 (CHCH2C 0 2Me), 39.7 (CH2C 0 2Me), 52.3 
(NCH3), 59.8 (PhCH2S 0 2), 63.7 (CH), 115.6 (ArCH), 124.4 (ArC), 124.7 (ArCH), 127.8 
(ArC), 128.8 (ArCH), 129.3 (2 x ArCH), 129.5 (2 x ArCH), 131.9 (2 x ArCH), 138.5 
(ArC), 162.4 (C O ), 170.6 (C O ).
MS (El mode) 447 (M+ + NH4, 36 %), 391(98), 237 (43), 188 (40), 174 (51), 160 (100), 
108 (49). HRMS C23H31N 0 5S requires 447.1948, found 447.1949.
O max (ATR, c m 1) 2360, 2341, 1736 (C=0, ester), 1660 (C=0, amide), 1602, 1475.
rac-tert- Butyl 2-(3S,4R-3-benzylsulfonyl-1 -methyl-2-oxo-1,2,3,4,-
tetrahydroquinolin-4-yl)acetate 200
K2C 0 3 (415 mg, 3.00 mmol) was added to a solution of (E)-tert-butyl 3-(2-(2- 
benzylsulfonyl-N-methylacetamido)phenyl)acrylate 198 (322 mg, 0.75 mmol) in DMF ( 6  
ml) at room temperature. The reaction was stirred until complete by TLC (approx 5 h). 
The reaction was quenched by addition of H20  (15 ml) and the mixture extracted into 
CH2CI2 (2 x 20 ml). The organic phase was dried (MgS04), filtered and concentrated in 
vacuo to give the crude product rac-terf-butyl 2-(3-benzylsulfonyl-1-methyl-2-oxo-
1,2,3,4,-tetrahydroquinolin-4-yl)acetate 200 as a brown solid (320 mg, 0.75 mmol, 99 
%) which was used without further purification. A portion of the product was 
recrystallised from hot methanol to provide colourless, rhombic crystals suitable for x- 
ray analysis.
The structure was confrimed by X-ray crystallography (see appendix I).
o
,'s ' Ph C23H27N 0 5S 
f Mol. Wt: 429.53
115
M.p. 174-175 °C
5h (400 MHz, CDCI3) 1.33 (9H, s, C(CH3)3), 2.41-2.47 (2H, m, ChbC02<-Bu), 3.54 (3H, 
s, NCH3), 4.06 (1H, t, J 7.5, CHCH2C 0 2f-Bu), 4.18 (1H, s, BnS02CHC0), 4.29 (1H, d, 
AB system, J 14.1, 1H of PhCfcb), 4.69 (1H, d, AB system, J 14.1, 1H of PhChh), 7.12 
(2H, apparent q, J 6 .6 , ArH), 7.14-7.34 (2H, m, ArH), 7.42-7.44 (3H, m, ArH), 7.61-7.63 
(2 H, m, ArH).
6 C (100 MHz, CDCI3) 28.3 (3 x C(CH3)3), 30.7 (CHCH2C 0 2f-Bu), 32.4 (NCH3), 41.1 
(CH2C 0 2f-Bu), 59.7 (PhCH2), 63.8 (BnSOjCHCO), 82.1 (C(CH3)3), 115.5 (ArCH), 124.6 
(ArCH), 124.8 (ArC), 127.9 (ArC), 128.9 (ArCH), 129.2 (ArCH), 129.3 (2 x ArCH), 129.4 
(ArCH), 129.5 (ArCH), 131.9 (ArCH), 138.5 (ArC), 162.5 (C=0), 169.3 (C=0).
MS (Cl mode) 430 (M* + H, 32 %), 391 (13), 374 (15), 274 (35), 160 (100). HRMS 
C23H27N 0 5S requires 429.1604 found 429.1593.
o ^  (ATR, cm"1) 3050, 2932, 1723 (C=0, ester), 1654 (C=0, amide), 1604, 1470, 
1371, 1310, 1132, 1137, 926.
rac-tert- Butyl 2-(3R,4/?-3-allyl-3-benzylsulfonyl-1 -methyl-2 -oxo-1 ,2,3,4-
tetrahydroquinolin-4-yl)acetate 201
K20O 3 (51 mg, 0.370 mmol) was added to a solution of terf-butyl 2-(3-benzylsulfonyl-1- 
methyl-2-oxo-1,2,3,4,-tetrahydroquinolin-4-yl)acetate 200 (53 mg, 0.123 mmol) in DMF 
(1.5 ml) and stirred at room temperature for 20 min. Allyl bromide (0.03 ml, 0.370 
mmol) was added and the reaction stirred at room temperature for 2 h. The reaction 
was then heated to 50 °C and stirred overnight. The reaction was cooled to room 
temperature and quenched by addition of H20  (10 ml). The mixture was extracted with 
EtOAc ( 2 x 1 0  ml) and the organic phase dried (MgS04), filtered and concentrated in 
vacuo to give the crude product. Purification by flash chromatography on silica gel 
gave rac-terf-butyl 2-(3R,4fi-3-allyl-3-benzylsulfonyl-1-methyl-2-oxo-1,2,3,4- 
tetrahydroquinolin-4-yl)acetate 201 as a white solid (44 mg, 0.093 mmol, 76 %) A 
portion of the solid was recrystallised from CH2CI2/Pet ether and analysed by X-ray 
crystallography.
The structure was confrimed by X-ray crystallography (see appendix I).
116
M.p. 201-202 °C
6 h (300 MHz, CDCI3) 1.40 (9H, s, C(CH3)3), 2.81-2.92 (2H, m, 1H of CH2CH= + 1H of 
CH2C0 2f-Bu), 2.95-3.10 (1H, m, 1H of ChhCH^, 3.29 (1H, dd, J 16.8, 2.4, 1H of 
ChhCXV-Bu), 3.52 (3H, s, NCH3), 4.05 (1H, dd, J 11.7, 2.4, CH), 4.43 (1H, d, AB 
system, J 12.6, PhChhSOz), 4.63 (1H, d, AB system, J 12.6, PhCHzSOz), 5.13 (1H, d, J 
16.8, 1H of =CH2), 5.27 (1H, d, J 10.5, 1H of = 0 ^ ) ,  5.81-5.93 (1H, m, CH=), 7.05-7.15 
(4H, m, ArH), 7.27-7.39 (5H, m, ArH).
6c (100 MHz, CDCI3) 28.3 (C(CH3)3), 31.0 (NCH3), 35.6 (C]i>CH=), 36.0 (CH2C 0 2f-Bu),
37.8 (CH), 59.2 (PhCH2S 0 2), 73.0 (SOzCCO), 81.2 (C(CH3)3), 114.9 (CH=), 121.2 
(=CH2), 124.3 (ArCH), 125.7 (ArC), 126.1 (ArC), 127.8 (2 x ArCH), 128.6 (2 x ArCH),
129.2 (2 x ArCH), 130.5 (ArCH), 132.2 (ArCH), 138.4 (ArC), 165.8 (C=0), 170.7 (C=0). 
MS (ES+ mode) 961 (69%, 2M+ + Na), 673 (30), 492 (92 %, M+ + Na), 214 (100). 
HRMS C26H310 5NNaS requires 492.1815 found 492.1815.
u max (ATR, cm'1) 3072, 2974, 1716 (C O , ester), 1655 (C O , amide), 1604, 1467, 
1368, 1298, 1128.
rac-terf-Butyl 
yl)acetate 2 02
2-(3R,4S-3-allyl-1 -methyl-2-oxo-1,2,3,4-tetrahydroquinolin-4-
t-BuO'
C19H25NO3
Mol. Wt: 315.41
rac-tert-Butyl 2-(3R, 4R-3-allyl-3-benzylsulfonyl-1 -methyl-2-oxo-1,2,3,4-
tetrahydroquinolin-4-yl)acetate 201 (64.1 mg, 0.14 mmol) and dry LiCI (56 mg, 1.23 
mmol) were added to THF (1 ml) and the mixture was thoroughly flushed with nitrogen. 
Distilled terf-butanol (0.33 ml, 3.43 mmol) was added to the mixture followed by Sml2 
(4.1 ml, 0.1 M solution in THF, 0.41 mmol). The reaction was stirred until the Sml2 
decolourised (approx 16 h) and the reaction mixture was diluted with CH2CI2 (10 ml) 
and washed with water ( 8  ml). The organic phase was dried (Na2S 0 4), filtered and 
concentrated in vacuo to give the crude product as a brown oil. Purification by flash 
chromatography on silica gel using 30 % EtOAc/Pet ether as eluent gave rac-tert-butyl 
2-(3R,4S-3-allyl-1-methyl-2-oxo-1,2,3,4-tetrahydroquinolin-4-yl)acetate 202 (34.1 mg, 
0.11 mmol, 79 %) as a 5:1 mixture of syn and anti diastereomers. The syn 
diastereomer could be separated by further careful, chromatography. Recrystallisation
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from CH2CI2/Pet ether gave colourless crystals suitable for analysis by X-ray 
crystallography.
The structure was confirmed by X-ray crystallography (see appendix I).
M.p. 96.5-98 °C
8 h (300 MHz, CDCb) 1.39 (9H, s, C(CH3)3), 2.17-2.32 (2H, m, 1H of CH2CH=CH2, 1H 
of CH2C0 2f-Bu), 2.51 (1H, dd, J 15.0, 4.5, 1H of CHzCO^-Bu), 2.76-2.91 (2H, m, 1H of 
ChkCH= + CHCO), 3.41 (3H, s, NCH3), 3.43-3.46 (1H, m, CH), 5.12 (1H, apparent d, J
8.4, 1H of =CH2), 5.17 (1H, apparent d, J 17.1, 1H of = 0 ^ ) ,  5.82-5.98 (1H, m, 
CH=CH2), 7.00-7.05 (2 H, m, ArH), 7.25-7.33 (2H, m, ArH).
5C (100 MHz, C D C I 3 ) 28.3 (3 x C(CH3)3), 30.1 (NCH3), 31.2 (CH2C 0 2t-Bu), 35.2 
(CH2CH=CH2), 36.0 (COCH), 44.3 (CH-CH2C 0 2t-Bu), 81.1 (C(CH3)3), 115.2 (ArCH),
117.3 (=CH2), 123.2 (ArCH), 128.2 (ArCH), 128.3 (ArCH), 136.1 (CH=CH2), 139.8 
(ArC), 129.5 (ArC), 171.1 (C=0), 171.3 (C=0).
MS (Cl mode) 316 (100 %, M+ ), 260 (24). HRMS C19H26N 0 3 requires 316.1907 found 
316.1910.
Umax (ATR, cm'1) 2970, 2353, 1727 (C=0, ester), 1676 (C=0, amide), 1470, 1373, 
1267.
2-(Benzylsulfanyl)-N-(2-bromo-4,6-difluorophenyl)-N-methylacetamide 203
Br C16H14BrF2NOS 
Mol. Wt: 386.25
Benzyl thiol (2.49 ml, 21.2 mmol) was added to a solution of 2-bromo-N-(2- 
bromophenyl)-N-methylacetamide 220 (7.00 g, 21.2 mmol) and NEt3 (7.43 ml, 52.9 
mmol) in DMF (150 ml) and the reaction stirred at room temperature overnight. The 
reaction mixture was diluted with 40 % EtOAc/ pet ether (100 ml) and washed with H20  
(3 x 100 ml). The organic phase was dried (MgS04), filtered and concentrated in vacuo 
to give the crude product 2-(benzylsulfanyl)-N-(2-bromo-4,6-difluorophenyl)-N- 
methylacetamide 203 as a clear oil which solidified on standing to give a white solid 
(7.21 g, 19.3 mmol, 91 %).
M.p. 50-51 °C.
118
6 h (400 MHz, CDCb) 2.86 (1H, d, AB system J 14.7, 1H of Chh), 2.93 (1H, d, AB 
system, J 14.7, 1H of Chh), 3.21 (3H, s, NCH3), 3.79 (1H, d, AB system, J 13.2, 1H of 
PhChhS), 3.84 (1H, d, AB system, J 13.2, 1H of PhChhS), 6.90-6.95 (1H, m, ArH), 
7.21-7.37 (6 H, m, ArH).
5C (100 MHz, CDCh) 32.7 (CH2), 36.0 (NCH3), 36.6 (PhCH2S), 105.3 (t, J25.0, ArCH),
117.2 (d, J 25.0, ArCH), 125.6 (d, J 11.7, ArCN), 125.8 (ArCH), 127.6 (m, ArCBr),
128.8 (ArCH), 128.9 (ArCH), 129.6 (ArCH), 129.8 (ArCH), 137.8 (ArCCH2), 159.7 (dd, J
13.0, 258.4, ArCF), 162.2 (dd, J 12.7, 253.9, ArCF), 169.7 (C=0).
MS (El mode) 387.04 (9 %, M+, (81Br)), 385.04 (9 %, M+ , (79Br)), 265.01 (28(81Br)),
263.01 (28 (79Br)), 184.1 (99), 91.1 (59). HRMS C16H14ONBrF2S requires 386.9928 
found 386.9925.
O max (ATR.cm 1) 2360, 1667 (C =0), 1586, 1485, 1427, 1363, 1317, 1260, 1126.
Anal, calculated C,6Ht4ONBrF2S: C 49.75; H, 3.65; N, 3.63; S, 8.36%. Found: C, 
49.74; H, 3.51; N, 3.67; S, 8.34.
(rE>)-fert-Butyl-3-(2-(2-benzylsulfanyl)-N-methylacetamido)-3,5- 
difluorophenyl)acrylate 204
Ph.
C02^-Bu C 2 3 H 2 5 F 2 N O 3 S  
Mol. Wt: 433.51
2-(Benzylsulfanyl)-A/-(2-bromo-4,6-difluorophenyl)-N-methylacetamide 203 (1.00 g,
2.67 mmol) was weighed into a microwave reactor vial. Pd(OAc) 2 (30.0 mg, 0.13 
mmol), P(o-tol) 3 (40.6 mg, 0.13 mmol) and distilled terf-butyl acrylate (2.35 ml, 16.0 
mmol) and the vial was sealed with a crimp cap septum. The vial was flushed with 
argon and dry o-xylene (2 ml) and NEt3 (0.14 ml, 2.94 mmol) were added. The vessel 
was placed in the microwave cavity and heated to 100 °C for 7 h. The reaction mixture 
was diluted with Et20  (20 ml) and quenched with H20  (5 ml). The organic phase was 
dried (MgS04), filtered and concentrated in vacuo to give the crude product as an 
orange oil. Purification by flash chromatography on silica gel eluting with 30 % 
EtOAc/Pet ether gave (rEj)-fe/f-butyl-3-(2-(2-benzylsulfanyl-N-methylacetamido)-3,5- 
difluorophenyl)acrylate 204 as an orange oil (1.17 g, 2.67 mmol, 100 %).
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6 h (400 MHz, CDCI3) 1.54 (9H, s, C(CH3)3), 2.83 (2H, apparent d, J 1.8, SChhCO), 
3.24 (3H, s, NCH3), 3.82 (2H, s, PhCJiS), 6.37 (1H, d, J 16.0, =CH-C02f-Bu), 6.90- 
6.95 (1H, m, ArH), 7.14-7.30 (6 H, m, ArH), 7.54 (1H, d, J 16.0, CH=CHC02f-Bu).
6 C (100 MHz, C D C I 3 ) 28.5 (3 x C(CH3)3), 32.5 (SCH2CO), 36.5 (PhCH2S), 37.0 (NCH3),
81.8 (C(CH3)3), 106.5 (t, J24.6, ArCH), 110.1 (d, J23.0, ArCH), 126.8-126.9 (m, ArC),
127.4 (2 x ArCH), 128.7 (ArC), 128.8 (2 x ArCH), 129.8 (=CHC02f-Bu), 136.0 (ArCH),
136.4-136.6 (m, ArCN), 159.4 (dd, J 12.7, 250.0, ArCF), 162.3 (dd, J 12.5, 244, ArCF),
165.6 (C=0), 171.5 (C=0).
MS (El mode) 433.2 (M+ , 6  %), 377.1 (36), 255.1 (99), 210.1 (60), 196.0 (61), 183.1 
(65), 166.1 (16), 91.1 (74), 57.1 (28). HRMS C23H25N 0 3SF2 requires 433.1523 found 
433.1523.
u max (ATR, cm'1) 2982, 2359, 1713 (C=0, ester), 1668 (C=0, amide), 1484, 1367, 
1314, 1153.
(E)-tert-Buty\ 3-(2-(2-benzylsulfonyl-N-methylacetamido)-3,5-
difluorophenyl)acrylate
Ph
.CO?f-Bu C23H25F2NO5S 
Mol. Wt: 465.51
Oxone (3.52 g, 5.73 mmol) was added to solution of (E)-tert-butyl 3-(2-(2- 
benzylsulfanyl-N-methylacetamido)-3,5-difluorophenyl)acrylate 204 (621 mg, 1.43 
mmol) in DMF (12 ml) and H20  (3 ml) and the reaction stirred overnight. The reaction 
was quenched by addition of H20  (20 ml) and the mixture extracted in CH2CI2 (2 x 30 
ml). The organic phase was dried (MgS04), filtered and concentrated in vacuo to give 
(E)-tert-butyl 3-(2-(2-benzylsulfonyl-N-methylacetamido)-3,5-difluorophenyl)acrylate as 
a pale orange oil (634 mg, 1.36 mmol, 95 %) which was used without further 
purification.
5h (300 MHz, C D C I 3 ) 1.55 (9H, s, C(CH3)3), 3.28 (3H, s, NCH3), 3.45 (1H, d, AB 
system, J 15.3, 1H of SOzCFbCO), 3.53 (1H, d, AB system, J 15.3, 1H of SOzCI^CO), 
4.57 (1H, d, AB system, J 14.0, 1H of PhCFbSOz), 4.70 (1H, d, AB system, J 14.0, 1H 
of PhCHzSOz), 6.40 (1H, d, J 15.9, =CHC02f-Bu), 6.93-7.00 (1H, m, ArH), 7.18-7.22 
(1H, m, ArH), 7.39-7.44 (3H, m, ArH), 7.53-7.58 (3H, m, 2 x ArH + PhCH=).
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6 c (100 MHz, CDCIj) 28.3 (3 x C(CH3)3), 37.1 (NCH3), 52.8 (SO2CH2CO), 59.6 
(PhCH2S 0 2), 81.8 (C(CH3)3), 106.5 (m, ArCF), 110.2 (m, ArCF), 126.8 (ArCH), 126.9 
(=CHCO), 128.4 (2 x ArC), 129.2 (2 x ArCH), 129.3 (2 x ArCH), 131.4 (2 x ArCH),
135.1 (ArC), 135.2 (PhCH=), 163.5 (C=0), 164.8 (C=0). C-F couplings were not seen 
due to signal to noise ratio.
MS (El mode) 483 (M* + NH4, 37 %), 427 (40), 273 (30), 213 (36), 108 (100), 91 (24). 
HRMS CzjH^NOsSFz requires 483.1760, found 483.1759.
o (ATR, c m 1) 2935, 1708 (C=0, ester), 1664 (C=0, amide), 1448, 1367, 1306, 
1249, 1147, 1129, 1037.
rac-tert- Butyl 2-(3S,4/?-3-benzylsulfonyl-6,8-difluoro-1 -methyl-2-oxo-1,2,3,4-
tetrahydroquinolin-4-yl) acetate 205
K2C 0 3 (606 mg, 4.38 mmol) was added to a solution of (E)-tert-butyl 3-(2-(2- 
benzylsulfonyl-N-methylacetamido)-3,5-difluorophenyl)acrylate (510 mg, 1.10 mmol) in 
DMF (5 ml) at room temperature. The reaction was stirred until complete by TLC 
(approx 3 h). The reaction was quenched by addition of H20  (15 ml) and the mixture 
extracted into CH2CI2 ( 2  x 2 0  ml). The organic phase was dried (MgS04), filtered and 
concentrated in vacuo to give the crude product tert-butyl 2-(3-benzylsulfonyl)-6,8- 
difluoro-1-methyl-2-oxo-1,2,3,4-tetrahydroquinolin-4-yl) acetate 205 as a brown solid 
(462 mg, 1.00 mmol, 92 %) which was used without further purification. A portion of 
the product was recrystallised from hot methanol to provide colourless, rhombic 
crystals suitable for X-ray analysis.
The structure was confrimed by X-ray crystallography (see appendix I).
M.p. 142-143 °C
5h (300 MHz, CDCb) 1.36 (9H, s, C(CH3)3), 2.45 (2H, app sept, J 7.9, CHzCOzf-Bu), 
3.59 (3H, d, J 6.9, NCH3), 3.97 (1H, app t, J 7.8, CHCH2C 0 2f-Bu), 4.12 (1H, s, 
BnS02CHCO), 4.28 (1H, d, AB system, J 14.1, 1H of P hC Ii), 4.65 (1H, d, AB system, 
J 14.1, 1H of PhChh), 6.82-6.90 (2H, m, ArH), 7.42-7.45 (3H, m, ArH), 7.59-7.62 (2H,
o
C 2 3 H 2 5 F  2 N O 5 S  
Mol. Wt: 465.51
m, ArH).
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6 c (100 MHz, COCI3) 28.2 (3 x C(CH3)3), 33.0 (CHCH2C 0 2t-Bu), 34.5 (t, J 16.0, NCH3),
39.8 (CHjCCy-Bu), 59.7 (PhChhSO;,), 63.5 (BnS02CHC0), 82.4 (C(CH3)3), 105.5 (t, J 
34.7, ArH), 111.7 (m, ArH), 127.4 (ArC), 129.3 (4 x ArCH), 129.5 (2 x ArC), 131.7 
(ArCH), 162.6 (C=0), 168.6 (C=0). ArC-F signals were not seen due to signal to noise 
ratio.
MS (Cl mode) 483 (M* + NH„, 45 %), 466 (M* + H, 12 %), 465 (M* , 5 %), 310 (52), 
196 (100). HRMS C23H25N 0 5SF2 requires 465.1416 found 465.1422. 
u max (ATR cm'1) 3079, 2967, 2939, 1726 (C=0, ester), 1664 (C=0, amide), 1491, 
1314, 1361, 1134, 1072.
tert- Butyl 2-(6,8-difluoro-1 -methyl-2 -oxo-1 ,2,3,4-tetrahydroquinolin-4-yl)acetate
206
o
t- BuO'
Mol. Wt: 311.32
Cleavage from solution-phase model, tert-Butyl 2-(3-benzylsulfonyl)-6,8-difluoro-1- 
methyl-2-oxo-1,2,3,4-tetrahydroquinolin-4-yl) acetate 205.
LiCI (32.8 mg, 0.75 mmol) was placed in a dry 25 ml round-bottomed flask and dried 
under vacuum for 5 min, the flask was then flushed with nitrogen. THF (1 ml) was 
added followed by a solution of ferf-butyl 2-(3-(benzylsulfonyl)-6,8-difluoro-1-methyl-2- 
oxo-1,2,3,4,-tetrahydroquinolin-4-yl)acetate 205 (40.1 mg, 0.086 mmol) in THF (1.5 ml). 
Sml2 (25 ml, 0.1 M solution in THF) was added and the reaction stirred for 18 h. The 
reaction mixture was diluted with CH2CI2 ( 1 0  ml) and quenched with saturated aqueous 
NaHC03 ( 8  ml). The organic phase was dried (MgS04), filtered and concentrated in 
vacuo to give the crude product. Purification by flash chromatography on silica gel 
using 30 % EtOAc/Pet ether as eluent gave terf-butyl 2-(6,8-difluoro-1-methyl-2-oxo-
1,2,3,4-tetrahydroquinolin-4-yl)acetate 206 (12.0 mg, 0.039 mmol, 45 %, unoptimised) 
as a pale yellow oil.
6 h (300 MHz, CDCI3) 1.48 (9H, s, C(CH3)3), 2.48 (2H, app d, J 7.5, ChfeCOzf-Bu), 2.61 
(1H, dd, J5.4, 5.1, 1H of CHa), 2.74 (1H, dd, J 5.4, 5.1, 1H of Chh), 3.40-3.47 (1H, m, 
CH), 3.45 (3H, d, J 6.3, NCH3), 6.79-6.86 (2H, m, ArH).
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5C (100 MHz, CDCIj) 28.3 (C(CH3)3), 33.4 (CH), 33.6 (NCH3), 37.2 (CH2), 38.8 
(CH2C 0 2t-Bu), 81.8 (C(CH3)3), 104.3 (ArCH), 110.4 (d, J 30.5, ArCH), 134.5 (2 x ArC),
169.5 (C=0), 170.4 (C=0). ArC-F signals were not seen due to signal to noise ratio. 
MS (Cl mode) 329 (M* + NH„, 91 %), 312 (M* + H, 100), 273 (18), 256 (49), 196 (15), 
160 (18). HRMS C,6H2oN0 3F2 requires 312.1406 found 312.1404.
Umax (ATR, cm'1) 2977, 2929, 1726 (C=0, ester), 1683, (C=0, amide), 1605, 1493, 
1362, 1310, 1259, 1145.
2-Bromo-N-(2-bromophenyl)-N-methylacetamide 209 see general procedure A
2-Benzylsulfanyl-N-[2-(1-(morpholin-4-yl)-1-oxo-prop-2-en-3-yl)phenyl]-N- 
methylacetamide 220
2-Benzylsulfanyl-A/-(2-bromophenyl)-A/-methylacetamide 175 (135 mg, 0.39 mmol) was 
added to a microwave reactor vial. Pd(OAc)2 (13.0 mg, 0.06 mmol), P(o-tol)3 (46 mg, 
0.15 mmol) and distilled acryloyl morpholine (0.15 ml, 116 mmol) were added to the 
vessel and it was sealed with a crimp cap septum. The vessel was flushed with argon 
and dry DMF (0.18 ml) and NEt3 (0.11 ml, 0.77 mmol) were added. The vessel was 
placed in the microwave cavity and heated to 100 °C for 10 h. The reaction mixture 
was diluted with Et20  (10 ml) and quenched with H20  (5 ml). The organic phase was 
dried (MgS04), filtered and concentrated in vacuo. The crude product was then 
retreated under the same reaction conditions. Purification by flash chromatography on 
silica gel eluting with 50 % EtOAc/Pet Ether gave 2-benzylsulfanyl-N-[2-(1-(morpholin-
4-yl)-1-oxo-prop-2-en-3-yl)phenyl]-N-methylacetamide 220 and as an orange oil (121 
mg, 0.29 mmol, 76 %).
§ h  (400 MHz, CDCI3) 2.83 (2H, app d, J 14.4, SCFbCO), 3.27 (3H, s, NCH3), 3.60-3.74 
(8H, m, ChU x 4), 3.86 (2H, s, PhCHzS), 6.83 (1H, d, J 15.6, CH=CHCO), 7.25-7.41 
(8H, m, ArH), 7.65 (1H, d, J 15.6, CH=CH), 7.63-7.68 (1Hm, ArH).
5C (100 MHz, C D C I 3 )  32.0 (SCH2CO), 37.4 (PhCH2S), 37.4 (NCH3), 67.1 (4 x CH2),
120.5 (CH=CHCO), 127.3 (ArCH), 128.3 (ArCH), 128.6 (ArCH x 2), 128.7 (ArCH),
129.2 (ArC), 129.5 (2 x ArCH), 129.6 (ArCH), 131.1 (ArCH), 133.2 (ArC), 137.6 
(PhCH=CH), 137.9 (CH=), 142.4 (ArC), 165.2 (C=Q), 170.0 (C=0).
o
123
MS (Cl mode) 428 (M+ + NH4, 16 %), 411 (16), 306 (18), 287 (28), 170 (23), 160 (23), 
160 (44), 8 8  (100). HRMS C23H30N3O3S requires 428.2002 found 428.2000. 
omax (ATR, cm'1) 2960, 2920, 2854, 1645 (C=0, amide), 1600, 1488, 1451, 1428, 
1301, 1228, 1195, 1041, 977.
2-(Benzylsulfonyl)-N-(2-bromophenyl)-N-methylacetamide 221
O O o
R X A , ^Bn N C16H16BrN03S
Br Mol. Wt: 382.27
mCPBA (1.70 g, max 55 % mCPBA, 6 . 6 6  mol) was added to a solution of 2- 
(benzylsulfanyl)-N-(2-bromophenyl)-N-methylacetamide 175 (389 mg, 1.11 mmol) in 
CH2CI2 (5 ml) at 0 °C. The reaction was allowed to warm to room temperature and 
stirred for until TLC showed the reaction to be complete (3 h). The reaction was 
quenched by addition of saturated, aqueous NaHC03 (10 ml) and diluted with CH2CI2 
(15 ml). The organic phase was washed with water (10 ml), and saturated aqueous 
NaHC03 (3 x 20 ml) dried (Na2S 0 4), filtered and concentrated in vacuo to give 2- 
(benzylsulfonyl)-N-(2-bromophenyl)-N-methylacetamide 221 as a white solid (394 mg,
1.03 mmol, 93% ).
8 H (400 MHz, CDCI3) 3.23 (3H, s, NCH3), 3.34 (1H, d, J 17.0, 1H of SOzChbCO), 3.56 
(1H, d, J 17.0, 1H of SOzChbCO), 4.36 (1H, d, J 14.0, 1H of PhCjiSOz), 4.80 (1H, d, J
14.0, 1H of PhChbSOz), 7.31-7.57 (7H, m 7 x ArH), 7.81-7.99 (2H, m, 2 x ArH).
5C (100 MHz, CDCI3) 36.7 (NCH3), 53.2 (SOzCHzCO), 128.6 (PhCH2S 0 2), 128.6 (ArC),
129.3 (ArCH x 2), 129.9 (ArCH), 130.1 (ArCH), 130.5 (ArCH), 130.9 (ArCH), 131.0 
(ArCH), 131.5 (2 x ArCH), 134.2 (2 x ArC), 160.3 (C O ).
MS (El mode) 401 (M+ + NH4 81Br, 55 %), 399 (M+ + NH4 79Br, 51 %), 220 (32), 188 
(28), 173 (25), 165 (61), 148 (39), 108 (99), 93 (38). HRMS BrC16H20N2O3S requires 
399.0373 found 399.0373.
u max (ATR, cm'1) 3066, 2990, 2932, 1721, 1662 (C O ), 1578, 1532, 1478, 1431, 1384, 
1320, 1219, 1121.
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4 . 1.2 G E N E R A L  P R O C E D U R E  A :  P R E P A R A T I O N  O F  c t - B R O M O  A M I D E S  F R O M  
S E C O N D A R Y  A N I L I N E S
2-Bromo-N-(2-bromophenyl)-N-methylacetamide 209
To a solution of 2-bromo-N-methyl aniline 156 (485 mg, 2.60 mmol) in CH2CI2 (10 ml) 
at 0 °C was added NEt3 (0.44 ml, 3.13 mmol) followed by bromoacetyl bromide (0.40 
ml, 3.13 mmol). The reaction was warmed to room temperature and stirred overnight. 
The reaction mixture was diluted with Et20  (25 ml) and quenched with saturated 
aqueous NH4CI (15 ml). The organic phase was dried (Na2S 0 4), filtered and 
concentrated in vacuo to give the crude product. Purification by flash chromatography 
on silica gel using 30 % EtOAc/Pet ether as eluent gave 2-bromo-N-(2-bromophenyl)- 
N-methylacetamide 209 as a pale orange solid (632 mg, 2.06 mmol, 79 %) which was 
used without further purification.
8h (400 MHz, CDCIj) 3.25 (3H, s, NCH3), 3.53 (1H, d, J 11.3, 1H of CFb), 3.69 (1H, d, J
11.3, 1H of CHz), 7.28-7.35 (1H, m, ArCH), 7.39-7.47 (2H, m, ArH), 7.70-7.73 (1H, d, J
7.5, ArH).
8c (100 MHz, CDCI3) 27.2 (NCH3), 37.2 (CH2), 123.5 (ArC), 129.6 (ArCH), 130.3 
(ArCH), 130.9 (ArCH), 134.4 (ArCH), 141.9 (ArC), 167.0 (C=0).
MS (Cl isobutane mode) 308.0 (100 %, M*. (81Br)), 306.0 (54, WT, 79Br)), 264.0 (18, 
(81Br)), 262.0 (11, (79Br)), 228.1 (41, (81Br)), 226.1 (28, (79Br)), 148.1 (63). HRMS 
C9H10NOBr2 requires 307.9109 found 307.9106.
Om» (ATR, cm'1) 3055, 3005, 2940, 1664 (C=0), 1465, 1363, 1303.
N-Benzyl-2-bromo-N-(2-bromophenyl)acetamide 210
o
C9HgBr2NO 
Mol. Wt: 306.98
O
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According to general procedure A: 2-Bromo-N-benzyl aniline 227 (1.46 g, 5.61 mmol) 
was treated with bromoacetyl bromide (0.59 ml, 4.60 mmol) and NEt3 (0.64 ml, 4.60 
mmol) in CH2CI2 (20 ml) to give N-benzyl-2-bromo-N-(2-bromophenyl)acetamide 210 
as a white crystalline solid (1.22 g, 4.60 mmol, 70 %) following purification by flash 
chromatography eluting with 10 % EtOAc/Pet ether.
M.p. 74.5-76.5 °C
8h (300 MHz, CDCfe) 3.56 (1H, d, AB system, J 11.4, 1H of ChhBr), 3.74 (1H, d, AB 
system, J 11.4, 1H of ChhBr), 4.14 (1H, d, AB system, J 14.4, 1H of ChhPh), 5.62 (1H, 
d, AB system, J 14.4, 1H of ChhPh), 6.92-6.96 (1H, m, ArH), 7.23-7.32 (7H, m, ArH), 
7.70-7.75 (1H, m, ArH).
8c (100 MHz, CDCI3) 28.0 (CH2Br), 52.5 (CH2Ph), 123.8 (ArC), 128.1 (ArC), 128.8 
(ArCH), 128.9 (2 x ArCH), 129.6 (2 x ArCH), 130.8 (ArCH), 131.6 (ArC), 134.2 (ArC),
136.4 (ArCH), 139.8 (ArCH), 166.5 (C=0).
MS (Cl mode) 403 (M* + NH4, 81Br x 2, 49 %), 401 (M* + NH„, 79Br, 81Br, 100 %), 399 
(M* + NH4, 79Br x 2, 60 %), 386 (®1Br x 2, 23), 384 (79Br, 81Br, 56), 382 (79Br x 2, 28), 
264, 106. HRMS C15H17N 0279Br requires 398.9702 found 398.9699.
Umax (ATR, cm'1) 3030, 2338, 1659 (C=0), 1430, 1388, 1292, 1195, 1023, 880.
2-Bromo-N-(2-bromo-4-/sopropylphenyl)-N-methylacetamide 211
Br C12H15Br2NO 
Mol. Wt: 349.06
According to general procedure A: 2-Bromo-4-/sopropyl-N-methyl aniline 224 (5.04 g,
22.0 mmol) was treated with bromoacetyl bromide (3.37 ml, 22.0 mmol) and NEt3 (3.70 
ml, 26.4 mmol) in CH2CI2 (80 ml) to give 2-bromo-N-(2-bromo-4-/sopropylphenyl)-N- 
methylacetamide 211 as an orange oil (5.79 g, 16.6 mmol, 75%) following purification 
by flash chromatography eluting with 30 % EtOAc/Pet ether.
8h (400 MHz, CDCI3) 1.29 (6H, d, J 7.8, CH(CH3)2), 2.96 (1H, sept, J 7.8, CH(CH3)2), 
3.56 (1H, d, AB system, J 9.2, 1H of ChhBr), 3.69 (1H, d, AB system, J 9.2, 1H of 
ChhBr), 7.22-7.34 (2H, m, ArH), 7.76 (1H, s, ArH).
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8 C (100 MHz, CDCI3) 24.0 (2 x CH(CH3)2), 27.5 (CH2), 34.0 (CH(CH3)2), 37.0 (NCH3),
123.0 (ArC), 127.6 (ArCH), 129.7 (ArCH), 132.1 (ArCH), 139.4 (ArC), 152.1 (ArC),
166.8 (C=0).
MS (Cl mode) 352 (M* . 81Br x 2, 16 %), 350 (M *, 81Br, 79Br, 38 %), 348 (M*. 79Br x 2, 
24 %), 272 (81Br x 2, 21)270 (81Br, 79Br, 32), 268 (79Br x 2, 18), 207 (28), 190 (100). 
HRMS C 12H16N 0 79Br2 requires 347.9593 found 347.9599.
u™, (ATR, cm'1) 2960, 2929, 2871, 1667 (C=0, amide), 1490, 1429, 1370, 1305, 
1216, 1119, 1052, 1027, 881.
2-Bromo-N-(2-bromo-4,6-difluorophenyl)-N-methylacetamide 212
b^ n
Dr CqHtBToF oNO
Br Mol. Wt: 342.96
According to general procedure A: 2-Bromo-4)6-difluoro-A/-methyl aniline 223 (1.16 g, 
5.22 mmol) was treated with bromoacetyl bromide (0.55 ml, 6.27 mmol) and NEt3 (0.88 
ml, 6.27 mmol) in C H 2 C I 2  (10 ml) to give 2-bromo-N-(2-bromo-4,6-difluorophenyl)-N- 
methylacetamide 212 as an orange oil (1.62 g, 4.72 mmol, 90%) following purification 
by flash chromatography eluting with 30 % EtOAc/Pet ether.
§ h  (400 MHz, CDCI3) 3.23 (3H, s, NCH3), 3.61 (1H, d ,  AB system, J 15.0, 1 H of CH2),
3.68 (1H, d ,  AB system, J 15.0, 1H of CHz), 7.00-7.04 (1H, m, ArH), 7.29-7.33 (1 H, m, 
ArH).
5C (100 MHz, C D C I 3 )  26.5 (NCH3), 36.2 (CH2), 105.5 (t, J 26.0, ArCH), 117.2 (d, J25.0, 
ArCH), 166.9 (C=0), ArC-F signals not seen due to signal to noise ratio.
MS (Cl mode) 363 (M+ 81Br, 81Br, 45 %), 361 (M+ 79Br, 81Br, 90 %) 359 (M+ 79Br, 79Br, 
49 %), 283 (29), 264 (78), 201 (54), 184 (99).
umax (ATR, cm'1) 3087, 2949, 1674 (C=0), 1587, 1484, 1427, 1371, 1315, 1169, 1126, 
995.
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2-Bromo-N-(2-iodophenyl)-N-methylacetamide 222
o
CgHgBrINO 
Mol. Wt: 353.98
According to general procedure A: 2-lodo-N-methyl aniline 225 (442 mg, 1.90 mmol) 
was treated with bromoacetyl bromide (0.20 ml, 2.28 mmol) and NEt3 (0.32 ml, 2.28 
mmol) in CH2CI2 (10 ml) to give 2-bromo-N-(2-iodophenyl)-N-methylacetamide 222 as 
an orange oil (491 mg, 1.45 mmol, 76 %) following flash chromatography eluting with 
40 % EtOAc/Pet ether.
8h (500 MHz, CDCfe) 3.03 (3H, s, NCH3), 3.29 (1H, d, AB system, J 11.5, 1H of Chh),
3.46 (1H, d, AB system, J 11.5, 1H of Chh), 6.93-7.08 (1H, m, ArH), 7.08-7.30 (2H, m, 
ArH), 7.76 (1H, m, ArH).
8C (100 MHz, CDCI3) 27.7 (NCH3), 37.3 (CH2), 129.6 (2 x ArCH), 130.5 (ArCH), 130.9 
(ArCH), 140.7 (ArC), 145.4 (ArC), 166.6 (C=0).
MS (Cl mode) 373 (M+ + NH4, 81Br, 82 %), 371 (M+ + NH4, 79Br, 99 %), 293 (11), 165 
(76), 148 (38). HRMS C9Hi3N2OBrl requires 370.9250 found 370.9253.
Umax (ATR, cm'1) 3052, 2931, 2348, 1660 (C=0), 1576, 1459, 1434, 1370, 1220, 1020.
4.1.3 GENERAL PROCEDURE B: N-METHYLATION OF PRIMARY ANILINES
2-Bromo-N-methyl aniline 15661
n-BuLi (9.50 ml of a 2.5 M sof in hexanes, 23.0 mmol) was added to a solution of 2- 
bromoaniline (8.00 g, 46.0 mmol) in THF (60 ml) at -40 °C, stirred for 15 min, allowed 
to warm to room temperature and stirred for a further 45 min. Mel (1.43 ml, 23.0 mmol) 
was added at -60 °C, stirred for 15 min, warmed to room temperature and stirred 
overnight. The procedure was repeated with a further 0.5 eq portion of /7-BuLi/Mel and 
again stirred overnight. The reaction was quenched with water (40 ml) and extracted 
with ethyl acetate (3 x 40 ml). The combined organic extracts were washed with 
saturated aqueous NaHCQ3, dried (MgS04), filtered and concentrated in vacuo. The
C7H8BrN 
Mol. Wt: 186.05
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crude product was purified by column chromatography on silica gel using 3 % ethyl 
acetate: pet ether as eluent and gave the product 156 as an orange oil (6.52 g, 35.0 
mmol, 76 % yield), and recovered 2-bromoaniline (0.85 g, 4.91 mmol, 10 %).
6 h (400 MHz, CDCI3) 2.74 (3H, s, CH3), 4.22 (1H, bs, NH), 6.43-6.50 (2H, m, ArH),
7.08 (1 H, t, J 8.4 ArH), 7.30 (1H, d, J 6.4, ArH)-
6 c (100 MHz) 31.0 (CH3), 110.0 (ArC), 111.2 (ArCH), 118.0 (ArCH), 129.0 (ArCH),
134.4 (ArCH), 146.4 (ArC).
MS (El mode) 187.0 (M+ , 81Br, 95 %), 186.0 (90), 185.0 (M+ , 79Br, 99 %), 184.0 (87),
105.1 (25), 83.0 (74), 77.1 (34), 47.0 (13). HRMS C7H7NBr requires 183.9762 found 
183.9758.
2-Bromo-4,6-difluoro-N-methyl aniline 223 61
^NH
Fv A / BrY  Y f  C7H6BrF2N
Mol. Wt: 222.03
F
According to general procedure B: 2-bromo-4,6-fluoroaniline (10.00 g, 48.1 mmol) was 
treated with n-BuLi (11.3 ml of a 2.13 M soln in hexanes, 24.0 mmol) and Mel (1.50 ml, 
24.0 mmol) in THF (60 ml) to give 2-bromo-4,6-difluoro-N-methyl aniline 223 as an 
orange oil (8.43 g, 38.0 mmol, 79 % yield) following purification by flash 
chromatography eluting with 5 % EtOAc/ Pet ether.
5h (400 MHz, C D C I 3 )  2.91 (3H, s, NCH3), 6.67-6.74 (1H, m, ArH), 6.92-6.97 (1H, m, 
ArH).
2-Bromo-4-/sopropyl-N-methylaniline 224
""NH
Br
Ci0Hi4BrN 
Mol. Wt: 228.13
According to general procedure B: 2-bromo-4-/sopropyl aniline (7.17 g, 33.5 mmol) was 
treated with n-BuLi (7.9 ml of a 2.13 M sof in hexanes, 16.7 mmol) and Mel (1.04 ml,
16.7 mmol) in THF (50 ml) to give 2-bromo-4-/sopropyl-N-methyl aniline 224 as an
129
orange oil (8.04 g, 22.1 mmol, 66 % yield) following purification by flash 
chromatography eluting with 10 % EtOAc/ Pet ether.
6 h (400 MHz, CDCI3) 1.23 (6H, d, J 7.0, 2 x CH3), 2.83 (1H, sept, J 7.0, CH), 2.90 (3H, 
s, NCH3), 6.60 (1H, d, J8.3, ArH), 7.10 (1H, d, J 8.3, ArH), 7.32 (1H, s, ArH).
6 C (100 MHz) 24.5 (2 x CH3), 31.2 (NCH3), 33.4 (CH), 110.0 (ArC), 111.2 (ArCH), 126.8 
(ArCH), 130.6 (ArCH), 138.9 (ArC), 144.4 (ArC).
MS (El mode) 229.1 (M+, 81Br, 26 %), 227.06 (M+, 79Br, 27 %), 214.0 (81Br, 64), 212.0 
(79Br, 70), 133.1 (43), 83.0 (99).
2-lodo-N-methylaniline 2 2 5 97
^NH
C7H8IN 
Mol. Wt: 233.05
According to general procedure B: 2-iodoaniline (4.00 g, 18.3 mmol) was treated with 
n-BuLi (3.65 ml of a 2.5 M sof in hexanes, 9.13 mmol) and Mel (0.57 ml, 9.13 mmol) in 
THF (45 ml) to give 2-iodo-N-methyl aniline 225 as an orange oil (2.46 g, 10.6 mmol, 
58 % yield) following purification by flash chromatography eluting with 10 % EtOAc/ Pet 
ether.
6 h (400 MHz, C D C I 3 )  3.09 (3H, s, NCH3), 6.44-6.49 (2H, m, 2 x ArCH), 7.15-7.18 (1H, 
m, ArH), 7.56-7.59 (1H, m, ArH).
2-Bromo-N-benzylaniline 227
HN^Ph
Br C13H12BrN 
Mol. Wt: 262.15
To a solution of 2-bromoaniline (4.00 g, 23.3 mmol) and NEt3 (3.89 ml, 28.0 mmol) in 
CH2CI2 (120 ml) at 0 °C was added benzoyl chloride (2.98 ml, 25.1 mmol). The 
reaction was stirred at room temperature overnight and quenched by addition of H20  
(100 ml). The organic phase was washed with H20  (80 ml), saturated aqueous 
NaHC03 (4 x 80 ml), dried (MgS04), filtered and concentrated in vacuo to give the 
crude benzoyl amide as a pale orange solid (5.43 g, 19.9 mmol). The crude amide was 
dissolved in THF (100 ml) and cooled to 0 °C and LiAIH4 (1.66 g, 43.8 mmol) added.
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The reaction was stirred at room temperature overnight and quenched with H20  (100 
ml). The organic phase was washed with H20  (3 x 50 ml), dried (MgS04), filtered and 
concentrated in vacuo to give 2-bromo-N-benzylaniline 227 as a pale yellow oil (5.74 g,
21.9 mmol, 94 % overall).
6h (500 MHz, CDCI3) 4.87 (2H, s, Chh), 4.87 (1H, bs, NH), 6.66-6.70 (2H, m, 2 x ArH), 
7.20-7.55 (7H, m, 7 x ArH).
5c (100 MHz) 48.3 (CH2), 110.0 (ArC), 112.0 (ArCH), 118.3 (ArCH), 127.6 (ArCH),
127.7 (2 x ArCH), 128.8 (2 x ArCH), 129.1 (ArCH), 132.7 (ArCH), 139.0 (ArC), 145.1 
(ArC).
MS (Cl mode) 264 (M+, 81Br, 92 %), 262 (M+, 79Br, 99 %). HRMS Ci3Hi2NBr requires 
261.0148 found 261.0146.
4.2 SOLID-PHASE SYNTHESIS
Merrifield thioacetate resin 39
c r * r
O
Merrifield resin (5.00 g, 6.00 mmol) was swollen in DMF (50 ml) for 15 min. Potassium 
thioacetate (1.88 g, 16.5 mmol) in DMF (10 ml) was added and the reaction mixture 
stirred slowly at room temperature for 24 h before washing according to the standard 
procedure.
Umax (ATR, cm'1) 2917, 2023,1687 (C=0), 1493,1450, 1130.
Thiol resin 4 8 39
C P SH
Thioacetate resin (5.15 g, 6.13 mmol) was swollen in THF for 15 min. LiBH4 (0.66 g,
30.6 mmol) was added and the reaction mixture stirred slowly at room temperature for 
48 h. The reaction was then quenched by dropwise addition of MeOH and washed 
according to the standard procedure.
omax (ATR, cm'1) 3024, 2918, 1601, 1493, 1450, 1065.
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4.2.1 GENERAL PROCEDURE C: IMMOBILISATION OF a-BROMO AMIDES 
USING THIOL RESIN 48
q T sJ I n.r 3
V
R2
S-Merrifield supported 2-sulfanyl-N-(2-bromophenyl)-N-methylacetamide 216
dr
Thiol resin 48 (1.00 g, 1.20 mmol) was swollen in DMF (10 ml) for 15 min. NEt3 (0.85 
ml, 6.00 mmol) was added followed by a solution of 2-bromo-N-(2-bromophenyl)-N- 
methylacetamide 209 (0.737 g, 2.40 mmol) in DMF (5 ml) and the reaction mixture 
stirred slowly for 24 h before washing according to the standard procedure.
Umax (ATR, cm'1) 2918, 1660 (C=0), 1493, 1450, 1365, 1061, 1028.
8C (MAS, 75 MHz, CH2CI2) 23.8 (ChhS), 36.9 (NCH3), 124.0 (ArCBr), 129.6 (ArCH),
130.6 (ArCH), 131.0 (ArCH), 134.5 (ArCH), 142.9 (ArCN), 170.2 (C=0).
S-Merrifield supported-2-sulfanyl-N-(2-bromophenyl)acetamide 151a
According to general procedure C: Thiol resin 48 (1.20 g, 1.49 mmol) was treated with 
2-bromo-N-(2-bromophenyl) acetamide 151 (872 mg, 2.78 mmol) in NEt3 and DMF.
Umax (ATR, cm'1) 3024, 2919, 1691 (C=0, amide), 1589, 1504, 1435, 1297, 1018.
R1 R2 R3 X No.
H H H Br 151a
H H Bn Br 2 1 0 a
H 'Pr Me Br 2 1 1 a
F F Me Br 2 1 2 a
H H Me Br 216
H H Me I 2 2 2 a
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S-Merrifield supported 2-sulfanyl-N-(2-bromophenyi)-N-benzylacetamide 210a
0 ^ S^ N ~ P h
(V
According to general procedure C: Thiol resin 48 (1.33 g, 1.59 mmol) was treated with 
2-bromo-N-(2-bromo)-N-benzylacetamide 210 (1.22 g, 3.18 mmol) in NEt3 and DMF.
umax (ATR, cm'1) 2914, 1658 (C O ), 1428, 1366, 1294.
S-Merrifield supported 2-sulfanyl-N-(2-bromo-4-/sopropylphenyl)-N-
methylacetamide 211a
0 ^ s- V
According to general procedure C: Thiol resin 48 (2.00 g, 2.40 mmol) was treated with 
2-bromo-N-(2-bromo-4-/sopropylphenyl)-N-methylacetamide 211 (2.51 g, 7.20 mmol) in 
NEt3 and DMF.
Umax (ATR, cm"1) 3024, 2920, 1661 (C=0), 1601, 1491, 1449, 1365, 1308, 1122, 1058, 
1026.
S-Merrifield supported 2-sulfanyl-N-(2-bromo-4,6-difluorophenyl)-N-
methylacetamide 212a
c r ~ X
According to general procedure C: Thiol resin 48 (3.94 g, 4.73 mmol) was treated with 
2-bromo-N-(2-bromo-4,6-difluorophenyl)-N-methylacetamide 212 (3.24 g, 9.46 mmol) 
in NEt3 and DMF.
Umax (ATR, cm'1) 3024, 2919, 1671 (C=0), 1590, 1481, 1428, 1363, 1313, 1111, 1057, 
995.
S-Merrifield supported 2-sulfanyl-N-(2-iodophenyl)-N-methylacetamide 222a
( X " s- V
dr'
According to general procedure C: Thiol resin 48 (650 mg, 0.78 mmol) was treated 
with 2-bromo-N-(2-iodophenyl)-N-methylacetamide 222 (550 mg, 1.56 mmol) in NEt3 
and DMF.
Umax (ATR, cm'1) 3024, 2917, 1659 (C=0), 1597, 1442, 1364, 1060, 904.
4.2.2 GENERAL PROCEDURE D: PALLADIUM-CATALYSED HECK REACTIONS 
ON SOLID-PHASE
( X , s ^ x n.r> 0
R2
R1 R2 R3 R4 No.
H H H Of-Bu 151b
H H Me Morph 209b
H H Bn Of-Bu 2 1 0 b
H 'Pr Me Of-Bu 2 1 1 b
F F Me Of-Bu 2 1 2 b
H H Me Of-Bu 217
S-Merrifield supported-2-sulfanyl-N-[2-(1 -ferf-butoxy-1 -oxo-prop-2-en-3-
yl)phenyl]-N-methyl acetamide 217
o
S-Merrifield supported 2-sulfanyl-N-(2-bromophenyl)-N-methylacetamide 216 (970 mg, 
0.95 mmol) was added to a microwave vial equipped with magnetic stirrer bar and 
swollen in DMF (0.33 ml) for 15 min. Pd(OAc)2 (21.3 mg, 0.95 mmol) and P(o-tol)3 
(28.9 mg, 0.95 mmol) were added followed by NEt3 (0.53 ml, 3.80 mmol) and o-xylene 
(0.81 mmol). The vial was stirred and flushed with nitrogen before sealing with a crimp 
cap. The vial was placed in the microwave cavity and heated to 100 °C for 20 h. The 
resin was then washed using the standard procedure and dried under vacuum before 
retreatment as above.
i w  (ATR, cm'1) 3023, 2923, 2861, 1723 (C=0, ester), 1661 (C=0, amide), 1449, 
1366, 1148, 1063.
8C (MAS, 75 MHz, CD2CI2) 28.5 (C(CH3)3), 33.1 (SCH2CO), 80.8 (C(CH3)3), 123.8-138.1 
(ArCH signals + support), 165.9 (C=0, ester), 169.5 (C=0, amide).
S-Merrifield supported-2-sulfanyl-N-[2-(1 -tert-butoxy-1 -oxo-prop-2-en-3-yl)phenyl] 
acetamide 151b
According to general procedure D: S-Merrifield supported 2-sulfanyl-N-(2-
bromophenyl) acetamide 151a (1.39 g, 1.35 mmol) was treated with tert-butyl acrylate 
(2.37 ml, 16.2 mmol), Pd(OAc)2 (30.2 mg, 0.14 mmol), P(o-tol)3 (41.0 mg, 0.14 mmol) 
and NEt3 (0.38 ml, 2.70 mmol) in DMF (1.5 ml).
S-Merrifield supported-2-sulfanyl-N-[2-(1 -(morpholin-4-yl)-1 -oxo-prop-2-en-3- 
yl)phenyl]-N-methylacetamide 209b
o
0 ^ S\ ^ N H  O
i w  (ATR, cm'1) 2919, 1716 (C=Ot ester), 1696 (C=0, amide), 1515, 1448, 1296, 
1147.
o
c P s- V  o
135
According to general procedure D: S-Merrifield supported 2-sulfanyl-N-(2-
bromophenyl)-N-methylacetamide 216 (642 mg, 0.58 mmol) was treated with acryloyl 
morpholine (0.44 ml, 3.51 mmol), Pd(OAc)2 (19.7 mg, 0.09 mmol), P(o-tol)3 (26.7 mg, 
0.09 mmol), and NEt3 (0.16 ml, 1.17 mmol) in DMF.
Umax (ATR, cm ') 3017, 2918, 1651(0=0, amide x2), 1435, 1365, 1303, 1228, 1114.
S-Merrifield supported-2-sulfanyl-N-[2-(1 -terf-butoxy-1 -oxo-prop-2-en-3-yl)
phenyl]-N-benzyl acetamide 210b
0 ^ S^ ^ N ^ P h  O
According to general procedure D: S-Merrifield supported 2-sulfanyl-N-(2-bromo)-N- 
benzylacetamide 210a (600 mg, 0.88 mmol) was treated with ferf-butyl acrylate (0.93 
ml, 6.33 mmol), Pd(OAc)2 (11.9 mg, 0.05 mmol), P(o-tol)3 (16.1 mg, 0.05 mmol), and 
NEt3 (0.15 ml, 1.06 mmol) in DMF and o-xylene.
i w  (ATR, cm’1) 3026, 2920, 1713 (C=0, ester), 1659 (C=0, amide), 1600, 1493, 
1474, 1452, 1390, 1367, 1319, 1147, 756.
S-Merrifield supported-2-sulfanyl-N-[2-(1 -fe/t-butoxy-1 -oxo-prop-2-en-3-yl)-4-
/sopropylphenyl]-N-methyl acetamide 211b
'Of-Bu
According to general procedure D: S-Merrifield supported 2-sulfanyl-N-(2-bromo-4- 
/sopropylphenyl)-N-methylacetamide 211a (1.50 mg, 1.37 mmol) was treated with tert- 
butyl acrylate (2.10 ml, 16.4 mmol), Pd(OAc)2 (30.6 mg, 0.14 mmol), P(o-tol)3 (41.5 mg, 
0.14 mmol), and NEt3 (0.38 ml, 2.73 mmol) in DMF and o-xylene.
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Umax (ATR, cm'1) 3017, 2916, 1721(C=0, ester), 1662 (C=0, amide), 1481, 1443,
1366, 1147.
S-Merrifield supported-2-sulfanyl-N-[2-(1 -terf-butoxy-1 -oxo-prop-2-en-3-yl)-4,6- 
difluorophenyl]-N-methyl acetamide 212b
o
Of-Bu
According to general procedure D: S-Merrifield supported 2-sulfanyl-N-(2-bromo-4,6- 
difluorophenyl)-N-methylacetamide 212a (2.50 g, 2.28 mmol) was treated with tert-butyl 
acrylate (3.50 ml, 27.3 mmol), Pd(OAc)2 (51.0 mg, 0.23 mmol), P(otol)3 (69.0 mg, 0.23 
mmol), and NEt3 (0.64 ml, 4.55 mmol) in DMF.
(ATR, cm'1) 3016, 2916, 1723 (C=0, ester), 1671 (C=0, amide), 1599, 1449, 
1358, 1251, 1142.
4.2.3 GENERAL PROCEDURE E: OXIDATION OF SULFIDES TO SULFONES
R1 R2 R3 R4 No.
H H H Of-Bu 151c
H H Me Morph 209c
H H Bn Of-Bu 2 1 0 c
H ‘Pr Me Of-Bu 237
F F Me Of-Bu 2 1 2 c
H H Me Of-Bu 217c
S-Merrifield supported-2-sulfonyl-N-[2-(1 -terf-butoxy-1 -oxo-prop-2-en-3-
yl)phenyl]-N-methyl acetamide 217c
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S-Merrifield supported-2-sulfanyl-N-[2-(1-terf-butoxy-1-oxo-prop-2-en-3-yl)phenyl]-N- 
methyl acetamide 217 (1.05 g, 0.99 mmol) was swollen in CH2CI2 (8 ml) for 15 min and 
cooled to 0 °C. K2C 0 3 (273 mg, 1.97 mmol) was added followed by mCPBA (443 mg, 
max. mCPBA 77 %, 1.97 mmol) and the reaction allowed to warm to room 
temperature. The reaction was stopped after 30 min by filtration of the resin, washing 
and drying.
Umax (ATR, cm’1) 3024, 2969, 2922, 2860, 1724 (C O , ester), 1660 (C O , amide), 
1602, 1490, 1450, 1367, 1147, 1061.
S-Merrifield supported-2-sulfonyl-N-[2-(1 -fe/t-butoxy-1 -oxo-prop-2-en-3-
yl)phenyl] acetamide 151c
According to general procedure E: S-Merrifield supported-2-sulfanyl-N-[2-(1-terf-
butoxy-1-oxo-prop-2-en-3-yl)phenyl] acetamide 151b (1.80 g, 1.67 mmol) was treated 
with mCPBA (750 mg, 3.35 mmol) and K2C 0 3 (463 mg, 3.35 mmol) in CH2CI2 (5 ml).
amide), 1598, 1493, 1386, 1322, 1250.
S-Merrifield supported-2-sulfonyl-N-[2-{1 -(morpholin-4-yl)-1 -oxo-prop-2-en-3- 
yl)phenyl]-N-methylacetamide 209c
According to general procedure E: S-Merrifield supported-2-sulfonyl-N-[2-(1-
(morpholin-4-yl)-1-oxo-prop-2-en-3-yl)phenyl]-N-methylacetamide 209b (705 mg, 0.61 
mmol) was treated with mCPBA (272 mg, 1.21 mmol) and K2C 0 3 (168 mg, 1.21 mmol) 
in CH2CI2 (5 ml).
Umax (ATR, cm'1) 3062, 3024, 2973, 2920, 2852, 1724 (C=0, ester), 1698 (C=Q,
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om„  (ATR, cm'1) 3058, 3024, 2918, 2853, 1644 (C=0, amide x 2), 1607, 1488, 1448,
1369, 1319, 1113, 1028, 1060, 882.
S-Merrifield supported-2-sulfonyl-N-[2-(1 -terf-butoxy-1 -oxo-prop-2-en-3-yl)
phenyl]-N-benzyl acetamide 210c
According to general procedure E: S-Merrifield supported-2-sulfanyl-N-[2-(1-ferf-
butoxy-l-oxo-prop-2-en-3-yl) phenyl]-N-benzyl acetamide 210b (610 mg, 0.51 mmol) 
was treated with mCPBA (230 mg, 1.02 mmol) and K2C 0 3 (142 mg, 1.02 mmol) in 
CH2CI2 (4 ml).
Umax (ATR, cm-1) 3060, 3026, 2978, 2923, 1724 (C=0, ester), 1655 (C=0, amide), 
1600, 1492, 1451, 1391, 1366, 1324, 1255, 1147, 1060, 1030, 755.
S-Merrifield supported-2-sulfonyl-N-[2-(1 -terf-butoxy-1 -oxo-prop-2-en-3-yl)-4- 
/'sopropylphenyl]-N-methyl acetamide 237
‘Of-Bu
According to general procedure E: S-Merrifield supported-2-sulfonyl-N-[2-(1-terf-
butoxy-1-oxo-prop-2-en-3-yl)-4-/sopropylphenyl]-N-methyl acetamide 211b (1.60 g, 
1.41 mmol) was treated with mCPBA (631 mg, 2.42 mmol) and K2C 0 3 (389 mg, 2.82 
mmol) in CH2CI2 (10 ml).
i w  (ATR, cm’1) 3017, 2921, 1723 (C=0, ester), 1660 (C=0, amide), 1493, 1450, 
1367, 1142, 1057.
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S-Merrifield supported-2-sulfonyl-N-[2-(1 -terf-butoxy-1 -oxo-prop-2-en-3-yl)-4,6-
difluorophenyl]-N-methyl acetamide 212c
According to general procedure E: S-Merrifield supported-2-sulfanyl-N-[2-(1-terf-
butoxy-1-oxo-prop-2-en-3-yl)-4,6-difluorophenyl]-N-methyl acetamide 212b (2.81 g, 
2.44 mmol) was treated with mCPBA (1.10 g, 4.89 mmol) and K2C 0 3 (679 mg, 4.89 
mmol) in CH2CI2 (10 ml).
umax (ATR, cm*1) 2922, 1724 (C=0, ester), 1668 (C=0, amide), 1597, 1450, 1367, 
1319, 1252, 1057.
4.2.4 GENERAL PROCEDURE F: CYCLISATION OF SOLID-SUPPORTED
SULFONE SUBSTRATES
R1 R2 R3 R4 No.
H H H Of-Bu 151d
H H Me Morph 209d
H H Bn Of-Bu 21 Od
H 'Pr Me Of-Bu 234
F F Me Of-Bu 212d
H H Me Of-Bu 218
S-Merrifield supported tert- butyl-2-(1 -methyl-2-oxo-3-sulfonyl-1,2,3,4-
tetrahydroquinolin-4-yl) acetate 218
f-BuO'
S-Merrifield supported-2-sulfonyl-N-[2-(1 -terf-butoxy-1 -oxo-prop-2-en-3-yl)phenyl]-N- 
methyl acetamide 217c (1.05 g, 0.96 mmol) was swollen in DMF (7 ml) for 15 min.
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K2C 0 3 (1.06 g, 7.64 mmol) was added and the reaction mixture stirred slowly overnight 
before washing using the standard procedure.
«ma* (ATR, cm'1) 3023, 2973, 2921, 2855, 1725 (C=0, ester), 1661 (C=0, amide), 
1488, 1449, 1367, 1148, 1060.
S-Merrifield supported fert-butyl-2-(2-oxo-3-sulfonyl-1,2,3,4-tetrahydroquinolin-4- 
yl) acetate 151d
o
f-BuO'
According to general procedure F: S-Merrifield supported-2-sulfonyl-N-[2-(1-terf-
butoxy-1-oxo-prop-2-en-3-yl)phenyl] acetamide 151c (2.64 g, 2.38 mmol) was treated 
with K2C 0 3 (1.97 g, 14.3 mmol) in DMF (15 ml).
Uma, (ATR, c m 1) 3058, 3024, 2977, 2920, 2850, 1723 (C=0, ester), 1698 (C=0, 
amide), 1599,1517, 1492, 1449, 1365, 1251, 1026.
S-Merrifield supported-1-methyl-2-oxo-4-[2-(morpholin-4-yl)-2-oxo-ethyl]-3-
sulfonyl-1,2,3,4-tetrahydroquinoline 209d
According to general procedure F: S-Merrifield supported-2-sulfonyl-N-[2-(1-
(morpholin-4-yl)-1-oxo-prop-2-en-3-yl)phenyl]-N-methylacetamide 209c (700 mg, 0.59 
mmol) was treated with K2C 0 3 (488 mg, 3.53 mmol) in DMF (6 ml).
Umax (ATR, cm'1) 3017, 2918, 1644 (C=0, amide x 2), 1443, 1369, 1308,1229, 1028.
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S-Merrifield supported ferf-butyl-2-(1 -benzyl-2-oxo-3-sulfonyl-1,2,3,4-
tetrahydroquinolin-4-yl) acetate 21 Od
o
f-BuO'
Ph-
According to general procedure F: S-Merrifield supported-2-sulfonyl-N-[2-(1-terf-
butoxy-1-oxo-prop-2-en-3-yl) phenyl]-N-benzyl acetamide 210c (605 mg, 0.51 mmol) 
was treated with K2C 0 3 (421 mg, 3.05 mmol) in DMF (6 ml).
Umax (ATR, c m 1) 3058, 3026, 2977, 2920, 1724 (C=0, ester), 1660 (C=0, amide), 
1600, 1493, 1451, 1390, 1367, 1323, 1255, 1147, 1060, 1029, 752.
S-Merrifield supported ferf-butyl-2-(1-methyl-2-oxo-3-sulfonyl-7,9-difluoro-1,2,3,4- 
tetrahydroquinolin-4-yl) acetate 212d
f-BuO'
According to general procedure F: S-Merrifield supported-2-sulfanyl-N-[2-(1-terf-
butoxy-1-oxo-prop-2-en-3-yl)-4,6-difluorophenyl]-N-methyl acetamide 220c (2.94 g,
2.47 mmol) was treated with K2C 0 3 (1.37 g, 9.88 mmol) in DMF (15 ml).
U n a , (ATR, cm'1) 2921, 1724 (C=0, ester), 1669 (C=0, amide), 1597, 1481, 1443, 
1366, 1252, 1142.
S-Merrifield supported ferf-butyl-2-(1 -methyl-2-oxo-3-sulfonyl-7-/sopropyl-1,2,3,4- 
tetrahydroquinolin-4-yl) acetate 234
Of-Bu
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According to general procedure F: S-Merrifield supported-2-sulfonyl-N-[2-(1-tert-
butoxy-1-oxo-prop-2-en-3-yl)-4-/sopropylphenyl]-N-methyl acetamide 237 (1.60 g, 1.30 
mmol) was treated with K2C 0 3 (1.52 g, 11.0 mmol) in DMF (15 ml).
«max (ATR, cm'1) 2922, 1721(0=0, ester), 1662 (C=0, amide), 1601, 1443, 1364, 
1143.
4.2.5 GENERAL PROCEDURE G: ALKYLATION OF CYCLIC SULFONES
S-Merrifield supported ferf-butyl-2-(1 -methyl-2-oxo-3-allyl-3-sulfonyl-7-/'sopropyl-
1,2,3,4-tetrahydroquinolin-4-yl) acetate 235
Of-Bu
S-Merrifield supported tert-butyl-2-(1-methyl-2-oxo-3-sulfonyl-7-/'sopropyl-1,2,3,4- 
tetrahydroquinolin-4-yl) acetate 234 (195 mg, 0.43 mmol) was swollen in DMF ( 6  ml) 
for 15 min. K2C 0 3 (353 mg, 2.55 mmol), Kl (424 mg, 2.55 mmol) and allyl bromide 
(0.22 ml, 2.55 mmol) were added and the reaction mixture stirred at 60 °C overnight 
before filtering and washing using the standard procedure.
Umax (ATR, cm'1) 3017, 2922, 1724 (C=0, ester), 1660 (C=0, amide), 1603, 1443, 
1366, 1142, 1056.
S-Merrifield supported terf-butyl-2-(1 -methyl-2 -oxo-3-prenyl-3-sulfonyl-7-
/sopropyl-1,2,3,4-tetrahydroquinolin-4-yl) acetate 2 3 6 93
S-Merrifield supported tert-butyl-2-(1-methyl-2-oxo-3-sulfonyl-7-/sopropyl-1,2,3,4- 
tetrahydroquinolin-4-yl) acetate 234 (625 mg, 0.54 mmol) was swollen in DMF (3 ml)
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for 15 min. K2C 0 3 (451 mg, 3.26 mmol), Kl (541 mg, 3.26 mmol), DBU (0.49 ml, 3.26 
mmol) and prenyl bromide (0.63 ml, 5.44 mmol) were added and the reaction mixture 
stirred at 60 °C overnight before filtering and washing using the standard procedure.
Umax (ATR, cm'1) 3028, 3018, 2924, 1725 (C=0, ester), 1661 (C=0, amide), 1603, 
1442, 1366, 1142, 1056.
4.2.6 TETRAHYDROQUINOLONE PRODUCTS FROM SOLID-PHASE SYNTHESIS 
ferf-Butyl 2-(1-methyl-2-oxo-1,2,3,4-tetrahydroquinolin-4-yl)acetate 196
Dry LiCI (250 mg, 5.88 mmol) was added to a round bottomed followed by THF (2 ml) 
and S-Merrifield supported terf-butyl-2-(1-methyl-2-oxo-3-sulfonyl-1,2,3,4- 
tetrahydroquinolin-4-yl) acetate 218 (479 mg, 0.44 mmol). The flask was thoroughly 
flushed with nitrogen and Sml2 (19.6 ml of a 0.1 M solution in THF, 1.96 mmol) was 
added. The reaction was slowly stirred until decolourisation of the Sml2 solution 
occurred (approx. 2 0  h) and the resin was filtered from the reaction mixture and 
washed and dried using the standard procedure. The filtrate was collected and 
concentrated in vacuo before partitioning between CH2CI2 (20 ml) and H20  (20 ml). 
The organic phase was dried (Na2S 0 4), filtered and concentrated in vacuo to give the 
crude product as a brown oil. Purification using flash chromatography on silica gel 
eluting with 30 % EtOAc/Pet ether gave tert-butyl 2-(1-methyl-2-oxo-1,2,3,4- 
tetrahydroquinolin-4-yl)acetate 197 (21.3 mg, 0.08 mmol, 35 %) as a colourless oil.
See earlier for data.
o
f-E
C16H21NO3 
Mol. Wt.: 275.34
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fert-Butyl 2-(7,9-difluoro-1 -methyl-2-oxo-1,2,3,4-tetrahydroquinolin-4-yl)acetate
206
o
F
■o
C 1 6 H 1 9 F 2 N O 3
Mol. Wt: 311.32
F
Dry LiCI (257 mg, 6.07 mmol) was added to a round bottomed followed by THF (5 ml) 
and S-Merrifield supported ferf-butyl-2-(1-methyl-2-oxo-3-sulfonyl-7,9-difluoro-1,2,3,4- 
tetrahydroquinolin-4-yl) acetate 212d (535 mg, 0.45 mmol). The flask was flushed with 
nitrogen and Sml2 (20.2 ml, 0.1 M solution in THF, 2.02 mmol) was added. The 
reaction was slowly stirred until decolonisation of the Sml2 solution occurred (approx. 
23 h) and the resin was filtered from the reaction mixture and washed and dried using 
the standard procedure. The filtrate was collected and concentrated in vacuo before 
partitioning between CH2CI2 (20 ml) and H20  (20 ml). The organic phase was dried 
(Na2S 0 4), filtered and concentrated in vacuo to give the crude product. Purification 
using flash chromatography on silica gel eluting with 30 % EtOAc/Pet ether gave tert- 
butyl 2-(7,9-difluoro-1-methyl-2-oxo-1,2,3,4-tetrahydroquinolin-4-yl)acetate 206 (20.6 
mg, 0.07 mmol, 27 %) as a pale yellow oil.
See earlier for data.
fert-Butyl 2-(6-/sopropyl-1 -methyl-2-oxo-1,2,3,4-tetrahydroquinolin-4-yl)acetate
230
Dry LiCI (247 mg, 5.83 mmol) was added to a round bottomed followed by THF (3 ml) 
and S-Merrifield supported te/f-butyl-2-(1-methyl-2-oxo-3-sulfonyl-7-/sopropyl-1,2,3,4- 
tetrahydroquinolin-4-yl) acetate 234 (502 mg, 0.43 mmol). The flask was flushed with 
nitrogen and Sml2 (19.4 ml, 0.1 M solution in THF, 1.94 mmol) was added. The 
reaction was slowly stirred until decolonisation of the Sml2 solution occurred and the 
resin was filtered from the reaction mixture and washed and dried using the standard
o
Of-Bu
C 1 9 H 2 7 N O 3  
Mol. Wt: 317.42
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procedure. The filtrate was collected and concentrated in vacuo before partitioning 
between CH2CI2 (20 ml) and H20  (20 ml). The organic phase was dried (Na2S 0 4), 
filtered and concentrated in vacuo to give the crude product. Purification using flash 
chromatography on silica gel eluting with 30 % EtOAc/Pet ether gave ferf-butyl 2-(6- 
/'sopropyl-1-methyl-2-oxo-1,2,3,4-tetrahydroquinolin-4-yl)acetate 230 (22.0 mg, 0.07 
mmol, 31 %) as a pale yellow oil.
Cyclative cleavage of S-Merrifield supported-2-sulfonyl-N-[2-(1-fe/f-butoxy-1-oxo-prop- 
2-en-3-yl)-4-/sopropylphenyl]-N-methyl acetamide 237
S-Merrifield supported-2-sulfonyl-N-[2-(1 -fe/f-butoxy-1 -oxo-prop-2-en-3-yl)-4-
/sopropylphenyl]-N-methyl acetamide 237 (540 mg, 0.47 mmol) was swollen in THF (5 
ml) for 15 min. Dry LiCI (269 mg, 6.34 mmol) was added and the flask was thoroughly 
flushed with nitrogen before addition of Sml2 (21 ml, 0.1 M solution in THF, 2.11 mmol). 
The reaction was slowly stirred until decolonisation of the Sml2 solution occurred and 
the resin was filtered from the reaction mixture and washed and dried using the 
standard procedure. The filtrate was collected and concentrated in vacuo before 
partitioning between CH2CI2 (20 ml) and H20  (20 ml). The organic phase was dried 
(Na2S 04), filtered and concentrated in vacuo to give the crude product. Purification 
using flash chromatography on silica gel eluting with 30 % EtOAc/Pet ether gave 230 
(19.0 mg, 0.06 mmol, 25 %) as a pale yellow oil and N-(2-bromo-4-/sopropylphenyl)-N- 
methylacetamide (13.0 mg, 0.05 mmol, 19 %) as a pale yellow oil.
SH (400 MHz, CDCI3) 1.26-1.29 (6 H, m, CH(CH3)2), 1.47 (9H, s, C(CH3)3), 2.50 (2H, dd, 
J 7.5, 2.1, CHzCOzf-Bu), 2.65 (1H, dd, J 16.0, 4.8, 1H of CFbCO), 2.80 (1H, dd, J 16.0, 
5.7, 1H of ChfeCO), 2.82-2.92 (1H, m, CH(CH3)2), 3.22 (3H, s, NCH3), 3.22-3.47 (1H, m, 
CH), 7.12-7.18 (3H, m, ArH).
8 c (100 MHz, C D C I 3 )  24.2 (CH(CH3)2), 24.3 (CH(CH3)2), 28.4 (3 x C(CH3)3), 29.7 
(NCH3), 33.0 (CH(CH3)2), 33.7 (CHCH2C 0 2f-Bu), 37.2 (CH2CO), 38.0 (CH2C 0 2f-Bu),
81.3 (C(CH3)3), 115.1 (ArCH), 125.8 (ArCH), 125.9 (ArCH), 128.5 (ArC), 137.9 (ArC),
144.0 (ArC), 169.3 (C O ), 171.0 (C O ).
MS (El mode) 318 (99 %, M+ + H), 262 (71), 222 (33), 218 (29), 202 (18). HRMS 
Ci9H28N 0 3 requires 318.2069 found 318.2068.
Umax (ATR, c m 1) 2963, 2929, 2361, 1724 (C O , ester), 1675 (C O , amide), 1501, 
1459, 1420, 1368, 1254, 1204, 1148.
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tert- Butyl 2-(3-allyl-7-/sopropyl-1 -methyl-2-oxo-1,2,3,4-tetrahydroquinolin-4-
yl)acetate 228
o
C 2 2 H 3 1 N O 3  
Mol. Wt: 357.49
Dry LiCI (219 mg, 5.18 mmol) was added to a round bottomed followed by THF (5 ml) 
and S-Merrifield supported terf-butyl-2-(1-methyl-2-oxo-3-allyl-3-sulfonyl-7-/sopropyl-
1,2,3,4-tetrahydrquinolin-4-yl) acetate 235 (462 mg, 0.38 mmol). The flask was 
thoroughly flushed with nitrogen and Sml2 (17.3 ml, 0.1 M solution in THF, 1.73 mmol) 
was added. The reaction was slowly stirred until decolourisation of the Sml2 solution 
occurred and the resin was filtered from the reaction mixture and washed and dried 
using the standard procedure. The filtrate was collected and concentrated in vacuo 
before partitioning between CH2CI2 (20 ml) and H20  (20 ml). The organic phase was 
dried (Na2S 0 4), filtered and concentrated in vacuo to give the crude product. 
Purification using flash chromatography on silica gel eluting with 30 % EtOAc/Pet ether 
gave fert-butyl 2-(3-allyl-7-/sopropyl-1-methyl-2-oxo-1,2,3,4-tetrahydroquinolin-4- 
yl)acetate 228 (13.2 mg, 0.04 mmol, 16 %, 3:1 mixture of diastereoisomers). Further 
careful chromatography allowed the major diastereomer to be isolated and analysed.
5h (400 MHz, C D C I 3 )  1.17-1.71 (6 H, m, (CH3)2CH), 1.36 (9H, s, (CH3)3C), 2.08-2.11 
(2H, m, 1H from C F h C ^  and 1H from CFUCOzf-Bu), 2.47 (1H, dd, J 14.9, 4.1 Hz, 1H 
from CHzCOzf-Bu), 2.75-2.80 (1H, m, CH), 2.80-3.29 (1H, m, 1H from ChhCH=), 2.77 
(1H, septet, J 6.9 Hz, , (CH3)2CH), 3.35 (3H, s NCH3), 3.35-3.40 (1H, m, CHCO), 5.09 
(1H, d, J 10.2 Hz, 1H from CH^CH-), 5.13 (1H, d, J 15.9 Hz, 1H from CH^CH-), 5.82- 
5.96 (1H, m, -CH=), 6.91 (1H, d, J 8.3 Hz, ArH), 7.06-7.13 (2H, m, 2 x ArH).
5C (100 MHz, CDCI3) 24.2 ((CH3)2CH), 24.3 ((CH3)2CH), 28.3 ((CH3)3C), 30.0 (NCH3), 
31.2 (CH2CH=), 33.7 (CH(CH3)2), 35.2 (CH2C 0 2f-Bu), 36.1 (CHCO), 44.3 (CH), 81.0 
(C(CH3)3), 115.2 (ArCH), 117.2 (CH2=), 125.9 (ArCH x 2), 126.4 (ArC), 136.2 (-CH=), 
137.8 (ArC), 143.7 (ArC), 170.1 (C=0), 171.3 (C=0).
MS (Cl mode) 358 (M+ + H, 100 %), 302 (41), 218 (43), 137 (22). HRMS C22H32N 0 3 
requires 358.2377 found 358.2381.
Umax (ATR, cm'1) 2959, 2925, 2855, 1727 (C=0, ester), 1674 (C=0, amide), 1459, 
1366, 1258, 1144, 1095.
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ferf-Butyl 2-(3-prenyl-7-/sopropyl-1 -methyl-2-oxo-1,2,3,4-tetrahydroquinolin-4-
yl)acetate 233
Dry LiCI (580 mg, 6.42 mmol) was added to a round bottomed followed by THF (2 ml) 
and S-Merrifield supported terf-butyl-2-(1-methyl-2-oxo-3-prenyl-3-sulfonyl-7-/sopropyl-
1,2,3,4-tetrahydroquinolin-4-yl) acetate 236 (580 mg, 0.48 mmol). The flask was 
thoroughly flushed with nitrogen and Sml2 (21.4 ml, 0.1 M solution in THF, 2.14 mmol) 
was added. The reaction was slowly stirred until decolourisation of the Sml2 solution 
occurred and the resin was filtered from the reaction mixture and washed and dried 
using the standard procedure. The filtrate was collected and concentrated in vacuo 
before partitioning between CH2CI2 (20 ml) and H20  (20 ml). The organic phase was 
dried (Na2S 0 4), filtered and concentrated in vacuo to give the crude product. 
Purification using flash chromatography on silica gel eluting with 15 % EtOAc/Pet ether 
gave terf-butyl 2-(3-prenyl-7-/sopropyl-1-methyl-2-oxo-1,2,3,4-tetrahydroquinolin-4- 
yl)acetate 233 (11.0 mg, 0.03 mmol, 12 %, 2:1 mixture of diastereomers) and 230 (18.7 
mg, 0.059 mmol, 19%). Further careful chromatography allowed the major 
diastereoisomer of 233 to be isolated and analysed.
8 h (400 MHz, CDCI3) 1.22 (3H, d, J 6.9 Hz, (CH3)2CH), 1.23 (3H, d, J 6.9 Hz, 
(CH3)2CH), 1.37 (9H, s, (CH3)3C), 1.58 (3H, s, CH3), 1.73 (3H, s, CH3), 2.03-2.11 (2H, 
m, 1H from CH2CH= and 1H from Cj^CO^-Bu), 2.47 (1H, dd, J 15.0, 4.0 Hz, 1H from 
CH2C0 2f-Bu), 2.55-2.57 (2H, m, 1H of C F L C ^  and CH), 2.77 (1H, septet, J 6.9 Hz, 
(CH3)2CH), 3.48 (3H, s, NCH3), 3.48-3.50 (1H, m, CHCO), 5.12 (1H, broad s, -CH=), 
6.91 (1H, d, J 8.3 Hz, ArH), 7.01-7.05 (2H, m, 2 x ArH).
8 c (100 MHz, C D C I 3 )  17.8 ((CH3)2C=), 23.9 ((CH3)2CH), 24.0 ((CH3)2CH), 25.8 
((CH3)2C=), 28.0 ((CH3)3C), 29.7 (NCH3), 29.7 (CH2CH=), 33.5 ((CH^zCH), 35.1 
(CH2C 0 2/-Bu), 35.8 (CHCO), 44.6 (CH), 80.6 (C(CH3)3), 114.8 (ArCH), 121.3 (CH=),
125.5 (ArCH x 2), 126.1 ((CH3)2C= or ArC), 133.5 ((CH3)2C= or ArC), 137.4 ((CH3)2C= 
or ArC), 143.3 ((CH3)2C= or ArC), 171.2 (C=0 x 2).
MS (Cl mode) 386 (M+ + H, 100%), 330 (20), 202 (15). HRMS C24H36N 0 3 requires 
386.2690 found 386.2700.
o
C 2 4 H 3 5 N O 3  
Mol. Wt: 385.54
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Umax (ATR, cm'1) 2961, 2924, 1724 (C=0, ester), 1675 (0=0 , amide), 1501, 1459,
1417, 1367,1328, 1265, 1145.
1 -Methyl-2-oxo-4-[2-(morpholin-4-yl)-2-oxoethyl]-1,2,3,4-tetrahydroquinoline 231
Dry LiCI (315mg, 7.43 mmol) was added to a round bottomed followed by THF (3 ml) 
and S-Merrifield supported-1 -methyl-2-oxo-4-[2-(morpholin-4-yl)-2-oxo-ethyl]-3-
sulfonyl-1,2,3,4-tetrahydroquinoline 209d (655 mg, 0.55 mmol). The flask was flushed 
with nitrogen and Sml2 (24.8 ml, 0.1 M solution in THF, 2.48 mmol) was added. The 
reaction was slowly stirred until decolourisation of the Sml2 solution occurred and the 
resin was filtered from the reaction mixture and washed and dried using the standard 
procedure. The filtrate was collected and concentrated in vacuo before partitioning 
between CH2CI2 (20 ml) and H20  (20 ml). The organic phase was dried (Na2S 0 4), 
filtered and concentrated in vacuo to give the crude product. Purification using flash 
chromatography on silica gel eluting with 60 % EtOAc/Pet ether gave the product 231 
(15.9 mg, 0.05 mmol, 18 % overall) as a pale yellow oil and acetamide 215 (22.3 mg,
0.10 mmol, 32 %).
8 h (400 MHz, CDCI3) 2.40-2.50 (2H, m, CH2CO), 2.65 (1H, dd, J 16.4, 3.2, 1H of 
CH2CO), 2.75 (1H, dd, J 16.4, 6.0, 1H of CtfeCO), 3.11-3.17 (1H, m, 1H of CHz), 3.28- 
3.36 (2H, m, 1H of Chh and 1H of CH2), 3.38 (3H, s, NCH3), 3.47-3.57 (6 H, m, 5H of 
CH2 + CH), 6.93-7.00 (2H, m, ArH), 7.18-7.24 (2H, m, ArH).
8 c (100 MHz, CDCI3) 29.4 (NCH3), 32.9 (CH), 36.3 (CH2CO), 36.9 (CH2CO), 42.0 
(CH2), 45.9 (CH2), 66.3 (CH2), 66.7 (CH2), 114.8 (ArCH), 123.2 (ArCH), 128.1 (2 x 
ArCH), 128.4 (ArC), 139.7 (ArC), 169.1 (C=0), 169.3 (C=0).
MS (Cl mode) 306 (M+ + NH4, 70%), 289 (100), 160 (20). HRMS C16H21N20 3 requires 
289.1547 found 289.1543.
»max (ATR, cm ’ ) 2922, 2856, 1645 (C=0), 1465, 1375, 1268, 131, 1115. 
tert-Butyl 2-(1 -benzyl-2-oxo-1,2,3,4-tetrahydroquinolin-4-yl)acetate 232
o
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C15H14BrNO 
Mol. Wt.: 304.18
Dry LiCI (264 mg, 6.24 mmol) was added to a round bottomed followed by THF (2.5 ml) 
and S-Merrifield supported fert-butyl-2-(1-benzyl-2-oxo-3-sulfonyl-1,2,3,4- 
tetrahydroquinolin-4-yl) acetate 21 Od (550 mg, 0.46 mmol). The flask was thoroughly 
flushed with nitrogen and Sml2 (21 ml, 0.1 M solution in THF, 2.10 mmol) was added. 
The reaction was slowly stirred until decolonisation of the Sml2 solution occurred and 
the resin was filtered from the reaction mixture and washed and dried using the 
standard procedure. The filtrate was collected and concentrated in vacuo before 
partitioning between CH2CI2 (20 ml) and H20  (20 ml). The organic phase was dried 
(Na2S 04), filtered and concentrated in vacuo to give the crude product. Purification 
using flash chromatography on silica gel eluting with 10 % EtOAc/Pet ether gave 232 
(30.0 mg, 0.09 mmol, 35 %) and N-benzyl-N-(2-bromophenyl)acetamide (19.3 mg, 0.06 
mmol, 26 %) as an inseparable mixture.
§H (400 MHz, CDCIs) 1.34 (9H, s, C(CH3)3), 1.74 (3H, s, NCOCH3 {acetamide}), 2.37- 
2.45 (2H, m, Chh), 2.66 (1H, dd, J 15.9, 4.6 1H of CJi), 2.83 (1H, dd, J 15.9, 5.8, 1 H of 
CFh), 3.37-3.40 (1H, m, CH), 3.92 (1H, d, J 15.0 1H of CHzPh {acetamide}), 4.96 (1H, 
app d, J 16.2, 1H of C jiP h), 5.24 (1H, app. d, J 16.2, 1H of CFhPh), 5.52 (1H, d, J 
15.0, 1H of CHzPh {acetamide}), 6.67-6.69 (1H, m, ArH), 6.80 (1H, d, J 5.0, ArH), 6 . 8 8  
(1H, t, J5.0, ArH), 7.01-7.22 (1H, m, ArH), 7.57-7.59 (1 H, m, ArH)- 
8 c (100 MHz, CDCI3) 28.5 (CH3 {acetamide}), 33.3 (C(CH3)3), 37.4 (CH), 40.0 
(CH2CO), 46.5 (CH2Ph), 51.6 (CH2Ph {acetamide}), 81.5 (C(CH3)3), 116.2 (ArCH),
116.3 (ArCH), 123.5 (ArCH), 124.2 (ArCH), 126.8 (ArCH), 127.0 (ArCH), 128.0 (2 x 
ArCH), 128.3 (ArCH), 128.4 (ArCH), 128.7 (2 x ArCH), 128.8 (ArC), 129.2 (ArCH),
129.6 (ArCH), 129.8 (ArCH), 131.6 (ArCH), 131.7 (ArCH), 137.3 (ArC x 2), 137.4 (ArC 
x 2), 139.4 (ArC), 141.5 (ArC).
MS (El mode) 169 (M+ + NH4, 229, 74 %), 352 (M+, 229, 32 %), 321 (42), 306 (M+, 
8,Br, acetamide, 8 8  %), 304 (M+ , 79Br, acetamide, 100 %), 224 (23), 108 (21). HRMS 
Ci5H|5N 0 79Br (acetamide) requires 304.0332 found 304.0334, C22H26NO3 (229) 
requires 352.1907 found 352.1907.
Umax (ATR, cm'1) 3063, 3031, 2975, 2929, 1722 (C=0, ester), 1668 (C=0, amide), 
1602, 1495, 1457, 1433, 1379, 1256, 1184.
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ferf-Butyl 2-(2-oxo-1,2,3,4-tetrahydroquinolin-4-yl)acetate 229
o
t- E
N O 
H
C 1 5 H 1 9 N O 3  
Mol. Wt: 261.32
Dry LiCI (327 mg, 7.72 mmol) was added to a round bottomed followed by THF (3 ml) 
and S-Merrifield supported terf-butyl-2-(2-oxo-3-sulfonyl-1,2,3,4-tetrahydroquinolin-4-yl) 
acetate 151d (635 mg, 0.57 mmol). The flask was thoroughly flushed with nitrogen and 
Sml2 (25.7 ml, 0.1 M solution in THF, 2.57 mmol) was added. The reaction was slowly 
stirred until decolourisation of the Sml2 solution occurred and the resin was filtered from 
the reaction mixture and washed and dried using the standard procedure. The filtrate 
was collected and concentrated in vacuo before partitioning between CH2CI2 (20 ml) 
and H20  (20 ml). The organic phase was dried (Na2S 0 4), filtered and concentrated in 
vacuo to give the crude product. Purification using flash chromatography on silica gel 
eluting with 5 % EtOAc/Pet ether gave 229 (3.4 mg, 0.01 mmol, 5 %) and A/-(2- 
bromophenyl)acetamide (7.0 mg, 0.03 mmol, 11 %).
8h (400 MHz, CDCI3) 1.44 (9H, s, C(CH3)3), 2.54 (1H, dd, J 9.2, 4.4, CH), 2.64-2.68 
(2H, m, CHzCOzf-Bu), 2.68-2.91 (2H, m, CFU), 7.12-7.26 (2H, m, 2 x ArH), 7.30-7.54 
(2H, m, 2 x ArH), 8.94 (1H, bs, NH).
MS (El mode) 279 (M+ + NH4, 5 %), 208 (21), 153 (29), 136 (99). HRMS C15H19N 0 3 
requires 261.1359 found 261.1352.
i w  (ATR, c m 1) 3276, 2974, 2926, 2859, 1724 (C=Ot ester), 1669 (C=0, amide), 
1560, 1543, 1498, 1443, 1316, 1258, 1150.
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